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Chemokines are chemotactic cytokines which play an important role in the 
migration of immune cells to distant tissues or compartments within tissues. 
These proteins have also been demonstrated to play a major role in cancer 
metastasis. The C-C chemokine receptor type 7 (CCR7) is a member of the 
chemokine receptor family. CCR7 along with its ligands CCL19 and CCL21 
plays an important role in innate immune response by trafficking of 
lymphocytes. In cancer, tumour cells expressing CCR7 migrate to lymphoid 
organs and thus disseminate to other organs. Neutralizing the interactions 
between CCL21/CCR7 would therefore be expected to inhibit the 
progression and metastasis of many different types of cancer to regional 
lymph nodes or distant organs. Our objective was to identify a potent small 
molecule antagonist of CCR7 as a prelude to the investigation of the role of 
this axis in cancer metastasis. In this study, we provided a brief description of 
chemokines and their role in health and disease with an emphasis on the 
CCR7/CCL19/CCL21 axis, as well as identification of a CCR7 antagonist 
“hit”. The potency of the CCR7 antagonist “hit” was optimised by 
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synthesizing different CCR7 antagonist analogues. The “hit” optimization 
process has led to discover the most active compound amongst a series of 
different analogues which have the ability to bind and block CCR7 receptor. 
The efficacy of the most active compound and other analogues were 
evaluated in vitro using a calcium flux assay which is based on detecting 
fluorescent light emitted upon release of calcium ions. To identify a suitable 
cell line, which expresses CCR7 and capably respond to it, amongst a panel 
of cell lines for in vitro assessment of potency of synthesised compounds, we 
used Western blot assay and later by flow cytometry assay. The activity and 
selectivity of the most effective compound against CCR7 receptor was 
evaluated in vitro by other functional assays such as “configured agarose 
spot assay” and scratch assay. We first configured the existing under 
agarose assay to fulfil our requirements and then used it to assess activity 
and selectivity of compounds. The configured agarose spot assay also 
describes the application of the agarose spot for evaluation of cells 
chemotactic response to multiple chemokines under identical experiment 
conditions. 
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1.1. Introduction 
Uncontrolled cell growth is an important characteristic of cancer. In most 
body tissues and organs, a balance is kept between cell proliferation and cell 
death. Sometimes, cells lose their ability to respond to the normal growth 
control mechanism and thus never stop their replication. This results in large 
clusters of cells that can be considered as a tumour or neoplasm. Tumours 
can be classified as benign or malignant depending on their behaviour, such 
as how fast they grow and how likely they tend to spread to certain parts of 
the body. Benign tumours are typically slow-growing and rarely spread to 
other parts of the body 1. However, malignant tumours tend to grow faster 
and have the potential to invade surrounding tissue and metastasise to 
distant organs. Malignant tumours (cancer) are defined as group of 
uncontrolled diseases characterized by self-sufficient in growth signals, by 
pass apoptosis, insensitivity to tumour suppressor gene, induce 
angiogenesis, ability to invade and metastasise to certain organs, 
immortality, avoiding immune destruction, promote inflammation, genome 
instability and cellular energetics deregulation 2. Metastatic cancer cells are 
uniquely characterised by their spreading throughout the body. They migrate 
from a primary site to other locations in the body. This process is called 
metastasis and it’s the major difference between benign and malignant cell 
growth. The process of tumour progression to metastasis is very complicated 
and only a few cells survive the whole processes to reach the invasion step 
3. Following initial growth of preliminary tumours, malignant cells invade 
surrounding tissues and enter blood circulation. Circulating tumour cells 
migrate out of the blood vessels into distant tissues 4. Tumour cells can 
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spread and migrate along tissue surfaces and into many different tissue 
spaces and cavities, however the main two routes of metastatic spread are 
through lymphatic and blood vessels 5. Tumour metastasis is the main cause 
of mortality in patients with malignant tumours. Different tumours metastasise 
to certain organs of the body based on the origin of the primary tumour. For 
instance, breast and prostate cancer cells tend to metastasise to bone while 
melanoma mainly metastasises to the brain, lung and liver. Secondary 
tumour site formation is based on many factors like blood flow, and the 
expression of specific receptors can accelerate metastasis 6. Cancer is the 
most widespread disease affecting people throughout the world. Although 
improved treatment regimens have reduced the death-rate resulting from 
cancer, it is still the major cause of death. The mortality rates of cancer have 
risen quickly in the world, especially in the last two decades, which has 
brought more attention to cancer research 7. Most physicians prescribe 
adjuvant therapy for patients with solid tumour as additional therapy after 
primary surgery to eliminate micro-metastatic disease. The adjuvant 
treatment is dependent on prognostic signs such as tumour size, grade, and 
most substantially, the existence of tumour cells in distant organs. Indeed, 
lymphatic metastasis is a marker for distant metastatic disease 8. Although 
many molecules are involved in cancer metastasis, there is no single precise 
mechanism of tumour cell migration to specific organs. The “seed and soil” 
theory describes directional metastasis, taking into account that certain 
organs have the suitable environment for cancer cells from the first organ 9. 
A wide range of the tumour host factors including growth factors, cytokines 
and chemoattractants support tumour cell growth, proliferation and migration. 
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Cytokine family members known as chemokines are involved in many steps 
of malignant transformation and tumour invasion and metastasis. Many 
different functions and mechanisms of action have been proposed for 
chemokines and their receptors in the growth and progression of tumours 10.  
1.2. Chemokines and chemokine receptors. 
The inflammatory cells, such as phagocytic leukocytes of the immune 
system, undergo accelerated controlled movement in response to a chemical 
stimulus toward the inflammation site which have the highest concentration 
of chemokine (chemoattractant gradient) to serve as a first line of defence 
against infection 11. Phagocytic leukocytes are part of the innate immune 
system which are involved in protecting the body from inflammation and 
foreign invaders. During injury, infected cells release chemotactic factors 
which recruit phagocytic leukocytes to the inflammation site through 
endothelial receptors. The interaction between chemotactic factors and 
phagocytic leukocyte Initiate changing in ion fluxes, increasing integrin 
avidity and transmembrane potential, changes in cell shape, production of 
superoxide anions, as well as improved locomotion 12. The chemotactic 
gradient released from cells attract leukocytes toward the site of injury or 
infection. Eventually they transmigrate and exit the bloodstream toward 
infected tissue and engulf infected cells or recruit the adaptive immune 
system to eradicate or stop pathogen growth. 
There are two well-known types of chemoattractants that have been 
identified. These chemoattractants are bacterial-derived N-formyl peptides 
and lipid molecules such as leukotriene B4 and platelet-activating factor 
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which all are activators of leukocytes 13. There are a number of chemotactic 
cytokines that have been shown to be selective for leukocyte subpopulations 
and these are called chemokines 14. Chemokines are a large family of 
structurally related cytokines which are involved in activation and migration of 
many different types of leukocytes 15. Unlike cytokines which were first 
discovered by observation of soluble bioactivities, chemokines were verified 
by molecular cloning efforts. The first ever chemokine discovered was in 
1961 and called platelet factor 4 (PF4). It took about three decades after 
identifying the first chemokine before several new members were discovered 
that described the common structural feature of the chemokine family 16.  
To date, more than 50 chemokines and 20 chemokine functional receptors 
have been identified 4. Chemokines play a key role in development, 
angiogenesis and haematopoiesis 17. They are 8–14 kDa, mostly basic, 
heparin-binding cytokines and small peptide ligands that play a major role by 
interacting with cell surface proteins, including integrins, to direct different 
types of cells toward specific anatomical sites 18. In general, chemokine 
receptors have about 340 to 370 amino acids length with a relatively small 
extracellular acidic N‐terminus, plus large numbers of serine and threonine in 
the short intracellular C‐terminal tail 19. They are classified into four groups 
(CXC, CX3C, CC and C). This classification is structural rather than 
functional and is based on the spacing of conserved cysteine residues near 
the N-terminus which dictate chemokines tertiary structure. C chemokines 
have only two conserved cysteines, whereas CXC, CC, and CX3C 
chemokines all have four conserved cysteines 20. The first and second 
cysteine residues in CXC and CX3C chemokines are separated by one or 
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three amino acids, whereas the first two cysteines of CC chemokines are 
adjacent 21 (Figure 1). 
 
Figure 1 Schematic illustrations of chemokines (C, CC, CXC, CX3C) and 
chemokine receptors (CR, CCR, CXCR, CX3CR) classification based on the 
spacing of conserved cysteine residues near the N-terminus 22. 
CXC subfamily are further classified into two groups based on the presence 
or absence of a tripeptide motif glutamic acid–leucine–arginine (ELR) in the 
N-terminal domain 20. The following chemokines, CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7 and CXCL8 are all ELR-positive chemokines. 
Figure 2 shows different chemokine receptors and their known chemokine 
ligands. The NH2 terminal group plays an important role in attraction between 
chemokines and neutrophils and also participating in angiogenic 
characteristic of these chemokines 23. Chemokines and their receptors are 
highly interconnected and have complex relationships: a single chemokine 
recognises and binds to many different receptors, while one chemokine 
receptor identifies several chemokines 24. 
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Figure 2 Schematic diagram shows known chemokines and chemokine receptors. 
There are 10 CCR family subunits and 7 CXCR family subunits as well as XCR1 
and CX3CR1 which are known as decoy receptors that only bind to ligand and do 
not elicit signal transduction 25. 
Based on their biological function, chemokines are also classified into 
homeostatic and inflammatory chemokines. The homeostatic chemokines 
are normally produced and secreted in many different organs or tissues in 
the absence of inflammatory stimuli and they have many different functions 
26. For example, they orientate the migration of lymphocytes to lymphoid 
tissues, are involved in immune surveillance, they function to localize T or B 
cells with antigens in the lymphatic system and they work to create a balance 
of lymphocytes throughout the lymphatic system 27. Inflammatory 
chemokines are only produced by cells in the presence of infection or pro-
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inflammatory stimuli. The function of inflammatory chemokines is to enhance 
the trafficking of the white blood cells toward the injured or infected tissues 
28. Even though these chemokines are classified into two classes, 
inflammatory and homeostatic, it shouldn’t be viewed as absolute. For 
example, one of the inflammatory chemokines is MCP-1 (CCL2) which, 
together with its receptor CCR2, is involved in controlling the migration of 
monocytes and macrophages in an inflammatory setting. However, this 
chemokine MCP-1 along with its receptor CCR2 have also been shown to 
have great effect on the development of polarized T helper cell responses, 
which shows that chemokines in some cases can work as both inflammatory 
and homeostatic 29.  
Most known chemokine receptors have the same monomeric structure and 
share very similar tertiary structures. They consist of chemokine domain at 
the flexible N terminal region which comes before the first cysteine residue 
and is responsible for receptor stimulation and activation. The N-terminus is 
followed by 10- to 20-amino acids that form an N-terminal loop, which is 
believed to be involved in receptor specificity, followed by a helix that 
contains 310 residue, a β-sheet with three antiparallel β-strands and a C-
terminal, cytoplasmic tail, and an α-helix that set against the β-sheet 30. The 
loops which connect the first β-strand with the second and the second with 
the third β-strand are similar in structure. They differ only in the chirality of 
the disulphide bonds. The first connecting loop is called 30s and the second 
connecting loop is called 40s. The disulphide bond of the CXCR chemokines 
and the CCR chemokines are identical. The only difference is that the CXCR 
chemokines contain disulphide bonds in the first cysteine residue with right-
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handed chirality. However, the CCR-binding chemokines contain disulphide 
bonds with left-handed chirality. However, the second disulphide bond is left-
handed in the two families 18. Some exceptions are found in the CXCR4 
receptor in which both bonds are left-handed. The monomeric structure of 
the CCR-binding chemokines is identical to the monomeric structure of the 
CXCR-binding chemokines. The only considerable differences were found in 
the dimeric and tetrameric structure. The chemokine receptor CCR4 was the 
first receptor to be identified as dimeric. The amino terminal of CCR-binding 
chemokine is rigid, not flexible as in case of CXCR-binding chemokines. The 
rigidity of the N-terminus is a result of forming the dimeric interface which 
makes the protein elongated with each helix. Other chemokines like CCR2 
was discovered to have a tetrameric structure 31.  
1.3. Function of Chemokines in Health and Disease 
Recently, chemokines and their receptors have received much attention due 
to their important role in tumour invasion and metastasis. Initially, they are 
described because of their correlation with inflammatory response, and by 
activation of leukocytes in the time of inflammation 32. The main function of 
chemokines is to facilitate the trafficking and migration of leukocytes between 
circulation and tissues. Chemokines and their receptors are involved in 
attracting leukocytes from blood circulation to the inflammation site. 
Chemokine receptors are expressed on the leukocyte cell surface and their 
ligands are released by the infected or inflamed cells. Chemokines bind to 
their receptors leading to increasing avidity of integrins, located on the 
leukocyte cell surface, to their ligands which provide firm attachment of the 
leukocyte to the endothelium. The interaction between chemokines and their 
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receptors initiate and activate downstream signalling which is responsible for 
enhancing leukocytes locomotion and transmigration. Once the leukocytes 
reach the site of inflammation, they come into contact with the inflamed 
tissue and eradicate the inflammation. Chemokines play a significant role in 
both innate and adaptive immunity. They are crucial in attracting different 
sets of inflammatory cells to the inflammation site depending on whether 
inflammation is innate or adaptive 36. The innate immune response is 
enhanced by the recruitment of neutrophil and monocyte cells to the site of 
inflammation. Other different cells like naive and memory CD4 cells are 
involved in the adaptive immune response which is induced by different type 
of chemokines and their receptors 37.  
Beside their role as regulators of immune cell circulation, chemokines are 
involved in many different other physiological and pathological processes 
such as maintenance of tissue homeostasis, controlling cell multiplication, 
tissue morphogenesis, angiogenesis, tumorigenesis, and metastasis 33. They 
promote angiogenesis during new formation of blood vessels in case of 
wound healing, tissue repair and embryonic development 34. For example, 
different chemokine receptors are expressed by platelets, leukocytes and 
endothelial cells during wound healing. These chemokines have an 
angiogenic effect on the endothelium to activate neovascularization of the 
granulation tissue. They also promote angiogenesis in different pathogenic 
conditions as observed in tumour growth and formation 35. Chemokines and 
chemokine receptors control angiogenesis in the tumour microenvironment. 
They promote tumour growth by regulating the formation of vascular 
networks from surrounding tissue 56. Different members of CXC chemokine 
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receptors family are identified to have regulatory effect on angiogenesis. It 
has been well studied that CXC chemokines promote blood vessel formation 
54. Chemokines that have positive ELR motif support tumour to form new 
blood vessels and are called angiogenic factors these include, CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8, which exert an 
angiogenic effect in prostate cancer. Conversely, chemokines that are ELR 
negative (ELR-), except CXCL12, show inhibitory effects on angiogenesis 
and block tumour vascularisation in a way that is still not defined 39.  
Chemokine receptors are highly expressed in certain types of cancer and are 
involved in cancer growth and progression. Normal tissue such as breast 
tissue expresses many types of chemokine like, CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7 and CXCL8, as well as tumour necrosis factor alpha 
(TNFα) and Interleukin 6 (IL-6), but at very low concentrations. However, 
these chemokines are found to be highly expressed during malignancy such 
as breast cancer, among these are CXCL8, CCL2, CCL4 and CCL5 which 
are the most studied chemokines 38. Following the binding between 
chemokines and their receptors, a series of multiple intracellular downstream 
signals are activated and this lead to activation of transcription factors which 
are responsible for tumour growth and progression. Chemokines also have 
the ability to guide metastasising tumour cells toward secondary organs by 
similar process which guide leukocyte toward inflammation site 39. 
1.4. Chemokines signalling Pathways 
In order for circulating white blood cells to reach intercellular sites, they must 
go through protective barriers such as the endothelium and the epithelium 40. 
Transmigration of leucocytes occurs in several steps including a sequential 
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cascade of pro-inflammatory cytokines, adhesion molecules and 
chemokines. Pro-inflammatory cytokines, such as TNF-α, IFN-γ and IL-1β 
activate endothelium and as a result, chemokines are secreted 41. 
Chemokines are molecules that control metastatic spreading of tumour cells 
to particular sites. They are expressed in the places where the tumour cells 
reside, whilst their ligands are expressed in distant tissues. For example 
CCL21 ligand is highly expressed in lymph nodes whilst its receptor CCR7 is 
highly expressed in breast cancer tissue 42. 
Chemokines exert their effects through G protein coupled receptors which 
contain seven transmembranous domains 43. The chemokine first bind to a 
specific and highly sulphated protein called glycosaminoglycan (GAG). They 
are linear heterogeneous polysaccharides which are often covalently bound 
to core proteins that are available on the membrane of cells or within the 
extracellular matrix 44. GAGs family are classified into many members 
including heparan sulfate which is known to function in association with many 
different biological processes such as cell adhesion, blood coagulation, 
angiogenesis, morphogenesis, and regulation of growth factors and cytokine 
effects 45. Heparan sulfate are further classified into many other families 
based upon their core protein structure. The two major families of the 
heparan sulfate are called glypicans and syndecans, which are linked to the 
plasma membrane by a glycosylphosphatidylinositol (GPI) linkage or a 
transmembrane domain respectively 46. These two families interact with 
several chemokines and enhance their local concentration and help in the 
formation of a chemokine gradient to guide the migration of cells from the 
circulation to the site of chemokine production 47. Chemokine receptors are 
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coupled to heterotrimeric Gαβγ proteins. Gαβγ subunits are dissociated 
following chemokines binding and induce release of Gα subunits and Gβγ 
subunits. A wide variety of enzymes, including phospholipid kinases, lipases 
and GEFs (guanine nucleotide-exchange factors), are activated following the 
release of the Gβγ subunits. These enzymes, in turn will activate and regulate 
other downstream signalling pathways that are important in growth and 
transcription 48. These pathways include: calcium mobilization and the 
activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and 
ERK2), p38 mitogen-activated protein kinase (p38 MAPK), phospholipase-
Cβ, phosphatidylinositol 3-kinase (PI3K), RAS, the RHO family of GTPases, 
p21-activated kinase (PAK), and NF-κB which are all involved in enhancing 
tumour cells growth and metastasis 49.  
Additionally, the released Gα subunits activate cyclic adenosine 
monophosphate (cAMP) via adenylate cyclase, and tyrosine kinases. 
Tyrosine kinases are important enzymes that work as mediators in the signal 
transduction pathway which lead to cell growth, proliferation and migration. 
They phosphorylate and activate the JAK (Janus kinase) and STAT (signal 
transduction and activators of transcription) signalling pathway which 
regulate transcription processes 50 (Figure 3). 
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Figure 3 Downstream signalling pathways activation followed by binding between 
chemokine and its receptor 51. 
The activation and enhancement of cancer cell tumorigenesis and 
neovascularization by chemokines can be indirect, by modulating leukocyte 
recruitment. In cancer, soluble factors are produced by epithelial cells and 
these in turn induce infiltration of CXC chemokines 52. The CXC chemokines 
can attract tumour-associated macrophages (TAMs) and tumour associated 
neutrophils to the tumour cells. These cells are the source of many other 
growth factors such as cytokines and enzymes such as proteolytic enzymes 
that are involved in angiogenesis, growth and migration of tumour cells 53. 
The tumour microenvironment can also activate chemokines to produce their 
action. The tumour microenvironment is very rich with cancer associated 
fibroblasts (CAFs) which promote carcinogenesis by secreting different types 
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of chemokines that promote and enhance cancer cell growth and metastasis 
54 (Figure 4).  
 
Figure 4     Schematic diagram of Tumour-Promoting Effects initiated by Stromal 
Fibroblasts within Invasive Human Mammary Carcinomas 55. 
1.5. The CXC Chemokine Receptor Type 4 
Recent studies have suggested the importance of the CXCR4 receptor along 
with CCR7 receptor as major receptors found to be expressed in different 
types of tumour cells and high level of these receptors were found in breast 
cancer 57. Further on in this study, we will investigate the selectivity of the 
most active compound against both receptors CCR7/CXCR4 using in vitro 
assay which we have called “agarose spot assay”. 
Many of the C-X-C chemokines have been identified, including platelet factor 
4 (PF4), Interleukin 8 (IL-8) and interferon- γ-inducible protein-10 (IP-10) 58. 
A number of the C-X-C chemokines were first detected based on their 
biological understanding of their ability to be expressed based on a particular 
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induction 59. For instance, based on their melanoma growth stimulatory 
activity, the growth-related oncogene α, β, and ɣ (GRO) family of C-X-C 
chemokines were primarily described 60. The chemokine receptor CXCR4 is 
one of the best studied chemokine receptors, primarily because of its role as 
a co-receptor for HIV entry and also its ability to mediate metastasis of many 
different types of cancer 61. CXCR4 was first cloned by many different 
laboratories and known as the orphan receptor because its endogenous 
ligand had not yet been recognised at that time. This receptor was then 
identified as fusin which was known as the co-receptor with CD4 for inducing 
HIV-1 virus infection. Then it was characterised as the SDF-1 / CXCL12 
receptor and subsequently named CXCR4 62. The chemokine CXCR4 
receptor activates migration of human stem cells to bone marrow and 
peripheral blood cells to lymph nodes by interaction with its ligand, CXCL12 
63. The receptor plays many different roles in B and T lymphocyte and 
activates and induces thymocyte migration 64. It is important in the earliest 
stages of B-cell lymphopoiesis, colonisation of bone marrow by multipotential 
haematopoietic cells, cardiac septum formation and in cerebellar neuronal 
layer formation 65. 
The activation of the CXCR4 receptor by its ligand leads to a rapid 
intensification of the affinity of the β1 integrin for the vascular cell adhesion 
molecule-1 (VCAM-1) which results in a greater than ten fold adhesion of the 
leukocyte to the place of inflammation 66. Integrins are receptors that attach 
cells to the extracellular matrix proteins. However, chemokine receptor 
CXCR4 has many other significant roles in addition to enhancing leukocyte 
chemotaxis such as embryogenesis, organogenesis, and vasculogenesis 67. 
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CXCR4 is crucial throughout the embryologic development, knocking out the 
CXCR4 receptor led to several vascular development defects of mice that 
eventually lead to death 68. CXCR4 receptor consists of 352 amino acids 
which is selectively bind to stromal cell derived factors (SDF-1) 69. SDF-1, 
which is also called CXCL12 was first isolated by Tashiro et al. from a murine 
bone marrow stromal cell line and was shown to have good inhibitory effect 
on infection by T-tropic HIV of HeLa-CD4 cells, human cervical epithelial 
carcinoma. 20. The CXC chemokine SDF-1 was found to encourage the 
proliferation of bone marrow B-cell progenitors in the presence of interleukin 
(IL)-7. Its amino acid sequence is notably similar species; nearly 99 % of 
them are identical between murine and human, assuming that the 
chemokines may play an essential role in animal physiology 70. Lately, there 
have been studies that revealed the involvement of CXCR4 in cancer growth 
progression and metastasis 43. Expression of CXCR4 in cancer metastasis 
appears to be due to Stromal Cell Derived Factor (SDF-1) secretion via 
stromal cells. SDF-1 binds to CXCR4 receptor and induces migration of 
cancer cells into distant tissue where tumour cells can grow and metastasis 
again. High levels of SDF-1 are available in the surrounding stromal cells 
that are commonly invaded by metastasising cells, like the bones 71. These 
high levels of SDF-1 attract CXCR4 which is expressed indifferent types of 
cancer, including breast cancer, ovarian cancer and melanoma cancer. It has 
been shown that following CXCR4/SDF-1 interaction, the transmembrane 
helices of the GPCR is enhanced and activated causing a change in the 
position on the intracellular part of the receptor, specifically the third 
intracellular loop, which is connected to the G protein 71. The Gα subunit 
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exchanges its guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP) allowing dissociation of Gα subunit from Gβγ subunits 72. Then 
phosphoinositide‐3 kinase (PI3K) is activated and generates 
phosphatidylinositol 3, 4, 5‐triphosphate (PIP3). PI3K and PIP3 localise in 
the leading edge of the cell in association with Rac protein 73. These 
downstream signalling pathways are in turn playing a critical role in 
promoting cell movement and metastasis (Figure 5).  
 
Figure 5 downstream signalling pathways of CXCR4 and its ligand, CXCL12 76. 
At the leading edge of the cell, the Rho GTPase plays the main role in 
activation of myosin, which in turn leads to produce actin–myosin complexes 
and pulls back the end side of the cell. RhoA belongs to the Ras superfamily 
of small GTP binding proteins that control configuration of actin stress fibers 
and focal adhesions 74. Migration and metastasis of either normal or 
malignant stem cells is a multi-step process. CXCR4 enhances a cell ability 
to migrate, enter blood circulation and arrive at the distant site, which 
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contains high expression of the CXCR4 ligand, SDF-1. At the end, the 
migrating cells adhere to the endothelium, invade new tissue and start 
proliferation 75. 
1.6. The C-C Chemokine Receptor Type 7 
Tumour metastasis resulted from lymphatic and haematogenous 
dissemination is one of the major causes of death in the world. The new 
tumour destination can be supported by many different factors, genetic, 
epigenetic and microenvironment factors 77.  
Recently, the C-C chemokine receptor model has been suggested to explain 
the migration of tumour cells to particular organs. They are part of Class I in 
the rhodopsin‐like G‐protein coupled receptor (GPCR) superfamily 78. The C-
C chemokine receptors are small proteins that have been recognised in 
mammals, but they have also been detected in many other different species 
like chicken, shark and possibly in nematodes 79. Their receptors are 
characterised by small proteins that induce cytoskeletal reorganisation and 
adhesion to endothelial cells 80. They are small pro-inflammatory receptors 
which participate in the selective mobilization and migration of leukocytes to 
their inflammatory location. The significant value of these chemokine 
receptors has brought considerable attention in recent years, since it has 
become known that they play major roles in a number of different disease 
development, such as inflammation, autoimmune disease, infectious 
diseases (HIV), and lately, cancer (especially in controlling metastasis) 81. 
The C-C chemokine system is very important in the growth and maturation of 
the B-cell lymphocytes, in particular CCL2 (MCP-1). Others such as CCL3 
(MIP-1α), CCL5 (RANTES) and CCR5 were reported to regulate T-cell 
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growth and progression. They play a major role in the maturation and 
migration of the dendritic cells (DCs) to tissues and lymph nodes. CCR1, 
CCR2, CCR5, CCR6 and CCR7 were found to have a critical role in 
migration of the monocytes toward lymph systems. Following activation of 
these receptors by their ligands dendritic cells become mature and leave 
tissues and travel to areas where antigens are available 27. The C-C 
Chemokine receptors play a major role in ruling the trafficking of many 
different types of leukocytes to secondary lymphoid organs like peripheral 
lymph nodes. They control leukocytes cellular composition, maturation, and 
migration 69. As well as maturation and support of secondary lymphoid 
organs. They are also associated with many immunological activities for 
instance the production of thymocytes 82 central and peripheral tolerance 83.  
The C-C chemokine receptor type 7 is a protein that belongs to the C-C 
chemokine receptors and normally consists of 340–370 amino acids. It is 
found in many different places throughout the human body in plasma 
membrane. The seven transmembrane helical domain cross the cellular 
membrane inside and outside. The N-terminus is located in the extracellular 
domain while the C-terminus is located in the intracellular region 84. The 
intracellular terminus is enriched with the multiple serine and threonine 
amino acids which become phosphorylated upon binding of the receptor with 
the ligands which play a major role in activation of signal transduction 
pathway that regulates cell growth, proliferation and migration. The 
extracellular region consists of highly conserved cysteine residue which upon 
activation upon binding with ligand forms disulphide bridges that connect N-
terminal with the extracellular loops and making the receptor conformation 85. 
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The only known ligands for CCR7 receptor are, CCL19 and CCL21. CCL21 
and CCL19/ELC are small cytokines which trigger their effect by binding to 
CCR7 receptor located on the cell surface. Their main function is in the 
migration of cancer cells to secondary lymphoid organs 86. They are 
originated by stroma cells inside the T cell zone of lymph node cortex 86. 
CCL21 is distinct from CCL19 in term of C-terminal tail. CCL21 consists of a 
uniquely long C terminal tail that has 32 amino acids, 12 of those are basic 
residues which permit strong binding to glycosaminoglycan and other 
molecules 87. CCL21 is small chemokine located in human chromosome 9 
and known as exodus-2, secondary lymphoid-tissue chemokine (SLC) and 
6Ckine because of the six conserved cysteine amino acids. The C-C motif 
chemokine 19 is small protein also located in the chromosome 9 and known 
as EBI1 ligand chemokine (ELC) 88. 
1.6.1. Expression and activation of CCR7 and its ligands. 
CCR7 receptor is expressed in many different cells but exclusively in mature 
and semi mature dendritic cells (DCs) 82. Resting and inactivated dendritic 
cells don’t express CCR7 until they become activated upon tissue injuries or 
activation by cytokines such as tumour necrotic factors TNF.  Other cells that 
mainly express CCR7, are naive and central memory T cells, CD4, CD25, T 
regulatory cells and many other cells 89. The CCR7 ligands, CCL19 and 
CCL21, are together expressed on the high endothelial venules (HEVs) 
which are post-capillary venules available in lymph nodes that enable 
lymphocytes to extravasate from blood toward lymph nodes., aggregated 
lymphoid nodules, fibroblastic reticular cells, stromal cells in T-cell areas of 
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LNs, thymus 90, spleen 69 and follicular dendritic cells which make the 
channels that direct T-cell movement in the lymphatic nodes.  
Many studies have been conducted in order to understand the underlying 
mechanisms of how C-C chemokine receptor type 7 signalling could manage 
leukocyte propulsion and migration. The chemokine receptor CCR7 plays an 
important role in Dendritic cells (DCs) and lymphocytes trafficking and 
homeostasis 91. The CCR7 receptor is highly expressed in DCs and 
lymphocytes. The chemotactic migration is controlled by G protein-coupled 
receptors like CCR7 that initiates and stimulates downstream signalling of 
mitogen-activated protein kinases (MAPKs). In response to CCL19 and 
CCL21 binding, MAPKs p38, extracellular signal regulated kinase 1/2 
(ERK1/2), and c-Jun N-terminal kinase (JNK) play major and significant part 
in CCR7-dependent travelling. Furthermore, the actin cytoskeleton is 
fundamental in chemotaxis organization. The adjustment of actin is 
organized by Rho guanosine triphosphatases and their downstream 
signalling, including serine/ threonine kinase Rho-associated kinase (ROCK) 
103. According to Riol-Blanco 98 CCR7 downstream signalling stimulates the 
mitogen activated protein kinase signalling module which starts to initiate 
trafficking, while the speed of leukocytes migration is controlled by Rho-
cofilin signalling axis. 
The travelling and migration of naive T cells toward peripheral lymph nodes 
from the blood stream consists of multiple steps. Starting from tethering and 
rotating, CC‐chemokine receptor 7 (CCR7) - mediated activation, stopping 
and trans-endothelial migration 93. Binding of the CCR7 ligands through their 
receptor leads leukocytes to go from rotation stage to arrest stage on the 
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surface of endothelial cells. The initial step involves attachment of 
lymphocyte L-selectin to peripheral node addressins (PNAD), which are 
collections of sialomucins with sialyl-LewisX-linked group that exist on high 
endothelial venules (HEVs) 94. As a result of this attachment of T cells to 
HEVs, cells are rotated to make CCR7 receptor available for the ligands. 
Next, the glycosaminoglycan (GAGs) on the luminal surface of HEVs 
immobilize CCL21 and CCL19 which make it available for binding to the 
rotating lymphocytes. Following this stage the integrins, which are 
transmembrane receptors, become active and re-allocated to lead the 
lymphocyte trans-endothelial migration.  The conformational changes of 
α1β2-integrins subunit on lymphocytes permit strong binding to it’s ligands, 
intercellular adhesion molecule 1 (ICAM1) and ICAM2. Also α4β7-integrins 
subunit binds to it’s ligand, mucosal addressin cell-adhesion molecule 1 
(MAdCAM) that is expressed on the surface of HEVs which finally lead the 
lymphocytes to perform lateral locomotion on the endothelial surface 
followed by trans-endothelial migration (Figure 6) 92.  
 
 
Figure 6 Process of lymphocyte migration to lymph nodes 92. 
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The CCR7 receptor and its ligands, CCL21 and CCL19, plays a critical role 
not only in homing cells to distant organs, but also work to mediate effects on 
B lymphocytes during inflammation 94. They play very essential roles in many 
different immunological regulations which are carried out through the process 
of immune response like, production of thymocytes 95.  
The CCR7 receptor exerts its effect through its ligands, but the effect may 
vary based on the type of ligand itself. The CCL21 ligand appears to have 
higher affinity to bind with its receptor than CCL19. This affinity is up to 10 
fold higher than CCL19 which makes the CCL21 a better candidate to 
produce an effect and form greater immobilized chemokine gradient 96. The 
different binding among the two ligands may also have a significant influence 
on the location of lymphocytes and DCs in the LN and spleen tissue 
microenvironment. The CCL19 is a very soluble ligand, while CCL21 stays 
membrane-bound due to the binding domain of the glycosaminoglycan. 
Because of differences between the two ligands, CCL21 and CCL19, they 
induce varied response although they act through the same receptor 82.  
They have special correlation to the G-proteins coupled receptor kinase 
(GRK)/β-arrestin system and therefore differentially phosphorylate CCR7 
(GRK)/β-arrestins are a small family of proteins that desensitize receptor to 
its ligand. Following binding between CCR7 receptor and its ligands, the 
receptor becomes active and simultaneously activates G proteins and 
arrestin-dependent signalling pathways via different biochemical steps. 
Receptor activation leads to dissociation of heterotrimeric G proteins into free 
Gα and Gβ subunits and undergoes phosphorylation by G protein-coupled 
receptor kinases (GRKs), and this boosts the binding of β-arrestins 97. 
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CCL19 but not CCL21 induced strong phosphorylation, β-arrestin-2 
recruitment, and CCR7 desensitisation 99. CCL19 initiates powerful CCR7 
phosphorylation and β-arrestin2 mobilisation, which is stimulated by both 
GRK3 and GRK6 while CCL21 stimulates GRK6 alone. The differences 
between the two activations lead to the distinctive ability of CCR7 ligands to 
stimulate clathrin-dependent receptor endocytosis (Figure 7).  
 
Figure 7.  Graphical interaction between CCR7/CCL19/CCL21. CCL19 and not 
CCL21 induces CCR7 receptor desensitisation 100. 
However, these ligands are both able to signal through GRK6 and β-
arrestin2 to ERK kinases 101. One hypothesis described the differences in 
response to phosphorylation, β-arrestin-2 recruitment, and CCR7 
desensitisation are because CCL21 is unable to recognise these cells, 
because of the active role of the CCL21 in supporting trafficking and 
migration of the CCR7 into lymphatic vessels in contrast to CCL19 which is 
produced locally in the T cells 102.  
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1.6.2. Cancer and CCR7 expression 
Recent studies have shown the ability of the CCR7 receptor to play a major 
role in cancer progression and metastasis. There are a lot of investigations 
where researchers have looked into the correlation between high expression 
of CCR7 receptor and cancer progression and metastasis. In 2001, Muller 40 
compared expression of different types of chemokine receptors including 
CCR7 on patients who were diagnosed with primary and invasive breast 
cancer. The tissues were collected from both groups and found that CCR7 
receptor was highly expressed in invasive breast cancer compared to 
primary breast cancer using real-time polymerase chain reaction (RT-PCR).. 
In the same study, the regional lymph node (axillary lymph nodes) tissues 
from both groups were collected and exhibited stronger CCR7 receptor 
expression in invasive breast cancer than primary breast cancer. CCR7 
receptor plays a crucial role in facilitating and directing tumour cells from 
breast cancer toward lymph nodes. This is logical since CCR7 receptor is 
highly expressed in breast cancer tissue and its ligands (CCL21 and CCL19) 
are highly expressed in the lymphatic vessels which will increase the 
probability of tumour metastasis 104. Wiley 105 have confirmed the correlation 
between CCR7 receptor tumour expressions and metastasise toward lymph 
nodes in mouse model through introducing the CCR7 gene into B16 
melanoma cells. The expression of CCR7-B16 cells at lymph node region 
was highly recognized using real-time polymerase chain reaction (RT-PCR). 
To demonstrate the metastasis of B16-CCR7 cells is mediated through 
CCL21, the CCR7 receptor was blocked with an anti-CCR7 antibody. The 
result showed less B16-CCR7 cells expression in the regional lymph nodes 
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which indicates the CCR7-mediated metastasis was blocked 105. The 
underlying mechanism which promotes involvement of CCR7 receptor in 
cancer cell metastasise to lymph nodes is very similar to leukocyte 
trafficking. The CCR7 receptor activates and initiates different downstream 
signalling following interaction with its biological ligands. Gαβγ subunits of the 
GPCR are dissociated following CCR7 receptor binding and induce release 
of Gα subunits and Gβγ subunits. Gβγ subunit stimulates and activates 
phospholipase C (PLC) and phosphatidylinositol 3 kinase (PI3K) pathways, 
while Gα subunit activates mitogen-activated protein kinase (MAPK) 106. The 
activated pathways in turn prompt intracellular actin polymerization and 
initiates cell survival and migration (Figure 8). 
 
Figure 8 downstream signalling pathways of CCR7 receptor and its ligands 107. 
Sanchez 108 has shown the effectiveness of CCR7 receptor in stimulation 
and activation of the intracellular signalling downstream that blocks apoptosis 
of mature dendritic cells 108. The activation of the receptor followed by 
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binding of the CCL21 and CCL19 ligands leads to inactivation and blocking 
of the well-known apoptotic signal of serum-starved DCs. These signals are 
due to high phosphatidyl exposure on the membrane, nuclear changes, and 
loss of mitochondria potential. CCR7 receptors initiate and activate 
intracellular signals that inhibit apoptosis of DCs, including, 
phosphatidylinositol 3_kinase/Akt1 (PI3K/Akt1), with a prolonged and 
persistent activation of Akt1. Figure 9 describes the use of scanning electron 
microscopy to highlight the reduction of the apoptotic cells when treated with 
CCL21 and CCL19 compared to control. The picture shows reduction of the 
cells that contain blebs or protrusion on the membrane of the cells by almost 
half in cells which treated with chemokines. Blebs are typically produced 
during apoptosis which is a physiological process involved in the normal 
development of tissue homeostasis 108. 
 
Figure 9 (A) Activation of CCR7 receptor by treating dendritic cells for 6 hours with 
CCL19 and CCL21 reduced the apoptotic blebs. However control cells showed 
increase in the apoptotic blebs, (B) Cells were stained with Hoechst 33342 which is 
used to visualize apoptotic nuclear morphology 108. 
Even though many studies have been conducted and determine many 
factors that affect the process of cell migration and trafficking, the underlying 
mechanism of metastasis of cells to lymph nodes is still not fully 
characterised. There are many different changes that occur inside cells in 
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order to enable migration or trafficking throughout and to the extracellular 
barriers, including the change in the cell-cell adhesion and initiation and 
activation of a number of proteolytic enzymes 108.  
1.6.3. Molecular basis of interaction between CCR7 and its ligands 
The extracellular portion of CCR7 is believed to be responsible for binding to 
heparan and other extracellular molecules which interact with the receptor 
but more importantly as a “beacon” to initially seek and bind to the 
chemokine protein which result in conformational changes of the receptor 
internal loops that initiate the signal. . Although, there is significant 
promiscuity between chemokines and chemokine receptors, CCL21 and 
CCL19 bind only to CCR7. In turn, the receptor itself has no other recognized 
endogenous activating ligands 109. It has been mentioned earlier in this 
chapter that both ligands exert their effect on CCR7 receptor differently.. In 
order to highlight the structure differences between two ligands, an alignment 
was made using an online resource, the clustalW2 algorithm. The alignment 
shown between CCL21 and CCL19 (Figure 10) illustrates the differences in 
the amino acid sequences. In contrast to CCL19, CCL21 consists of 111 
amino acids as a result of the uniquely extended C-terminus tail while CCL19 
typically contains 77 residues. This elongated tail at CCL21 C-terminus bind 
to heparan sulfate glycosaminoglycan (GAG) at the receptor surface hence, 
making a local concentration of CCL21 chemokine to be presented to the 
receptor 110. Also, CCL21 contains six cysteine residues compared to the 
regular four residues which are available in CCL19. Cysteine residues are 
sterically smaller and much more reactive than other amino acids. They 
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contain a sulphur atom which are very important in making covalent bond 
with cysteines. Hence, availability of more number of cysteine is essential for 
stabilization of the ligand-receptor binding. In addition to this, the N-terminus 
which is responsible for binding with the receptor is different between the two 
ligands (Figure 10). As a result of these variations, both ligands bind to the 
receptor differently and hence the affinity and effect will be different.  
 
Figure 10 CCL-19 and CCL-21 Alignments using clustalW2 algorithm 
It has been reported that the elimination of the N-terminal of the CCL19 
results in a deterioration of binding to the receptor. This impairment is a 
result of the deletion of the Glu6 and Asp7 which play a key role and are 
responsible for the activation of the receptor and affinity bindings 111. Ott 112 
has evaluated the underlying mechanism by which these ligands produce 
their effects on the CCR7 receptor. The first six amino acids of the CCL19 
were successfully replaced with the equivalent residues of the CCL21 in 
order to measure the tendency of the chimeric ligand to stimulate and 
activate CCR7. The N-terminal of the CCL21 (SDGGAQ) were substituted 
with identical N-terminal domain of CCL19 (GTNDAE) and resulted in 
activation of the CCR7 receptor 112. Sasaki 113 investigated the antagonist 
properties of the deleted N-terminal of the CCL21 ligand. The few 
modifications in the amino acids at the N terminal are reported to have 
resulted in significant changes. Truncation of the pyroglutamate residue at 
the N terminus of the CCL21 results in nearly 50-fold decrease of agonistic 
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activity on monocytes. Removal of the first two amino acids resulted in nearly 
entire loss of the activity. However, the activity is recovered when further 
deletion is obtained 113. Site-directed mutagenesis studies by Ott 114 have 
identified two residues in the CCR7 receptor , Lys3.33 (137) and Gln5.42 
(227) (the two numbers given for each residue represent the transmembrane 
domain (TMD) and the number of the residue in the helix respectively) as an 
important residues for binding with CCL21 ligand, (Figure 11). Site-directed 
mutagenesis is a technique used to create specific, targeted modifications in 
amino acids. The technique used to generate specific change in the amino 
acid sequence of the receptor or ligand to understand the significance of 
specific amino acid in binding. Normally, alanine amino acid is used to 
replace other amino acids because it is not bulky and chemically inert 
(unable to make bonds) 114. 
 
Figure 11 Schematic diagram of CCR-7 receptor shows mutated residues in black 
colour and most conserved amino acids are shown in grey colour. The residues 
were replaced with alanine amino acid which is chemically inert. The binding affinity 
with the ligand of each mutated residue was assessed using binding assay. 114. 
Ott 111 in a different study also showed the crucial effect of the N terminus as 
both responsible for the high attraction of the ligand binding and receptor 
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activity. The side chain of these residues, Asn3, Asp4, and Asp7, are 
important for high-affinity binding of CCL19 to CCR7, while the acidic amino 
acids Glu6 and Asp7 were shown to have a significant effect on agonist 
activity 111. Otero 115 have further demonstrated that the Ser/Thr motif at the 
tip of the intracellular tail of the CCR7 receptor is essential for binding and 
activation 115. CCL19 and CCL21 are both activators for the CCR7 receptor 
that promotes the ERK1/2 mitogen-activated protein kinase signalling 
pathway. CCL19 promote phosphorylation by 4-fold more than CCL21. Site-
directed mutagenesis of the CCL19 has been used to determine the residues 
which are responsible for inducing phosphorylation. Replacing specific 
residues with alanine, it was shown that Thr-373–376 and Ser-378 are 
essential for CCL19-receptor phosphorylation, whereas amino acids serine 
356, 357, 364, and 365 are crucial for basal receptor phosphorylation by 
protein kinase C (PKC) 116. CCL21 seems to be found in all interactions with 
CCR7, which makes it the primary ligand involved in all metastasis of solid 
tumour to lymph nodes. Love 84 solved the solution structure of CCL21 and 
identified its oligomeric state, and specified CCL21 amino acids putatively 
participated in binding to the N-terminus of CCR7 using nuclear magnetic 
resonance spectroscopy (NMR). The figure below shows the solution 
structure of the residues 8-70 of CCL21 with its unsaturated N-terminus 
linked by the N-loop, a three-stranded β-sheet, α-helix and unstructured C-
terminus (Figure 12A). The figure also shows the chemical shifts mapping 
onto the surface of CCL21 which indicates the regions responsible for CCR7 
binding (Figure 12B). Chemical shift mapping or perturbation is an 
experimental technique used to determine the binding affinity site between 
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ligand and receptor using NMR spectroscopy. Chemical shifts are peaks 
obtained in NMR due to the change in energy resulted from binding between 
ligand and receptor in specific region. If there is no binding affinity between 
ligand and the receptor, there will be no chemical shifts. CCL21 ligand was 
titrated with CCR7 peptide (responsible for binding with the ligand) and the 
chemical shifts were monitored by NMR spectroscopy 84. 
 
Figure 12 Solution structure of CCL21 using NMR spectroscopy. (A) CCL21 
solution structures (B) Chemical shift mapping onto the surface of CCL21 which 
suggests binding site responsible for binding with the CCR7 receptor. Dark blue 
indicates region with high chemical shift perturbations or high binding affinity to the 
receptor while regions in light blue and white have less binding affinity and no 
binding affinity to the receptor respectively. 84. 
1.6.4. Discovery of a lead CCR7 receptor antagonist. 
In the early 80’s, cytokines were isolated which allowed immune cells to 
communicate between each other and destroy pathogens. They have been 
identified and validated as potentially drugable and can be antagonised by 
small molecules 117. Although cytokines such as interleukin 1 (IL-1) and 
tumour necrotic factor (TNF) as proinflammatory were first defined as good 
targets, few molecules have been discovered which have the ability to block 
these receptors 117. Also the number of small molecules that were detected 
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as blockers for the growth factors in the past was very few. Most of these 
antagonists which block pro inflammatory cytokines are peptide based 
antagonist or monoclonal antibodies. This gave the perception that the 
chance of discovering a small molecule that antagonises chemokine 
receptors was very slight. However, nowadays the vast majority of the 
companies and academics undertake research on chemokines focus on 
small molecules that inhibit or block these receptors. Because the chemokine 
receptors belong to the G-protein-coupled receptors (GPCRs), they possess 
the best targets for therapeutic interference amongst the other receptors. 
The GPCRs are widely spread throughout the human body and are involved 
in many different types of diseases. Chemokines are very important targets 
for drug development due to their roles in different disease like functions in 
acute and chronic inflammation, HIV and lately in cancer. Fortunately, in the 
past six years the number of patents for small molecule inhibitors has 
increased quickly due to involvement of these chemokines in HIV 
progression. The majority of these antagonists contain piperidine, piperazine 
quaternary nitrogen or bicyclam groups with two or more aromatic rings 118. 
The similarity in the chemokine inhibitor structures could be a result of the 
availability of the highly conserved binding pocket within the transmembrane 
region. The structure similarity of the antagonists gives a clear indication of 
the structure similarity of chemokine receptors. Because chemokine 
receptors are GPCRs, they are closely related to other classes of GPCRs. 
Some of these blockers might cross-react with several biogenic amine 
receptors. For instance a small molecule piperazine based structure which 
inhibits chemokine receptor CCR5 is found to cross-react with muscarinic 
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acetylcholine receptors. Also, The CCR2 spiropiperidine based structure 
antagonist was detected to have an effect on 5-HT1A receptors. Blocking the 
CCR7 receptor with antagonist can inhibit migration of cancer cells to their 
common destination 40. Glycosaminoglycan (GAG) is believed to be the most 
important target that plays an important role in the spatial distribution of 
chemokines. The binding site of GAG with chemokine ligands is called 
heparan sulfate which make the chemokine ligands available for the CCR7 
receptor. Even though chemokines have high structural similarity with each 
other, there are differences in the specific GAG binding sites between 
chemokines that are not conserved amongst the classes. Thus interfering 
with the crucial interaction, between chemokines and GAGs, is maybe one 
intervention point for inhibition of the system 119. The other possible strategy 
that inhibits the chemokines effect is by targeting chemokine receptor 
complex downstream signalling which leads to cell survival and migration 120.  
In order to identify a CCR7 receptor antagonist, the structure of the receptor 
has first to be modelled using a homology modelling. The accuracy of the 
structural characterization of the chemokine receptor CCR7 is essential to 
understand and determine the binding of the receptor with its ligand. 
Homology modelling is a technique used in this study to create 3D structure 
of the human chemokine receptor CCR7 based on availability of 3D model of 
similar protein structure, this work was carried out with help from Professor 
Colin Fishwick at the University of Leeds. The homology model of CCR7 
receptor was built from bovine rhodopsin GPCR-7TM. The CCR7 primary 
sequence was initially aligned to the bovine rhodopsin sequence (PDB code 
1U19) and CXCR4 both of which belong to the GPCRs family of proteins. 
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Each homology model was subjected to Maybridge screening library, and the 
top-scored ligands were chosen for in vitro screening. The top selected hits 
obtained from the modelling were tested by using calcium flux assay, this 
work was conducted at the University of Bradford by Dr Victoria Vinader. 
However, none of these molecules were active against CCR7 receptor. At 
this stage, survey of the literature was undertaken and we found a patent, in 
which a method for assessing ligand affinity for the CCR7 receptor was 
revealed 121. The patent described methods for screening for therapeutic 
compounds valuable in the treatment of CCL21 mediated and CCR7 
receptor mediated disorders. To demonstrate the application of the method, 
the patent describes two compounds which bind to the CCR7 receptor and 
prevent binding of CCL21 ligand. One of these, compound 1 (ICT5189) was 
amenable to chemical synthesis (Figure 13).  
 
Figure 13 lead compound 1 (ICT5189) as described in the literature 
The method described in the patent does not reveal if compound 1 is an 
agonist or an antagonist, so we decided to prepare this compound and 
assess its activity in a calcium flux assay. As will be discussed shortly, the 
molecule was successfully synthesised (see chapter 2) and was shown to be 
an antagonist of CCR7. Hence, the molecule was taken as a lead compound 
and different analogues were then synthesised to study the structure activity 
relationship of the desired molecule. 
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1.7. Aims and Objectives 
As discussed in this section the CCR7 receptor is involved in promoting and 
regulating cancer cells metastasis toward lymph nodes. Therefore the aim of 
this project is to prepare a novel CCR7 chemokine receptor antagonist using 
ICT5189 as a lead to reduce cancer progression and metastasis. 
This will be achieved as follows: 
1. Synthesis of novel analogues of ICT5189, a compound identified as 
having CCR7-binding potential. 
2. Characterisation of CCR7 expression in a panel of cell lines to identify 
a suitable cell line for antagonist screening using immunodetection 
techniques such as Western blot and flow cytometry 
3. Development & validation of assays to evaluate the novel compounds 
including calcium flux assay and under agarose assay. 
4. utilisation of the assays developed & validated in 3 to screen for 
CCR7 anatgonistic activity of the novel analogues & develop improved 
analogues based on SAR information 
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2. Chapter 2: Synthesis of CCR7 receptor antagonists. 
 
 
 
 
 
 
 
 
 
  
39 
 
2.1. Introduction 
We described in chapter 1 the origins of compound 1, ICT5189, as a lead. To 
confirm that compound 1 not only binds to the receptor CCR7 but that it can 
also antagonise it, we set out to synthesize and pharmacologically 
characterise it. Note that the lead optimisation described in this chapter 
involves synthesis of the compounds followed by determining the value of 
antagonist potency using a calcium flux assay. These values inform the next 
cycle of synthesis and so in this chapter, IC50 values for antagonist activity of 
compounds are given. However, methods for biological testing and the 
related discussions are given in chapter 3. 
2.2. Synthesis of compound 1, ICT5189.  
A retrosynthesis of the lead compound 1 is proposed below (Scheme 1). We 
envisaged that compound 1 can be synthesised from reductive amination 
between aldehyde 2 and 6-amino-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide, 
3, which in turn can be prepared from  2-aminophenol, 4. 
 
Scheme 1 Proposed retrosynthesis of compound 1 
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2.2.1. Synthesis of compound 3, ICT5888  
The preparative work begun with the synthesis of compound 5, ICT13001, 
using a route described in the literature, 121 by condensation of 2-
aminophenol 4 with chloromethanesulfonyl chloride 6 (Scheme 2). The 
electrophilic sulfonyl group is attacked by the lone pair of electrons on the 
nitrogen atom to initially form intermediate sulphonamide 7. The second step 
was a cyclisation that involves the addition of strong base, K2CO3, in 
methanol. Under these conditions, the hydroxyl group was deprotonated and 
the corresponding nucleophilic phenoxide anion displaces the chloride to 
afford compound 5 in 60% yield. 
 
Scheme 2 condensation and cyclisation step mechanism 
The product from this reaction was purified by flash column chromatography 
on silica gel and analysed by mass spectroscopy to confirm cyclisation and 
displacement of the chlorine atom. Proton and carbon NMR was also used to 
confirm molecular structure. The two single peaks at 10.59 ppm and 5.20 
ppm in proton NMR represent hydrogen atoms in NH and CH2 respectively. 
Hydrogen atom of the NH is de-shielded and its resonance frequency rose to 
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give signal appearing downfield. The de-shielding effect of hydrogen atom is 
a result of the sulfonyl group which has high electronegativity. Chemical 
shifts obtained centring at 6.83 ppm and 7.07 ppm correspond to aromatic 
hydrogen atoms at positions 6 and 7, and positions 5 and 8 respectively.  
Also 13C NMR shifts at 141.91 ppm, 127.09 ppm and 76.39 are assigned for 
quaternary ArC-O, ArC-N, and CH2 respectively. Chemical shifts at 123.5 
ppm are assigned for C-6 and C-8, and shifts at 119.9 ppm and 118.1 ppm 
are assigned for C-5 and C-7 respectively. The proton and 13C data were in 
agreement with previously published data 122. The compound was sent to 
mass spectroscopy for characterization and gave a peak at 186.83 which 
represent the [M+H]+ ion. The next step in the preparation was to form azo 
compound 8, ICT13003 using aniline 9 as a building block. This involves a 
coupling between diazonium salt 10 and aromatic sulphonamide 5. To form 
the diazonium salt, concentrated hydrochloric acid was added dropwise to 
the stirred solution of aniline 9 and sodium nitrite in water (Scheme 3). The 
diazonium ion was formed as a result of the reaction between nitrous acid, 
(generated in situ from hydrochloric acid and sodium nitrite), and aniline, 
according to the mechanism shown in Scheme 3. 
 
Scheme 3 mechanism of dizonium salt formation 
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The resulting diazonium salt 10 is used immediately for the next reaction due 
to its instability. Diazonium salts tend to be unstable in presence of water and 
temperatures higher than 10 ˚C, and decompose to form nitrogen gas. The 
azo compound 8 was formed by adding freshly prepared solution of 
diazonium salt 10 to a solution of compound 5 and K2CO3 in MeOH. The 
mixture was filtered and the filtrate was purified by chromatography on silica 
gel to give compound 8 in 31 % yield as a dark red-brown solid (Scheme 4). 
 
 
Scheme 4 Mechanism of compound 8 formation 
As shown in the proposed mechanism (Scheme 4), the azo bond is formed 
on the carbon atom which is in the para position to the NH atom, as this is 
the position favoured electronically under reaction conditions (vide infra). 
Presumably, whilst sulfonylamino group is not as electron donating as the 
oxygen atom, under basic reaction conditions it is deprotonated so it 
becomes more electron donating than oxygen. Hence the electrophilic 
substitution occurs at the position para to the nitrogen rather than the 
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position para to oxygen. The newly formed azo compound was submitted for 
the proton and carbon NMR and mass spectrum to confirm its formation. 
Peak obtained at 1H NMR δ 11.28 ppm represent the hydrogen atom at NH 
and peaks at 7.86 ppm, 7.59 ppm represent hydrogen atom at 
phenyldiazene. Chemical shifts obtained centring at 7.67 ppm, 7.56 ppm and 
7.00 ppm correspond to aromatic hydrogen atoms at positions 7, 8 and 5 
respectively. Also 13C NMR shifts at 147.1 ppm 129.9 ppm 79.4 ppm are 
assigned for quaternary ArC-O, ArC-N, and CH2 respectively. 13C NMR shifts 
at 143.5 ppm and 117.8 ppm are assigned to C-6 and C-7 respectively, and 
shifts at 119.0 ppm and 108.1 ppm are assigned for C-8 and C-5 
respectively. However, because the signals in the aromatic region of the 
NMR spectra were complex, it was not possible at this stage to confirm the 
position of the azo substitution.  
The last step in the synthesis of compound 3 was catalytic hydrogenation of   
the azo compound 8, to form the required aromatic amine 3. The reaction 
was carried out in ethanol with platinum oxide added as a catalyst. The 
reaction mixture was stirred overnight under hydrogen gas. The resulting 
product was purified by flash column chromatography on silica gel to afford 
compound 3 in 38 % as a light brown solid (Scheme 5).  
 
Scheme 5 Last step in synthesising compound 3 
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The newly installed NH2 was identified using infra-red spectrum with two 
bands appeared around 3394 cm-1 and 3345 cm-1. The NH2 group was also 
identified by proton NMR as a broad peak at around 5.07 ppm.  At this stage, 
we wanted to prove that the substitution of amine was at position C-6 as 
proposed in Scheme 4, and not on C-7. To illustrate successful synthesis of 
the desired compound, we used cambridgesoft’s ChemDraw ultra v 12 
software to simulate the chemical shifts of both possible substitutions and 
compare it to the NMR spectrum of the compound we obtained. Figure 14 
below shows three different spectra. The two spectra to the right side of the 
picture are predicted by chemdraw software which represent para (C-6) and 
meta (C-7) substitution of the amine group. The spectrum at the left side 
represent the aromatic region of compound 3. In the case of substitution at 
C-6, the predicted proton chemical shift of H-5 and H-7 appeared upfield and 
close together (5.94 and 5.93 ppm), and proton chemical shifts of H-8 
appeared downfield (6.27 ppm) due to the effect of amine substitution, which 
is an electron donating group. Although the actual values of chemical shift 
are different, this pattern closely resembles the actual chemical shifts in 
compound 3 where proton chemical shift of H-5 and H-7 appeared upfield 
and close together (6.22 and 6.26 ppm), and proton chemical shifts of H-8 
appeared downfield (6.54 ppm) In contrast, when amine group is substituted 
at C-7 position, predicted proton chemical shifts of H-5, H-6 and H-8 are all 
different. 
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Figure 14 comparison between aromatic proton chemical shifts of compound 3, and 
simulated spectra of 6- and 7-substituted amino 1H-benzo[e][1,3,4]oxathiazine 2,2-
dioxide. 
The synthetic route to compound 3 using the literature process was 
successful, although difficulties were experienced in making the azo 
compound 8, as it is not stable. In addition to this, extensive purification was 
required during the synthesis and yields in general were not satisfactory. 
Therefore, we devised an alternative synthesis of compound 3 by the direct 
nitration of compound 5 to yield compound 11, ICT13031 (Scheme 6).  
 
 
Scheme 6 Synthesis of compound 3 in different pathway.  
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The required nitro-compound was successfully made by the addition of a 
mixture of glacial acetic acid and one equivalent of 70% nitric acid to a 
solution of compound 5 and sodium nitrite dissolved in glacial acetic acid. 
The amount of nitric acid was found to be critical, as any excess of the nitric 
acid will afford a compound with two nitro groups at para positions to NH and 
O atoms (C-6 and C-7). The nitration step also yielded an isomer of 11 
where the nitro was substituted at C-7 (the para position to oxygen), 
nevertheless, the desired compound 11 could be isolated by chromatography 
in sufficient quantity for us to complete the synthesis of compound 3. 
Catalytic amount of palladium on charcoal was added to the compound 11, in 
ethyl acetate under hydrogen atmosphere to afford the desired amino-
compound 3 cleanly and in good yield (Scheme 7). 
 
 
Scheme 7 Reduction of the compound 11 to give compound 3. 
2.2.2. Synthesis of Aldehyde, 2. 
With compound 3 at hand, we set out to prepare aldehyde 2. The 2-position 
of oxazole is chemically sensitive, so we decided to start from commercially 
available protected aldehyde 12 as starting material and react this aldehyde 
with a Wittig reagent, (Scheme 8). 
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Scheme 8 synthesis of compounds 13 and 14. 
Wittig reagents are very important in chemistry especially in making alkenes. 
The synthesis of compounds 13, ICT13040 and 14, ICT13041 was started by 
refluxing the protected oxazole 12 with commercially available phosphorane 
15, the reaction mechanism is explained in Scheme 9. The phosphorane 
attacks the carbonyl atom and initially yields a betaine intermediate which 
undergoes ring closure to form cis or trans oxaphosphetane intermediate that 
breaks down to yield the corresponding cis and trans alkene and 
triphenylphosphine oxide. 
 
Scheme 9 reaction mechanism of coupling Wittig reaction with aldehyde 
In this reaction, two isomers were obtained with, E, 13 and Z, 14 geometry, 
after purification using flash chromatography (1:9 EtOAc:PE). The 
assignment of the geometric isomers was done by 1H NMR coupling 
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constants of trans isomer which are higher than the coupling constants of cis 
isomer (Scheme 10).  
 
Scheme 10 chemical shifts and coupling constant of isomers 13 and 14 
The synthesised aldehyde 13 and amine 3 were then coupled together. 
Compound 13 and compound 3 were dissolved in ethanol and stirred 
overnight at room temperature in order to make imine 16 (Scheme 11). The 
imine formed was then reduced under hydrogen in the presence of platinum 
oxide to facilitate reduction of the double bond. The reduction step was 
successfully achieved, and confirmed by 1H and 13C NMR analysis as well as 
mass spectrum, to form compound 17, ICT13042. 
 
Scheme 11 Synthesis diagram of compound 17. 
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Proton chemical shifts obtained at 3.06 ppm, 2.72 ppm and 1.88 ppm 
represent hydrogen atoms at propyl amino carbons. Carbon-13 chemical 
shifts at 30.92 ppm, 29.69 ppm and 23.07 ppm confirmed formation of propyl 
amino carbons. Mass spectrum was also obtained showing a peak at 466.7 
which corresponds to the [M+H]+ ion. Isomer 14 was also coupled with 
compound 3 and reduced in a separate reaction and was found to give the 
same result obtained from isomer 13. The final step in the synthesis is the 
deprotection of the triisopropylsilane group. The protection group was 
removed by dissolving compound 17 in tetrahydrofuran (THF) and treatment 
with a solution of tetra-butyl ammonium fluoride (TBAF) in THF for 10 to 15 
minutes at room temperature under nitrogen atmosphere (Scheme 12). 
 
Scheme 12 De-protection step of compound 1. 
The completion of the reaction was monitored by thin layer chromatography 
(TLC). The reaction mixture was directly impregnated on silica and purified 
by flash chromatography to give compound 1 as dark brown solid. The 
formation of compound 1 was proved by proton and carbon NMR. A peak 
obtained at 7.86 ppm in proton NMR and 153.38 ppm in 13C NMR represent 
the hydrogen and carbon atoms at the 2-position of the oxazole ring in which 
the silyl protecting group was replaced by a hydrogen.  
The synthesised compounds, 3 and 1 were tested to check their activity as 
antagonists of CCR7 receptor using calcium flux assay. We found that both 
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compounds, 3 and 1 reduced the amount of fluorescence released from 
calcium flux assay with IC50 around 10±2.5 µM and 8.2±1.2 µM respectively. 
The results confirmed that both compounds, which were previously shown to 
bind CCR7, were antagonists. Compound 1 showed small enhancement 
against CCR7 receptor over compound 3 which is relatively insignificant. So, 
we concluded that the elongation at the amino side chain might not be 
important for activity. However, we decided to do further investigation by 
making different side chains elongated at the amine position. It was decided 
to determine if having sulphonamide as a different group at amino group side 
chain will improve the activity against CCR7 receptor or not, so we made 
compounds 18, ICT13081 and 19, ICT13088. The preparative work simply 
started by condensation of sulfonyl chloride with the primary amine. 
Compounds 18 and 19 where synthesised by dissolving compound 3 in 10 
ml of pyridine and the corresponding sulfonyl chloride was then added at 0 
°C. The reaction mixture was left stirring at room temperature for six hours 
under nitrogen atmosphere and then was poured over ice and water. A solid 
was formed and collected by filtration, yielding the corresponding 
sulphonamides in very good yields (Table 1).  
 
Compound R Yield (%) 
18, ICT13081 
 
80% 
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19, ICT13088 
 
70% 
Table 1 amino side chain analogues as part of compound 3 SAR 
The synthesised compounds, 18 and 19 were tested to check their activity as 
antagonists of CCR7 receptor using calcium flux assay. Both analogues 
showed no enhancements in the activity with IC50 values around 12.6±2.1 
µM and 11.6±3.0 µM respectively compared to compound 3 which showed 
activity against CCR7 receptor with IC50 value around 10±2.5 µM. Therefore, 
we assured that the amine tail side chain is not important for activity against 
CCR7 receptor. Taking into account the difficulties and time consuming of 
synthesizing compound 1, It was decided to continue on using compound 3 
as our lead compound to investigate structure activity relationship. We then 
wanted to make sure if the amino group (NH2) is important for activity or not. 
We tested compounds 5 and 11 where the amine group was replaced with 
hydrogen and nitro group respectively. The activity of compound 5 was lost 
against the CCR7 receptor which indicated that the amine group of 
compound 3 itself is crucial for activity, removal of this group has lost the 
activity with IC50 ˃10 µM (9.6% inhibition at 14.2 µM), Appendix I. 
Compound 11 was also tested using full dose dependant response and 
again the activity was dropped with IC50 around 16.4±3.0 µM. We concluded 
that whilst the chain elongation might not contribute to the activity, a polar 
group at position C-6 would. Table 2 summarizes IC50 values obtained from 
different analogues tested using calcium flux assay. 
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Compound IC50 
5, ICT13001 >10 µM (n = 3) 
1, ICT5189 8.2±1.2 µM (n = 4) 
18, ICT13081 12.6±2.1 µM (n = 3) 
11, ICT13031 16.4±3.0 µM (n = 3) 
19, ICT13088 11.6±3.0 µM (n = 4) 
3, ICT5888 10±2.5 µM (n = 4) 
Table 2 IC50 values of different compounds 
2.2.3. Synthesis of analogues of compound 3, ICT5888  
Following the biological evaluation of compound 3 as a weak CCR7 
antagonist, we set out to prepare different analogues of this compound in 
order to look for structure activity relationships and gain access to more 
potent antagonists of the CCR7 receptor. We decided to first look at three 
key structural features of the molecule: the role of NH, the role of sulfonyl 
group and the cyclic ring (Scheme 13). To assess the significance of the NH, 
we decided to make compound 20, ICT13047 in which the NH was replaced 
by an NMe. To assess the significance of the sulfonyl, we decided to make 
amide 21, ICT13008 and to assess the role of the ring, to make the ring 
opened compound 22, ICT13029. The activity of the resulting derivatives 
would then be evaluated against CCR7 receptor and compared to that of 
compound 3, by calcium flux assay. 
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Scheme 13 Proposed synthesis of compound 3 analogues 
The preparative work towards compound 20 started with a methylation step, 
which involved the addition of a methyl group to the nitrogen atom of the 
sulphonamide group. As illustrated in the Scheme 14 below, methyl iodide 
and potassium carbonate were added to a solution of compound 5 in 
acetone. The resulting mixture, was stirred at room temperature for 24 hours 
under nitrogen. The mixture was then filtered and purified by flash column 
chromatography on silica gel to afford compound 23, ICT13006 as white 
solid material. The compounds were characterised by proton and carbon 
NMR as well as mass spectrum. A new peak correlating to 3 hydrogens 
appeared in the proton NMR at 3.19 ppm, confirmed the introduction of an N-
methyl group.  Also a peak at 32.0 ppm in the carbon NMR represents the 
newly added methyl group. The next step to prepare compound 20, was 
nitration of compound 23 at para position to nitrogen. Compound 23 was 
exposed to the same nitration conditions utilised when synthesising 
compound 11. However, the nitration produced a complex reaction mixture 
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which was very difficult to separate by flash column chromatography 
(Scheme 14). 
 
 
Scheme 14 N-methyl synthesis pathway. 
Alternatively, it was decided to carry out the reaction the other way around, 
which is, to methylate compound 11, instead of nitrating compound 23 
(Scheme 15). Known amount of iodomethane was added dropwise to a 
solution of compound 11 dissolved in acetone in presence of potassium 
carbonate and the mixture was stirred overnight. The mixture was filtered, 
and the reaction mixture was purified by flash chromatography on silica gel 
to yield compound 24, ICT13046 as a yellow solid. Compound 24 was then 
reduced in presence of palladium on charcoal under hydrogen gas to yield 
compound 20, ICT13047.  
 
 
Scheme 15 Synthesis procedure of compound 20 
Our next synthesis plan was to prepare the carboxamide analogue of 
compound 3, nitration of commercially available cyclic amide 25, ICT13007 
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gave two positional isomers. As illustrated in the scheme below, compounds 
26, ICT13004 and 27, ICT13011 were synthesised by addition of a mixture of 
concentrated glacial acetic acid and nitric acid to a solution of 2H-benzo-
oxazin 25 dissolved with sodium nitrate in glacial acetic acid, (Scheme 16) 
123. 
 
Scheme 16 Synthetic pathway of compounds 26 and 27.  
The two isomers were separated by flash chromatography on silica gel and 
their structure was confirmed by proton and carbon NMR. The major product 
was assigned as the 6-nitro derivative compound 27,  because the hydrogen 
signal from position 6 in compound 25 had disappeared, due the hydrogen 
being substituted. The minor product was assigned as the 7-nitro derivative 
compound 26,  because the hydrogen signal from position 7 in compound 25 
had disappeared, due the hydrogen being substituted with the nitro group to 
give compound 26. In both cases, mass spectrometry confirmed the 
molecular ion mass for the proposed structure. Compounds 26 and 27 were 
reduced under hydrogen atmosphere to give the corresponding amino 
compounds and the compounds were assessed for biological activity. The 
desired isomer, compound 26, where the nitro group is at position 7 was 
obtained in lower yield compared to isomer 27, where the nitro substitution is 
at position 6. Also, as the reaction was scaled up, there was more of the 
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undesired isomer. In addition, purification of the two isomers was also an 
issue, as isomers share similar retention times on TLC, which made the 
mixture difficult to separate. Therefore, an alternative synthetic procedure 
that was devised that enables only the synthesis of the desired isomer. As 
illustrated below, sodium bicarbonate was added to a solution of 
commercially available 2-amino-5-nitro phenol 28 in acetonitrile which was 
stirred under reflux (Scheme 17). 2-Chloroacetylchloride 29 was then added 
dropwise and was left stirring on ice bath for 40 minutes. The reaction 
mixture was then refluxed on an oil bath for 2 h to form compound 26, which 
was then purified by recrystallization as brown solid 124.  
 
 
Scheme 17 Synthetic pathway of compound 26.  
Proton NMR chemical shifts of compound 26 was identical with proton NMR 
chemical shifts of the compound which was synthesised by direct nitration of 
compound 25. Mass spectrum was also obtained with a peak at 195.09 
which is for (M+H)+. The nitro group substituent in compound 26 and 27 was 
reduced under hydrogen atmosphere in presence of palladium on carbon as 
a catalyst to yield compounds 21, ICT13008 and 30, ICT13010 respectively, 
(Scheme 18). The signals observed by proton NMR at 4.87 and 4.89 ppm 
represent newly introduced amine for compounds 21 and 30 respectively.  
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Scheme 18 Synthetic pathway of compound 21 and 30.  
In purpose of making more analogues of the cyclic amide compound, both 
isomers, compounds 21 and 30 were then coupled with benzaldehyde 31 to 
give imines 32 and 33 respectively (Scheme 19). The nucleophilic addition 
reaction starts by condensation of aromatic primary amine and aldehyde to 
form imine. Small quantity of reaction mixture was analysed by proton NMR 
to characterize formation of imine in both compounds 32 and 33. 
 
Scheme 19 synthetic pathway of compound 32 and 33.  
Hydrogen atoms at imine moiety was used to characterise the formation of 
the compound. Peaks obtained from proton 1H NMR at 8.66 ppm and 8.64 
ppm corresponds to the hydrogen atom of imine, of compounds 32 and 33 
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respectively. The C-N double bond in compounds 32 and 33 was then 
reduced by sodium borohydride as reducing agent. The solution of both 
isomers were separately dissolved in anhydrous ethanol and treated with 
sodium borohydride, to give compounds 34, ICT13012 and 35, ICT13016 as 
brown solids (Scheme 20).  
 
Scheme 20 Synthesis of compounds 34 and 35. 
The appearance of a new CH2 group peaks at 4.20 ppm and 4.30 ppm in the 
proton 1H NMR of compounds 34 and 35 respectively confirms the 
successful synthesis of the molecules which were tested as CCR7 receptor 
antagonist by calcium flux assay.  
Our next structure activity relationship study was to assess the relevance of 
the oxathiazine cyclic ring in the potency of the compounds. In particular, 
would equivalent acyclic compounds retain activity, or is the ring essential for 
potency? So a number of different analogues were made. A methoxy group 
replaced O-CH2- portion of the ring, and different compounds with different 
sulphonamide substituents were made and assessed for their biological 
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activity. Compound 22, ICT13029 was made by addition of methanesulfonyl 
chloride 36 to a solution of 2-methoxy-4-nitroaniline 37 dissolved in 
anhydrous pyridine (Scheme 21). After the addition was over, the solution 
was stirred for 5h at room temperature and then poured over ice and water. 
Solid was formed and then was recrystallized from acetone-hexane to give 
compound 38, ICT13019 as yellow crystals. Compound 38 was reduced 
under hydrogen in the presence of catalytic amounts of palladium on carbon 
over 24 hour at room temperature to give compound 22, ICT13029. The 
proton and carbon NMR of SCH3 group was detected at 3.31 ppm and 43.4 
ppm respectively. Mass spectrum was also used and obtained at 217.0 
which is for (M+H)+ which proves formation of the analogue. 
 
 
Scheme 21 Synthesis pathway of compound 22 
The synthesised compounds were tested and compared with our lead 
compound 3 to check their activity as antagonists of CCR7 receptor using 
calcium flux assay. Results obtained indicated the importance of NH 
substitution for the activity of this series of compounds. Methylation of the N 
atom in presence and absence of amine group exemplified by compounds 20 
and 23 respectively has reduced the efficacy as antagonists of CCR7 
receptor with IC50 ˃10 µM (26% and 15% inhibition at 14.2 µM respectively). 
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So, we thought that the NH position should not be substituted to retain its 
activity. The first synthesised amide analogue was compound 21 which was 
tested and compared to compound 3. The activity of compound 21 was lost 
with IC50 ˃10 µM (11% inhibition at 14.2 µM) compared to compound 3 which 
showed activity with IC50 around 10±2.5 µM (44% inhibition at 14.2 µM). This 
reflects the importance of having sulphonamide group at this position in order 
to elicit antagonistic activity. We tried to make different analogues of 
compound 21 just to check if the activity will increase or not. Compounds 30, 
34 and 35 were all made in purpose of making sure the activity we saw 
previously is related to the cyclic sulphonamides. The activity of these 
analogues were lost as a result of changing the cyclic sulphonamide group to 
amide. All of these analogues were analysed with IC50 value higher than 10 
µM (8%, 9% and 17% inhibition at 14.2 µM respectively). The activity was 
lost obviously due to the lack of sulphonamide group at compound 21 
compared to compound 3 which altered the nature of interaction between 
compound and receptor. So, based on these findings we can conclude that 
in this cyclic series, the sulfonyl group is important for the activity of the 
molecules. Interestingly compounds 38 and 22 were tested and showed 
comparable effect to compound 3. Compound 38 which has nitro group 
showed 39% inhibition at 14.2 µM with low solubility in aqueous medium. 
However, Compound 22 showed activity with IC50 around 11.6±1.3 µM (40% 
inhibition at 14.2 µM) which is comparable to compound 3 with better 
solubility. We decided to make more of the open chain sulphonamides 
analogues which are considerably easy to synthesise multiple derivatives.  
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Compound IC50 
20, ICT13047 >10 µM (n = 3) 
21, ICT13008 >10 µM (n = 3) 
22, ICT13029 11.6±1.3 µM (n = 3) 
23, ICT13006 >10 µM (n = 3) 
30, ICT13010 >10 µM (n = 3) 
34, ICT13012 >10 µM (n = 3) 
35, ICT13016 >10 µM (n = 3) 
38, ICT13019 >10 µM (n = 3) 
Table 3 IC50 values of compound 3 analogues 
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2.2.4. Synthesis of analogues of compound 22, ICT13029.  
Following the discovery that ring open compounds, for example compound 
22 are active, we started to prepare different analogues of this compound in 
order to investigate structure activity relationships and look for more potent 
antagonists of the CCR7 receptor. We decided to look at modifications to the 
main structural features of the molecule, as illustrated in Scheme 22.  
 
Scheme 22 Proposed synthesis of compound 22 analogues 
Our first structure activity relationship investigation in this synthesis plan was 
to assess the significance of sulphonamide group at position 1, we decided 
to convert it to amide. The activity of the resulting compound was evaluated 
against CCR7 receptor and compared to compound 3 by calcium flux assay. 
We explored the importance of having sulphonamide at position 1 by making 
compound 39, ICT13138 which was synthesised by Mr Nile Saunders as part 
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of his MChem project whilst in our research group and tested on calcium flux 
assay (Figure 15).  
 
Figure 15 Structure of compound 39  
The activity of this compound was compared with the activity of compound 
40, ICT13062 (synthesised below) which have the same structure but with a 
sulphonamide group at position 1 instead of a carboxamide. The activity of 
compound 39 was dropped with IC50 >10 µM (25% inhibition at 14.2 µM), 
however compound 40 showed activity with IC50 around 9.5±1.1 µM. this 
confirms the previous findings when we discussed the importance of having 
sulphonamide group on the cyclic compounds. We had previously shown 
that the activity of compound 3, which has a cyclic sulphonamide group, was 
recorded an IC50 around 10±2.5 µM; however the activity of compound 21, 
which has the cyclic amide group was dropped as shown previously. Both 
observations confirm the importance of having sulphonamide group over the 
amide group for CCR7 antagonism.  
Our next investigation plan was to assess the significance of the R group in 
NHSO2R, we decided to make different analogues starting from small 
aliphatic group exemplified by methyl and butyl group and then move on to 
try different aromatic groups like phenyl and methylbenzene group and then 
more lipophilic groups like tert-butylbenzene and biphenyl group. We 
prepared different analogues at position 1 where the sulphonamide group is 
attached, whilst keeping the methoxy group and amino group at position 2 
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and 4 respectively. This will enable us to directly compare SAR of different 
analogues. As illustrated below different compounds namely 41, 42, 43, 44, 
45, 46 and 47 were made and characterised by NMR and mass spectrum 
analysis (Table 4). 
 
Compound R Yield (%) 
38, ICT13019 CH3 82% 
41, ICT13018 CH2-Cl 90% 
42, ICT13022 Bu 70% 
43, ICT13060 CF3 78% 
44, ICT13021 
 
81% 
45, ICT13020 
 
62% 
40, ICT13062 
 
77% 
46, ICT13133* 
 
NS 
47, ICT13135* 
 
NS 
* These compounds were prepared by Mr Nile Saunders as part of his MChem project 
and are included here so that the role of the sulphonamides are more fully explained 
Table 4  N-(2-methoxy-4-nitrophenyl) sulphonamide derivatives 
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The successfully synthesised compounds in Table 4 were dissolved 
separately in ethanol and reduced using a catalytic palladium on carbon to 
yield the corresponding aniline derivatives. Table 5 below summarizes 
successfully reduced compounds namely 48, 49, 50, 51, 52, 53, 54, 55 and 
56 which were characterised by NMR and mass spectrum and then tested 
for their biological activities as antagonists of CCR7 receptor using calcium 
flux assay. 
 
Compound R Yield % 
22, ICT13029 CH3 85% 
48, ICT13036 Bu 89% 
49, ICT13063 CF3 89% 
50, ICT13035 
 
88% 
51, ICT13034 
 
83% 
52, ICT13070 
 
73% 
53, ICT13119* 
 
NS 
54, ICT13134* 
 
NS 
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Table 5 N-(4-amino-2-methoxyphenyl) sulphonamide derivatives.  
Following biological data analysis, we found that compound 40 has similar 
activity, with IC50 around 9.5±1.1 µM, to compound 3 which showed activity 
with IC50 around 10±2.5 µM. Unfortunately compound 40 with nitro group 
attached at position 4 was sparingly soluble in aqueous medium. Compound 
52 activity was improved with IC50 around 5.7±1.3 µM compared to the 
activity of compound 22 (IC50 around11.6±1.3 µM), this enhancement is due 
to substitution of tert-butylbenzene group at position 1 instead of methyl 
group. We decided at this point to keep this group at this position and further 
investigate the importance of other positions. Interestingly compounds 49 
showed significant activity against CCR7 receptor with IC50 around 1.7±1.5 
µM which may reflect increased acidity of the sulphonamide NH. Hence 
further investigation on the role of acidity of the NH on potency of 
compounds is merited. Most of the other synthesised compounds in this 
series were tested and showed no improvement in the activity compared to 
compound 3 (Table 6).  
 
55, ICT13137* 
  
NS 
56, ICT13136* 
 
 
NS 
* These compounds were prepared by Mr Nile Saunders as part of him MChem project 
and are included here so that the role of the sulphonamides are more fully explained. 
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Compound IC50 
38, ICT13019 >10 µM (n = 3) 
40, ICT13062            9.5±1.1 µM (n = 3) 
46, ICT13133 >10 µM (n = 3) 
47, ICT13135 >10 µM (n = 3) 
22, ICT13029           11.6±1.3 µM (n = 3) 
48, ICT13036 15.5±1.1  µM (n = 3) 
49, ICT13063 1.7±1.5 µM (n = 3) 
50, ICT13035            12.1±2.1 µM (n = 3) 
51, ICT13034       11.6±1.6 µM (n = 3)  
52, ICT13070 5.7±1.3 µM (n = 3) 
53, ICT13119 12.6±1.3 µM (n = 3) 
54, ICT13134 >10 µM (n = 3) 
55, ICT13137 >10 µM (n = 3) 
56, ICT13136 >10 µM (n = 3) 
Table 6 IC50 values of different compounds 
The next modifications were targeted towards the methoxy group at position 
2, whilst keeping the methylsulphonamide and nitro groups at positions 1 and 
4 respectively unchanged. The commercially available compound, 57, 
ICT13052 that has phenoxy group at position 2 was tested on our calcium 
flux assay and compared with the activity of compound 3. Compound 57 was 
then dissolved in ethanol and nitro group was reduced under hydrogen in 
presence of palladium on charcoal to give compound 58, ICT13050 
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(Scheme 23). Compound 58 was tested on calcium flux assay to assess the 
effect of substitution at methoxy position (see below). 
 
 
Scheme 23 Nitro-Reduction of compound 57 
Further to this investigation, we explored the importance of having other 
substitutions at positions 2 whilst keeping tert-butylbenzene group at position 
1 unchanged. Commercially available 2-amino-5-nitrobenzoic acid 59 was 
dissolved in methanol and treated with thionyl chloride and refluxed overnight 
to obtain the corresponding methyl ester, 60. The amine function in aniline 
compound 60 is considerably less nucleophilic due to the presence of two 
electron withdrawing substituents and this molecule was found not to 
undergo a reaction with sulfonyl chlorides using pyridine as base. Therefore, 
compound 60, ICT13064 was dissolved in tetrahydrofuran THF and treated 
with sodium hydride before addition of commercially available sulfonyl 
chloride, 61 to give compound 62, ICT13067 (Scheme 24). 
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Scheme 24 Synthesis of compound 62 and 63 
The methyl ester of compound 62 was then hydrolysed to carboxylic acid by 
reflux heating with a solution of sodium hydroxide for one hour to give the 
corresponding acid compound 63, ICT13074 (Scheme 24). Reduction of the 
nitro group at position 4 of the compound 62 was then carried out under 
hydrogen in presence of palladium on charcoal overnight to give compound 
64, ICT13089 (Scheme 25). 
 
 
Scheme 25 Reduction of compound 62  
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To assess the importance of having methoxy group at position 2 of 
compound 52 we have tested the commercially available compound 65, 
ICT13055, which has OH group at position 2 instead of methoxy group, using 
our calcium flux assay and compared its activity with the activity of 
compound 52 (Figure 16).  
 
Figure 16 commercially available compound 65 
The activity of different analogues which targeted methoxy group at position 
2 in calcium flux assay were determined. The substitution of methoxy group 
at position 2 with phenoxy group reduced the activity against the CCR7 
receptor. Hence, compounds 57 and 58 had IC50 around 15.1±2.4 µM and 
˃10 µM (4% inhibition at 14.2 µM) respectively. This is in comparison to 
compound 22 which showed activity against CCR7 receptor with IC50 around 
11.6±1.3 µM. Also, substitution of methoxy group with hydroxyl group has 
dropped the activity. Compound 65 has IC50 of 16.3±2.1 µM. This is in 
comparison with compound 52 which has methoxy group attached at position 
2, IC50 around 5.7±1.3 µM. this indicated the significance of methoxy group 
substituted at position 2 over the phenoxy or hydroxyl group. Substitution of 
methoxy group at position 2 with methyl ester exemplified by compound 62 
has increased activity against CCR7 receptor with IC50 around 3.4±0.9 µM. 
this is in comparison with compound 40 which has methoxy group 
substituted at position 2, and an IC50 of 9.5±1.1 µM. However, solubility of 
this compound, which have nitro group, in the aqueous medium is still an 
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obstacle to testing. Luckily, the solubility of compound 64 were enhanced 
yielding our first analogue with activity below 1µM, IC50 was around 0.8±1.0 
µM. 
Compound IC50 
57, ICT13052 15.1±2.4 µM (n = 3) 
58, ICT13050 ˃ 10 µM (n = 4) 
62, ICT13067 3.4±0.9 µM (n = 3) 
64, ICT13089 0.8±1.0 µM (n = 4) 
65, ICT13055 16.3±2.1 µM (n = 4) 
Table 7 IC50 values of different compounds 
For further investigation for the structure activity of compound 22, position 4 
was also substituted to explore the effect of this position on CCR7 receptor. 
We first introduced methoxy group at position 4 and compared it with 
compound 64. Compound 66, ICT13108 was made by making the 
corresponding methyl ester 67, ICT13093 of commercial available compound 
68 which was then treated with commercially available compound 61 to give 
compound 66 (Scheme 26). 
 
Scheme 26 synthesis of compound 66 
72 
 
Commercially available 4-bromo-2-methoxyaniline 69 was dissolved in 
anhydrous pyridine, the reaction mixture was cooled down to 0 °C, and 4-
(tert-butyl) benzene-1-sulfonyl chloride 61 was added dropwise and was left 
stirring for 5h under nitrogen atmosphere. Diluted hydrochloric acid was 
added to the solution mixture to neutralize the base and then extracted with 
ethyl acetate to afford a crude material which was purified by flash column 
chromatography to give compound 70, ICT13122 as white crystals (Scheme 
27).  
 
Scheme 27 synthesis of compound 70. 
Compound 71, ICT13078, where no group on position 4 is present, was 
made by reacting 2-methoxy aniline 72 with 4-t-butylbenzenesulfonyl chloride 
61, same method mentioned previously (Scheme 28). If the IC50 of the 
compound was increased, which means the efficacy was reduced, this will 
give a clue that substitution at this position is important to make interaction 
with the function group of the amino acid of the receptor.  
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Scheme 28 synthesis of compound 71. 
We then attempted to prepare an analogue with a methyl ester at position 4. 
4-amino-3-methoxybenzoic acid 73 was dissolved in methanol and the 
reaction mixture was treated with thionyl chloride dropwise and refluxed 
overnight. The resulting methyl ester 74, ICT13084 was then dissolved in 
pyridine and treated dropwise with 4-t-butylbenzenesulfonyl chloride 61 
dissolved in dichloromethane to give compound 75, ICT13069 (Scheme 29).  
 
Scheme 29 Synthesis of compound 75. 
We also made compound 76, ICT13113 which was simply synthesised by 
making the ethyl ester 77, ICT13111 of commercially available compound 73 
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which was then treated dropwise with 4-t-butylbenzenesulfonyl chloride 61 to 
give compound 76. 
Compound 75 was then hydrolysed to its corresponding acid by treating the 
parent ester with a solution of sodium hydroxide and heating under reflux for 
an hour to afford compound 78, ICT13072. Compound 75 was also reduced 
to alcohol. Compound 75 was dissolved in anhydrous THF and cooled down 
to -78 ˚C using dry ice and acetone bath. Lithium triethylborohydride (super 
hydride) in THF was added carefully and the resulting solution was left 
stirring for 5 hour under nitrogen atmosphere until the reaction was 
completed. The reaction was then warmed to room temperature and 
quenched with methanol and water and then was extracted with ethyl 
acetate. The resulting crude material was then purified by flash column 
chromatography to give compound 79, ICT13091 (Scheme 30).  
 
Scheme 30 synthesis of compounds 78 and 79  
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The methyl ester of compound 76 was further investigated and converted to 
amide to find out the effect of this substitution if it would change the efficacy 
of the compound or not. So, compound 75 was dissolved in ammonium 
hydroxide under nitrogen atmosphere and was left stirring at room 
temperature for 5 days. The reaction mixture was then extracted with ethyl 
acetate to give a crude material which was purified using flash column 
chromatography to give compound 80, ICT13092 (Scheme 31).  
 
Scheme 31 synthesis of compound 80.  
The synthesised compounds were tested to check their activity as 
antagonists of CCR7 receptor using calcium flux assay. The IC50 obtained for 
compound 66 was around 2.9±1.0 µM, which is poorer than that for 
compound 64 with IC50 around 0.8±1.0 µM. In compound 71 which has no 
substitution at position 4, the activity was lost against CCR7 receptor with 
IC50 around 31.9±3.2 µM. We concluded from this, that a substituent at the 4-
position is crucial for activity and its nature also impacts on potency. This 
was confirmed previously when testing the role of amine group of cyclic 
compounds 3. Compound 5 which has hydrogen atom instead of amine 
group has abolished the activity with IC50 >10 µM compared to compound 3 
which showed activity with IC50 around 10±2.5 µM. Substitution of position 4 
with bromine or amide exemplified by compounds 70 and 80, has shown 
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good activity against CCR7 receptor with IC50 around 1.0 µM. However, 
when carboxylic acid or benzyl alcohol was introduced, the activity was 
reduced. Compounds 78 and 79 showed activity with IC50 around 6.8±2.7 µM 
and 9.5±2.8 µM respectively. Interestingly, the most active compound was 
observed when the amine group was substituted with methyl ester or ethyl 
ester. Methyl ester substitution activity which is exemplified by compound 75 
was recorded with IC50 around 0.19±0.2 µM which represent significant 
improvement compared to our lead compound. Also compound 76 which is 
the ethyl ester of compound 75 showed comparable activity with IC50 around 
0.24±0.3 µM. Based on these findings, compound 75 was identified as our 
most active compound and its activity was confirmed using another in vitro 
assays, “agarose spot assay”, (see chapter 3) and also in scratch assay 
which was done within our research group. Table 8 below summarizes IC50 
values obtained from different analogues tested using calcium flux assay. 
Compound IC50 
66, ICT13108 2.9±1.0 µM (n = 3) 
71, ICT13078 31.9±3.2 µM (n = 3) 
70, ICT13122 1.0±0.9 µM (n = 3) 
80, ICT13092 0.8±0.9 µM (n = 3) 
78, ICT13072 6.8±2.7 µM (n = 3) 
79, ICT13091 9.5±2.8 µM (n = 3) 
75, ICT13069 0.19±0.2 µM (n = 4) 
76, ICT13113 0.24±0.3 uM (n = 4) 
Table 8 IC50 values of different compounds  
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The methyl ester at position 4 appears to be important for activity and its 
better than other substitutions so far. It is apparent that we no longer need 
the aniline functionality present in compound 52. So, it was decided to keep 
this ester group at this position and do more investigations. We prepared a 
number of ICT13069 analogues, where the sulphonamide moiety (NSO2R) is 
decorated with different substituents, while keeping the methoxy and the 
methyl ester groups unchanged. Table 9 below shows different analogues to 
compound 75 namely, compounds 81 and 82. 
 
Table 9  compound 75 analogues 
The analogues were made by addition of the corresponding sulphonyl 
chloride compounds to a solution of compound 74 in pyridine. The mixture 
was left stirring at room temperature for 5 hours. All compounds were 
purified using flash chromatography on silica gel to afford the analogous 81 
and 82. Compound 81 is further hydrolysed to its corresponding acid by 
treating the parent ester with a solution of sodium hydroxide and heating 
under reflux for an hour to afford compound 83, ICT13071 (Scheme 32).  
Compound R Yield % 
81, ICT13073 CH3 73% 
82, ICT13085 
 
89% 
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Scheme 32 synthesis of compound 83 
We mentioned earlier that compound 76, which is the ethyl ester of 
compound 75, also displayed similar activity obtained from biological results 
to compound 75 with IC50 around 0.24±0.31 µM. So, more substitutions to 
compound 76 at position 1 (NSO2R) while keeping the ethyl ester at position 
4 were prepared out and summarized in the table below which describes the 
synthesis of analogues 84, 85 and 86.   
 
Compound R Yield % 
84, ICT13114 
 
60% 
85, ICT13130 
 
96% 
86, ICT13126 
 
95% 
Table 10 compound 76 analogues 
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Because of similarity of enhancement of the activity which resulted from the 
elongation of the side chain of the methyl ester of compound 75, it was then 
decided that it might be worthy to elongate this side chain a bit more. Making 
the propyl ester of the compound or isopropyl ester could reach out the 
function groups at the receptor amino acids and interact with them. More 
substitutions illustrated in the table below namely analogues 87 and 88.   
 
Compound R Yield % 
87, ICT13143 
 
91% 
88, ICT13144 
 
85% 
Table 11 compounds 87 and 88 
The synthesised compounds were tested using our calcium flux assay. 
Substitution of tert-butylbenzene with methyl group (compound 81) reduced 
the activity of the compound tremendously. The activity of compound 81 was 
recorded with IC50 around 37.7±3.2 µM, this is in comparisons with 
compound 75 which showed activity with IC50 around 0.19±0.2 µM. We can 
conclude that the tert-butylbenzene is important for activity. Also compound 
83 which is the corresponding acid of compound 81 was tested and activity 
was dropped with IC50 around 74.4±4.0 µM. This reflects the significant of 
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methyl ester substitution group over the carboxylic acid group. This was 
confirmed previously when testing compounds 75 and 78. We compared the 
activity of methyl ester, ethyl ester and propyl ester of compounds 82, 84 and 
88, which all have the same substitution group at position 1 and 2, to check 
the importance of elongated ester at position 4. The activity of those 
compounds was reduced toward more elongated ester with IC50 around 
4.1±1.3 µM, 4.8±1.2 µM and 6.2±2.6 µM respectively, this was also proved 
when testing compound 75 and 76. Substitution of tert-butylbenzene of 
compound 76 with biphenyl group exemplified by compounds 86 has 
reduced the activity of the compound with IC50 around 5.2±1.2 µM. However, 
substitution with Dansyl chloride 85 group has shown to improve the activity 
of the compound. We think the activity of the compound has increased 
tremendously, the IC50 obtained from testing on calcium flux assay reached 
50nM which marks a significant enhancement in the activity. It is worth to 
mention that this molecule was synthesised at the very end of the project, so 
most of the in vitro assays (agarose and scratch assay) were taken place 
using compound 75. Table 12 below summarizes different IC50 values of 
different analogues. 
Compound IC50 
81, ICT13073 37.7±3.2 µM (n = 3) 
83, ICT13071 74.4±4.0 µM (n = 3) 
82, ICT13085 4.1±1.3 µM (n = 3) 
84, ICT13114 4.8±1.2 µM (n = 3) 
86, ICT13126 5.2±1.2 µM (n = 3) 
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85, ICT13130 0.05±0.1 µM (n = 4) 
88, ICT13144 6.2±2.6 µM (n = 3) 
Table 12 IC50 values of compound 75 analogues 
Our next synthesis plan was to investigate the significance of position 5, we 
first attempted to check the importance of having methoxy group at position 5 
instead of position 2 and compared it with compound 22 which has methoxy 
group at position 2. The commercial available compound 89, ICT13053 
(Figure 17) was tested on our calcium flux assay.  
 
 
Figure 17 structure of commercial available compound 89 
We next decided to make compound 90, ICT13068 and compare it with 
compound 66 to determine if any changes at that position 5 would affect the 
activity of this molecules against CCR7 receptor or not. We started with 
commercially available methyl 2-amino-4,5-dimethoxybenzoate 91, which 
was dissolved in anhydrous pyridine to this solution, solution of (4-tert-
butylbenzene)-1-sulfonyl chloride 61 in anhydrous dichloromethane was 
added and was left stirring at room temperature for 5 hours to give 
compound 90 (Scheme 33). 
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Scheme 33 synthesis of compound 90 
We also evaluated commercially available compound 92, ICT13123 to 
assess the importance of position 5 again by having carboxylic acid attached 
at this position in a compound where the sulphonamide group is reversed 
and has methoxy group at position 2. (Figure 18). Unlike the other 
compounds hitherto synthesised, compound 92 is a reverse sulphonamide. 
 
 
Figure 18 commercial available compound 92 
The activity of investigated position 5 analogues against CCR7 receptor was 
assessed using our calcium flux assay. The activity of compound 89, which 
has methoxy group at position 5, was compared with the activity of 
compound 22, which has methoxy group at position 2. We found that, the 
activity of compound 89 was reduced tremendously with IC50 value ˃10 µM 
(6% inhibition at 14.2 µM), however the activity of compound 22 was 
recorded with IC50 around 11.6±1.3 µM (40% inhibition at 14.2 µM). This 
indicates the importance of having methoxy group at position 2. The activity 
of compound 90 which has methoxy group at position 5 was directly 
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compared with the activity of compound 66. The activity of compound 90 was 
reduced with IC50 around 11.5±2.0 µM, however the activity of compound 66 
was recorded with IC50 around 2.9±1.0 µM. The activity was also lost with 
IC50 around 32.1±3.0 µM when position 5 of the reverse sulphonamide was 
substituted with carboxylic acid moiety, compound 92. We concluded from 
this investigation that substitution at, position 4 is favoured to potency, 
however further investigation is needed to confirm this since the range of 
compounds we used was limited. Table 13 below summarizes different IC50 
values of different analogues. 
Compound IC50 
89, ICT13053 ˃10 µM (n = 3) 
90, ICT13068 11.5±2.0 µM (n = 3) 
92, ICT13123 32.1±3.0 µM (n = 3) 
Table 13 IC50 values of different compounds 
The last stage in our structure activity relationship investigation was to 
synthesise reverse sulphonamides in which the nitrogen and sulphonyl are 
juxtaposed. The preparative work started by dissolving commercially 
available 2,4-dimethoxybenzene-1-sulfonyl chloride 93 in THF and 4-t-
butylaniline 94 was added to the solution and stirred under nitrogen for 5h. 
Diluted hydrochloric acid was added and the solution extracted with ethyl 
acetate. The crude material was purified by flash column chromatography to 
give compound 95, ICT13121 as white powder (Scheme 34).  
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Scheme 34 synthesis of compound 95. 
We then synthesised different analogues namely, compounds 96, 97, 98 and 
99   in purpose of investigating the importance of reverse sulphonamide as 
CCR7 receptor antagonist which is summarizes in the figure below. 
 
Figure 19 number of reverse sulphonamide analogues synthesised. * These 
compounds were prepared by Mr Nile Saunders, and $ These compounds were prepared by Mario 
Izidro as part of their projects and are included here so that the role of the sulphonamides are more 
fully explained. 
We also tried to have methyl ester at position 2 instead of methoxy group, 
compound 100, ICT13147 was synthesised by Mr Mario Izidro as part of his 
master project (Figure 20). 
 
Figure 20 Structure of compound 100.  
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The synthesised analogues were tested using our calcium flux assay and 
compared with the most active compound, 75. Compound 97 showed a 
significant improvement in activity with IC50 around 0.10±0.3 µM compared to 
sulphonamide compound 40 (IC50 around 9.5±1.1 µM). However we thought 
because of the poor solubility of this compound in aqueous medium this 
result should be treated cautiously and more investigation required to confirm 
its activity. The activity of the reversed sulphonamide compound 96 with IC50 
of 0.7±0.08 µM was also better than corresponding sulphonamide compound 
52, IC50 around 5.7±1.3 µM. The activity of compound 96 is more reliable 
than the activity of compound 97 because of the better solubility in aqueous 
media. We also tried to have no substitution at position 4 exemplified by 
compound 98 which was compared with the activity of normal sulphonamide 
compound 71. Both compound have the same substitution groups at position 
1 and 2 whilst no substitution group was at position 4, the only differences is 
in the reversed sulphonamides. The activity of compounds 98 and 71 was 
tremendously reduced with IC50 around 26.6±3.7 µM and 31.9±3.2 µM 
respectively due to the lack of position 4 substitution. Methyl amide 
substituted at position 4 of compound 99 showed activity with IC50 around 
2.7±1.3 µM. We can compare activity of this compound with the activity of 
compound 79, the normal sulphonamide that has amide at position 4, which 
showed activity with IC50 around 0.8±0.9 µM. So, we thought substitution of 
methyl group at amide probably is behind the modest reduction in the 
compound activity. Substitution of methoxy group at position 4 on the 
reversed sulphonamide also showed some activity with IC50 around 4.5±1.8 
µM, exemplified on compound 95. We then tried to have methyl ester group 
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at position 2 and methoxy group at position 4 in order to make direct 
comparison with compound 66. Compound 100 was synthesised by Mr Mario 
Izidro as part of his master project and tested to find the activity of the 
compound was recorded with IC50 around 3.5±1.9 µM. There was no 
significant differences between the activity of this compound and compound 
66 which showed activity IC50 around 2.9±1.0 µM. We concluded reversed 
sulphonamide seems to have significant effect on CCR7 receptor. Further 
investigation needs to be carried out in order to explore the importance of 
having reverse sulphonamide on many other compounds especially the most 
active compound, 75. Table 14 below summarizes different IC50 values of 
different analogues. 
 
Compound IC50 
97, ICT13124 0.10±0.3 µM (n = 3) 
96, ICT13120 0.7±0.08 µM (n = 3) 
98, ICT13145 26.6±3.7 µM (n = 3) 
99 , ICT13146 2.7±1.3 µM (n = 3) 
95, ICT13121 4.5±1.8 µM (n = 3) 
100, ICT13147 3.5±1.9 µM (n = 3) 
Table 14  IC50 values of different analogues
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Figure 21 structure activity relationship scheme of the newly discovered CCR7 receptor antagonist
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2.3. Structure activity relationship: summary of findings 
The conclusions of structure activity relationship of CCR7 receptor antagonist 
starts with compound 1. During the synthesis process of this molecule, the 
tailless compound 3 was discovered and tested on calcium flux assay which 
proved to be as active as compound 1. The IC50 of compound 3 and 1 was 
obtained around 10±2.5 µM and 8.2±1.2 µM respectively (Table 2). In order to 
confirm the NH2 elongated side group is not contributing to activity, we tried 
different group such as sulphonamide and hence the activity remained the 
same. This confirms the result obtained from compound 1, so we abandoned 
further investigation at this amino position. Taking into account time consuming 
and synthesis difficulties of making compound 1, the newly discovered 
compound 3 was considered to be our new lead compound. Investigation of 
structure activity relationship of this compound started by making substitution at 
R2 position, illustrated in the Figure 21 above. Methyl substitution at this 
position reduced the activity against CCR7 receptor. This illustrates the 
importance of the cyclic NH for the activity. We then looked at R1 position. The 
activity was lost when this position has no substituted group. The sulphonamide 
group is also found to be required for activity. When this functional group was 
replaced with amide, we found the activity was lost. Different analogues were 
synthesised in regard to improve the cyclic amide activity, however all 
molecules were shown to lose their activity against the CCR7 receptor. A 
number of different analogues were also made in order to understand the 
relevance of the oxathiazine cyclic ring in the potency of the compounds. The 
cleavage of the ring at the bond highlighted in green, Figure 21, afforded non 
cyclic analogues. A number of different analogues in this series were 
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synthesised and tested to find the activity reduced, with exception to compound 
22, IC50 around 11.6±1.3 µM, where the activity remained the same. We 
decided to make more of the ring open analogues, particularly as it is easy to 
make many different derivatives in this series of compounds. So, different 
analogues were made to explore different variations to compound 22. This new 
configuration to the lead compound, 3, has led us to discover the most active 
compound in the series, compound 75 which is described in the figure above. 
The IC50 value for compound 75 was recorded around 0.19±0.2 µM which 
marks significant enhancement compared to our starting point compound 3. The 
structure activity relationship of the newly discovered CCR7 receptor 
antagonist, 75, has revealed the importance of different positions. Firstly, 
position 1, is very important and essential for the activity, the substitutions at 
this position started from small group such as methyl group and then with many 
different aromatic and highly lipophilic group. Most of these different groups 
were tested using calcium flux assay and the optimum activity was shown when 
tert-butylbenzene group is substituted at this position. Sulphonamide group is 
crucial for the activity, substitution of this group with amide has dropped the 
activity. So, in order to get optimum activity, tert-butylbenzene group and 
sulphonamide group has to be substituted at position 1. Secondly, position 2 is 
also very important for activity, substitution in this position with phenoxy or 
hydroxyl group has reduced the activity. However, substitution with methoxy or 
methyl ester group has improved the activity. Methyl ester group seems to have 
promising activity, however additional investigation has to be done to further 
explore other positions whilst keeping methyl ester group substituted at position 
2. Thirdly, position 4 is also crucial for activity, having no substitution group at 
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this position dropped the activity. However, when this position was substituted 
with many different groups, better enhancement in the activity was observed. 
The activity of this position was varied depending on the substituted group, the 
greatest potency was achieved when this position was substituted with methyl 
ester, 75. Ethyl ester of compound 75 showed comparable activity to compound 
75, so different analogues were made in purpose to look for better activity 
molecules. Compound 85, which has dansyl group substituted at position 1 
showed significant activity with IC50 around 50nM, so more investigation has to 
take place to explore activity of this compound. Fourthly, substitution at position 
5 seems not to be important for the activity, different groups substituted at 
position 5 reduced the activity against CCR7 receptor tremendously. So, we 
thought position 5 should not be substituted in order to retain compound activity. 
Finally, reverse sulphonamide group substituted at position 1 showed significant 
increase in the activity. We thought the reverse sulphonamide group substituted 
at position 1 has an important activity against the CCR7 receptor, further 
investigation has to take place to explore the importance of having reverse 
sulphonamide on compound 75.  
Compound 75 is the most active compound we have synthesised against the 
CCR7 receptor. The activity of this compound is confirmed by calcium flux 
assay and different in vitro assays like scratch assay and “agarose spot assay” 
(chapter 3). The compound is novel and fairly soluble in aqueous medium. The 
partition coefficient (cLogP) of the compound was calculated using National 
Chemical Database and was determined around 4.37 which is less than 5 and 
hence compliant to the Lipinski's Rule of Fives. Also the molecule has a 
molecular weight of 377.45 g/mol which is below the 500 mark set by the Rule. 
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So further modifications including adding more groups to this molecule to 
increase its potential interaction at the binding site, may be carried out. To 
conclude, compound 75 is a novel molecule with significant inhibitory effect 
against CCR7 receptor, and with good solubility in aqueous medium.  
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3. Chapter 3: Pharmacological characterization of CCR7 receptor 
antagonists 
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3.1. Introduction 
In the previous chapter, we discussed the potency optimisation of CCR7 small 
molecule antagonists. The potency of the antagonists was measured by a 
calcium flux assay and later by another functional assay, which we have termed 
“agarose spot assay”. In this chapter, we first describe the development of the 
calcium flux method and will then describe the “agarose spot assay” which was 
used as a secondary assessment of potency and selectivity for CCR7 
antagonist.  
Chemokine receptor CCR7 belongs to the transmembrane G protein-coupled 
receptor (GPCR) superfamily. GPCRs are involved in binding with many 
different signalling molecules, including neurotransmitters, hormones, and 
peptides 125 and play decisive roles in managing and controlling many different 
physiological functions. Small molecules that modulate the interaction of 
GPCRs, such as CCR7, with their endogenous ligands are therefore medicinally 
important and a number of methods are developed for measuring the level of 
this modulation.  GPCRs are very sensitive to their ligands which once bound to 
the receptor, initiate and activate different intracellular signalling pathways 
which include mobilisation of calcium ions inside cells. Hence, a key outcome of 
GPCR activation is an increase in cytoplasmic concentration of calcium ions 
released from endoplasmic reticulum (ER). Hence, calcium mobilisation assays 
are one of the most important screening methods used in the field of GPCR 
drug discovery 126. There are of course, a number of other methods used to 
screen for small molecules which have the ability to modulate GPCR signalling. 
One of these methods is ligand binding assay which is used to determine the 
binding affinity of compounds to a GPCR compared with that of the natural 
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ligand. However, the ligand binding assay can’t be used to determine if the 
compound is agonist or antagonist and also it is restricted to the availability of 
the radio labelled ligand. Therefore, calcium flux assay is one of the favoured 
functional assay used as a screening platform to evaluate and measure activity 
of compounds against GPCR. The assay has the ability to measure activity of 
both agonist and antagonist which makes it a better technique to use over 
ligand binding assay. In order to assess and evaluate the potency of different 
CCR7 receptor antagonists using calcium flux assay, we first needed to identify 
suitable cell line models which express CCR7 receptor and efficiently respond 
to it. We used Western blot assay to qualitatively determine expression of 
CCR7 receptor in number of cell lines in our cell bank. Western blot assay 
determines expression of protein but it does not tell if the protein is cytoplasmic 
or membranous. In order to have full picture of CCR7 receptor expression on 
these cell lines, we used flow cytometry assay to determine expression of 
CCR7 receptor on cell surface. The ability of cancer cell to mobilize calcium 
ions from internal stores differs from cell line to another. Hence, we lastly 
required to assess the aptitude of those cancer cells, which were shown to 
express CCR7 receptor using calcium flux assay. Cells which responded to the 
ligand and mobilized calcium ions perfectly were used to measure compounds 
activity against CCR7 receptor. We then assessed and evaluated the most 
active compound obtained from calcium flux assay in vitro using “agarose spot 
assay” and scratch assay.  
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3.2. Characterization of CCR7 receptor antagonists potency using 
calcium flux assay 
Calcium ions play an essential part in GPCR mediated cell signalling 
transduction pathway. In order for cells to survive and function properly, the 
intracellular Ca2+ concentration must be controlled 127. The resting concentration 
of calcium in the cytoplasm is normally between 10–100 nM. This concentration 
is maintained through balanced processes involving release of the ions from 
reservoirs such as endoplasmic reticulum (ER) to the cytoplasm, and active 
transport of the ions to and from the extracellular space. When an external 
signal, for instance binding of a ligand to GPCR occurs, a transient 10 fold 
increase in cytoplasmic calcium concentration is observed 128. Hence, the 
interaction between chemokines and their receptors leads to activation and 
initiation of a complex set of downstream signalling pathways which will include 
calcium mobilization from internal calcium stores. Calcium flux assay is based 
on measurement and detection of fluorescent light that is emitted by a calcium 
sensitive fluorescence dye, upon binding with calcium ions released into the 
cytoplasm. The effective concentration of ligand (see below) was used to treat 
cells with and without antagonists. In order to measure the activity of small 
molecules, serial dilution of antagonist concentrations was added to cells 
containing dye taking into account some wells were left as control. Calcium ions 
are mobilized as a result of interaction between CCL21 or CCL19 ligands 
(which are discharged from Fluoroskan Ascent FL instrument) and their 
receptor CCR7 on cell membrane. Calcium ions released upon interaction binds 
with the dye used in the assay (Fluo-4 NW) and emits fluorescence. Figure 22 
below explains how florescence is produced upon binding of ligand with its 
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receptor. The amount of fluorescence obtained in response to the addition of 
the ligand is measured at Ex 485 nm, Em 538 nm wave length using Fluoroskan 
Ascent FL instrument at room temperature (see experimental). The principle of 
this assay is based on inhibition of calcium channel opening mediated through 
G-protein coupled receptor (GPCR) followed activation of CCR7 receptor upon 
binding to its ligand. The amount of fluorescence measured in presence of 
antagonist should be reduced if the antagonist is potent.  
 
 
Figure 22 basic principle of calcium flux assay. Picture adopted from 
www.moleculardevices.com 
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3.3. Characterization of CCR7 Receptor expression using Western blot. 
Western blot or immunoblotting is a powerful technique used in cell and 
molecular biology to identify, in qualitative and semi quantitative way, specific 
proteins in a given sample based on their size 129. Western blotting is different 
from Southern and northern blotting which are based on detecting specific 
fragments of DNA and RNA sequences respectively. Western blot technique 
uses electrophoresis to identify mixtures of proteins based on their molecular 
weight 130. In this study, we used Western blot in order to investigate and 
evaluate expression of CCR7 receptor in a panel of in house tumour cell lines 
and to compare our result with those reported in literature to have CCR7 
receptor expression. So, human caucasian colon adenocarcinoma (SW620) 131, 
human breast cancer cell line (MDA-MB-231) 132, human primary glioblastoma 
cell line (U-87 MG) 133, human prostate cancer cell lines (DU-145) 134, human 
prostate cancer cell lines, (PC-3) 135, human colon adenocarcinoma (DLD-1) 136, 
human breast cancer cell line (MCF-7) 137 138, Drug resistant human breast 
cancer cells (MCF-7/ADR) human colorectal adenocarcinoma cell line (HT-29) 
139 and human umbilical vein endothelial cells (HUVECs) 140 were selected and 
screened for CCR7 receptor expression. β-Actin was used as loading control, 
which is commonly used for western blot. If the expression of β–actin shows an 
equal loading, we can assume the equal loading of protein and hence we 
estimate the comparative expression of CCR7 receptor on these cell lines. 
Results obtained from cell lines screening for CCR7 receptor expression and β-
Actin were broadly in agreement with literature findings. Figure 23 below shows 
cell lines with CCR7 protein expression. The amount of CCR7 protein 
expressed was determined based on the intensity of the band obtained. MCF-7 
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and DU-145 cell lines appear to have high expression of CCR7 receptor 
compared to the rest of the cells. The assay was repeated at least three times 
to confirm results. These findings were also confirmed in a different study using 
knocked down CCR7 receptor in human oral squamous cell carcinoma cells 
(OSC-19) as a negative control to make sure the antibody used in the assay is 
specific for CCR7 receptor. With exception of knocked down OSC-19 cells, all 
other tested cell lines showed CCR7 receptor expression. This was carried out 
by Mrs Haneen Basheer as part of her PhD project whilst in our research group. 
 
CCR7 Expression β–Actin expression 
 
 
 
 
 
 
 
Figure 23 Expression of CCR7 receptor protein in a panel of human cancer cell lines by 
western blot. β–Actin was used as loading control. (We thank Dr Hanadi Talal for help in 
the execution of this experiment)  
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3.4. Determining the efficacy of the agonist 
Initially, we wanted to determine from results obtained above which cell line has 
good response to ligand and hence mobilize calcium efficiently from internal 
stores. We also wanted to determine the effective concentration of the ligand 
required for optimum performance of the assay. The reason this is practically 
important is that in determination of potency of an antagonist, the assay detects 
absence of fluorescence. Therefore, we wanted to use a cell line in which the 
fluorescent response to the chemokine ligand is high so that changes can be 
more accurately determined. We decided to choose cell lines which were 
confirmed expression of CCR7 receptor using Western blot. The ability of these 
cells to release calcium ions upon interaction between receptor and ligand is 
measured by calcium flux assay. Functional assay is always a way to determine 
the involvement of the receptor in response to cellular pathway. CCL21 and 
CCL19 are both ligands for the CCR7 chemokine receptor. We decided to 
determine the effective concentration EC50 of both ligands, CCL21 or CCL19, to 
be used during the assay. Different serial dilution of both ligands were applied 
to cells containing dye using Fluoroskan Ascent FL instrument 
(ThermoScientific) in order to obtain dose dependant curve (see below). Cells 
were first optimized at 5 x 105 cells per well just to cover the well bottom as a 
monolayer. Cells were left to attach overnight in 10 % FCS containing medium 
at 37 °C. Medium was removed completely so that we make sure the ligand will 
not be diluted as this will affect the whole analysis. The dye was then added per 
well and the plate incubated half an hour before using the Fluoroskan Ascent FL 
instrument (ThermoScientific) to measure fluorescence emitted. Serial dilution 
of both ligands were prepared and applied to the plate respectively. The 
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fluorescence emitted as a result of calcium mobilization upon binding of the 
ligands with their CCR7 receptor is measured and plotted (Figure 24). All EC50 
obtained are calculated automatically using sigmaplot software. Although the 
intensity of Western blot bands obtained for both cell lines, MCF-7 and DU-145, 
are higher than the intensity band of U87-MG cell line, U87-MG cells were 
found to have better response to the ligand than MCF-7 and DU-145. This might 
be due to that although these two cell lines have high expression of CCR7, the 
protein is mostly present in the cytoplasm rather than cell membrane. Western 
blot assay based on disruption of the outer cell membrane and hence the 
expression measures both proteins inside the cells and cell surface. U87-MG 
cells, showed good responses to both ligands, CCL21 and CCL19. It was 
reported in literature that CCL21 ligand appears to have higher affinity to bind 
with its receptor than the CCL19 96. This was confirmed in our assay as 
illustrated from Figure 24 below, CCL21 showed higher activity than CCL19. 
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Figure 24 CCL19 (A) and CCL21 (B) Dose Response Curve using U-87 MG. The 
curves were obtained by three in vitro experiments. Mean ± SD of triplicate 
determination is given. 
The CCL21 EC50 was at 14.8±1.34 nM compared to CCL19 which was 
71.7±2.09 nM. It was therefore decided to use CCL21 instead of CCL19 through 
all our assays. However, we observed that there was variability of the 
fluorescent obtained from one well to another. U87-MG cells are astrocyte and 
we felt that some of the problems we experienced in result variability were due 
to the lack of a uniform monolayer of the cells. To provide a robust assay for 
evaluating our antagonists, we tested a number of other cell lines. At this stage, 
it was decided to use flow cytometry techniques which can be adapted to detect 
expression of proteins on the cell surface. Therefore, flow cytometry is 
advantageous over Western blot and would avoid problems we had. Concurrent 
studies in our research group using flow cytometry, indicated that the CCR7 
receptor is highly expressed in human pancreatic carcinoma, epithelial-like cell 
line (Panc-1) and human oral squamous cell carcinoma cells (OSC-19) 
B 
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(Appendix II). Also, a review of the literature, indicated that, human T cell 
lymphoblast-like cell line (CCRF-CEM) 141 showed high expression of the CCR7 
receptor. These cell lines were also tested by Mrs Haneen Basheer using 
Western blot assay which confirmed expression of CCR7 receptor. Initially, we 
tested Panc-1 and CCRF-CEM cell lines to determine whether the response of 
those two cell lines are better than U-87 MG, or indeed that the fluorescence 
variation was less pronounced. So, serial dilution of CCL21 ligand 
concentrations were used as before and the response curves obtained from 
both cell lines were similar to ones obtained with the U-87 MG. We only used 
CCL21 ligand in this assay because it’s more potent than CCL19 as described 
in previous result. As illustrated in Figure 25 below, the half maximum effective 
concentration (EC50) was obtained around at 11.06±1.12 nM and 15.03±1.89 for 
CCRF-CEM and Panc-1 cell lines respectively.  
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Figure 25 CCL21 Dose Response Curve using (A).CCRF-CEM and (B). Panc-1 cells. 
The curves were obtained by three in vitro experiments. Mean ± SD of triplicate 
determination is given. 
However, after analysis of the data, there was still some variations in 
fluorescence obtained and hence make different response from one well to 
another. The fluorescent variation was not that significant but we wanted to 
make sure the variations as small as possible. Further investigations took place 
using OSC-19 cells to ascertain if it would afford less fluorescent variability in 
our results. OSC-19 cells produce a very consistently uniform monolayer, which 
covers the wells completely; so we decided to try these cells and determine if 
we could reduce the variability we experienced with previous attempts. Full 
dose response curve were performed for both ligands CCL21 and CCL19, and 
we were satisfied that we obtained the most consistent results, with little 
variability. Figure 26 below shows the full dose response curve of both ligands 
using OSC-19 cell lines. 
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Figure 26  CCL19 (A) and CCL21 (B) Dose Response Curve using OSC-19 cells. The 
curve were obtained in three in vitro experiments. Mean ± SD of triplicate determination 
is given. 
The EC50 obtained from treating OSC-19 cells with CCL21 and CCL19 ligands 
were around 13.48±2.01 nM and 73.28±3.45 nM respectively, which were 
comparable with previous results. It was concluded from the results obtained 
A 
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above that CCL21 is more active and potent than CCL19, so CCL21 was 
considered as a ligand to be used for further analysis. The minimum 
concentration required to achieve maximum response in the assay was 
estimated at 100nM. It was therefore decided that OSC-19 cell line will be used 
to test the efficacy of compounds because these cells showed the least 
variation obtained from the data analysis. So far, we have the cells, we know 
what ligand to use and we know the effective concentration to be applied in the 
assay. The next aspect to investigate was if the percentage of the Foetal Calf 
Serum (FCS) in the medium used would have an effect on the ability of the cells 
to respond in the calcium flux assay. According to the manufacturer's 
instructions for Fluo-4 NW calcium flux assay protocol, 10% FCS is used when 
culturing cells into 96-well plate 142. However, we felt it worthy to try if culturing 
these cells with 0% FCS, would stress the cells into producing more CCR7 and 
thus improve the response toward the ligand, CCL21. 96-well plate was cultured 
with OSC-19 contain 10% and 0% FCS and left over 24 hours in the incubator. 
The next day medium was removed, dye added and the ability of cells to 
mobilize calcium ion were tested using 100nM CCL21 ligand. The test was 
repeated at least three times to confirm findings. The result shown below 
illustrates that the response of OSC-19 cells toward the CCL21 ligand did not 
change (Figure 27). So, it was decided to use 10% FCS during the whole 
process to follow the manufacturer's instructions and also to make sure the cells 
were attached perfectly to the bottom of the wells. So, CCL21 ligand was used 
at 100nM concentration using OSC-19 cell line, which express CCR7 receptor, 
and the medium should contain 10% FCS. 
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Figure 27 Calcium mobilization using OSC-19 cells contain 10%FCS and 0% FCS. 
The curves were obtained in three in vitro experiments. Mean ± SD of triplicate 
determination is given. 
3.5. Determining the efficacy of the antagonists 
The optimised calcium flux assay, described above, was used to determine the 
efficacy of the antagonists described in chapter 2 to examine their ability to 
block CCR7 receptor. If the antagonist is potent, it will block the effect of the 
ligand (CCL21) on the receptor, so the amount of fluorescence emitted would 
be reduced. With this in mind, the first synthesised compounds, 3, ICT5888 and 
1, ICT5189 were tested to check their activity against CCR7 receptor. (Note: all 
antagonist data and IC50 curves are available in the Appendix I). Different 
antagonist concentrations were prepared in order to have full dose dependent 
concentration and hence we could conclude the half maximal inhibitory 
concentration (IC50) which measures how effective the drug is. A stock solution 
of each compound was prepared by dissolving known amount of compound in 
DMSO which was then diluted so that the amount of DMSO is not toxic to the 
cells in the top concentration of antagonist. The top concentration of the 
antagonists used in the well after addition of the ligand was 142 µM. We wanted 
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to make sure the effect that we got is actually directly from the antagonist used 
and not because of the toxic effect of DMSO. The final percentage of DMSO 
used in our top concentration (142 µM) was 0.14% which gets even more 
diluted in the next serial dilution. Some cells are too sensitive and respond 
differently toward DMSO. To confirm that the response we got from OSC-19 
cells (which express CCR7 receptor) was not affected by DMSO, control wells 
were used containing corresponding quantities of DMSO and buffer without the 
antagonist, which then were treated with the cognate ligand. No reduction of 
fluorescence was observed with all wells which contain the same percentage of 
DMSO and have no antagonist. This reflects the amount of DMSO used in our 
top antagonist concentration is not toxic to the cells especially we only incubate 
the antagonists solution with the cells for half an hour at 37 °C which is 
relatively short period. Since the assay looks for absence of fluorescence, an 
important consideration in interpreting any reading in this assay is purely 
derived from antagonism and not from other factors that can lead to absence of 
fluorescence, such as cell death at the concentrations used. Therefore, a 
chemosensitivity assay (MTT based method) was carried out for different 
molecules and our top active molecules. The MTT based assay is the most 
commonly used assays for the detection of cytotoxicity following exposure to 
toxic compounds 26. The results obtained from the MTT cytotoxicity assay was 
done on dose dependant response. This was carried out by Mrs Haneen 
Basheer as part of her PhD project whilst in our research group. It was 
established from these studies that concentrations used in this assay were not 
toxic to cells (Appendix III). Before carrying out the assay, we determined that 
the compounds were highly pure using Liquid chromatography–mass 
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spectrometry (LC-MS), melting point and Nuclear magnetic resonance 
spectroscopy (NMR) (see experimental). All tested compounds must show 
highly purity otherwise the impurities would have an effect on cells and hence 
will affect the result obtained. We then prepared the required serial dilutions of 
antagonists which were similarly prepared from the corresponding stock 
solutions by adjusting the second dilution by assay buffer as required. OSC-19 
cells were first plated into 96-well plate overnight to give enough time for cells to 
attach to the bottom of the wells, medium was then completely discarded and 
replaced with Fluo-4 NW dye loading solution and the plate was incubated half 
an hour. Antagonists serial dilutions were then added to wells whilst some wells 
were left as control in order to measure the fluorescent obtained from cells in 
presence and absence of the antagonist. The most potent compound was 
always included in the assay as a reference to determine the effectiveness of 
the other tested compounds. The plate was then incubated another half an hour 
before taking to Fluoroskan Ascent FL instrument (ThermoScientific). After, it 
was transferred into a Fluoroskan Ascent FL instrument and the fluorescence in 
response to the addition of 20 µl CCL21 (100nM) was measured at room 
temperature. In order to run the calcium flux assay more time efficiently, we first 
tested compounds using two different concentrations of each compound and 
compared together with the lead compound, 3, ICT5888, at identical experiment 
conditions and if we observe good activity, we carry out full concentration 
dependant response to get IC50 value. All runs were done at least in triplicate (n 
≥ 3). All data and IC50 values obtained in this assay was analysed using Prism 
software. 
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In order to proof that the most active compound is active against CCR7 
receptor, we evaluated its potency using different in vitro techniques like 
“agarose spot assay” (see below) and scratch assay (Appendix IV). Initially, we 
modified the existing under agarose assay to fulfil our demand and then we 
applied the configured under agarose assay to investigate activity and 
selectivity of the top active compound toward multiple chemokine receptors. We 
also applied these modification to compare activity of our top active compound 
with much less active compound against CCR7 receptor. 
 
3.6. Agarose spot method for in situ analysis of chemotactic responses 
to multiple chemoattractants. 
3.6.1. Introduction  
As discussed previously, chemokines play vital role in cell migration and 
invasion. However, the pharmacology of the chemokine system can be 
complex. The chemokine system comprises almost 50 chemokines divided into 
four subfamilies (CXCL1-18, CCL1-CCL28, XCL1-2, and CX3CL1) which bind 
and activate 18 chemokine cell surface receptors (CXCR1-6, CCR1-10, XCR1 
and CX3CR1) and four atypical receptors (ACKR1-4) 143. Although a number of 
chemokine receptors are selectively activated by a single chemokine (such as 
CXCR4, which is activated by CXCL12), there is generally speaking a 
significant degree of promiscuity between ligands and receptors in the 
chemokine system. In other words, some chemokine receptors are activated by 
more than one chemokine (for example CCR7 is activated by CCL19 and 
CCL21), in addition, the same chemokine can activate more than one 
chemokine receptor (for example CCL2 activates both CCR2 and CCR4) 144. 
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These issues highlight the need for protocols to assess the chemotactic 
responses to multiple chemoattractants, or through multiple chemotactic 
receptors. There are of course, a number of protocols to study cell migration 
and chemotaxis in response to a single chemoattractant. They include methods 
using Boyden chamber 145, Zigmond chamber 146, Dunn chamber 147, Insall 
chamber 148 and under-agarose method 149. However, none of these methods is 
yet adapted for investigation of cellular migration in response to multiple 
chemokine axes. Our group previously developed the agarose spot assay. The 
experimental configuration of the assay is as follows:  two agarose drops 
contain one chemokine ligand and other two drops contain control, phosphate 
buffered saline (PBS). The drops were applied to a glass bottomed petri dish as 
a spot which is allowed to solidify and then immersed under media containing 
cells (Figure 28).  
 
Figure 28 Schematic representations of a glass backed 35 mm petri dish. Two agarose 
drops containing the same chemoattractant, and two agarose drop as control (original 
design) 150. (Picture reproduced courtesy of Dr. Victoria Vinader). 
Over time, chemokine molecules slowly leach out from the agarose spot, 
creating a transient gradient. Cells which contain the cognate chemokine 
receptors respond to the chemokine and migrate against this gradient towards 
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the spot and eventually migrate under the spot. The evaluation of the number of 
cells and the distance they travel under the spot provides quantitative 
information on the chemotactic aptitude of cells towards chemokines. The 
media can be supplemented by small molecule antagonists, or other agents, 
which can modulate this chemotactic response 150. In this method, we will 
discuss a modification to the configuration of this assay which permits the time-
dependant analysis of cell migration in response to multiple chemokines at the 
same time. We will study the chemotactic aptitude of different cell lines towards 
different chemoattractants under identical experiment conditions. We will also 
evaluate the reduction of cells migration toward agarose spots contain 
chemoattractants by antagonists. The effectiveness of compound 75 as CCR7 
antagonist will be evaluated under agarose spot assay and compared to much 
less active compound 3. The selectivity of compound 75 will be investigated 
against two different receptors, CCR7 and CXCR4. We used CXCR4 receptor 
in this study because it is very important in dual CXCR4 and CCR7 antagonism. 
This is evident by clinical observations which support the hypothesis that the 
CXCR4 and CCR7 axes may work in tandem to promote the dissemination of 
cancer. For example, co-expression of CXCR4 and CCR7 in breast 151, cervical 
152, thyroid 153,154, and gastric 14 correlates to poorer prognosis and exacerbated 
metastasis compared to expression of either receptor alone. These 
observations highlight that in these cancers, dual CXCR4 and CCR7 
antagonism may be more beneficial than antagonism of either alone.  
Therefore, an experimental setting that allows the investigation of CXCR4 and 
CCR7 antagonism at the same time is extremely appropriate. This assay can be 
adapted to other chemoatractants/receptor pairs; however for the purpose of 
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this research, we have concentrated on CCR7/CCL21, CCL19 and 
CXCR4/CXCL12. We investigated CXCR4 and CCR7 expression and 
antagonism using the same experiment condition. In this assay we used four 
agarose drops per petri dish, however more drops can be applied in order to 
compare more chemokine receptors at the same time. Four agarose spots were 
used and each spot contains different chemokine ligand and the last drop was 
used as control. The experimental configuration of the assay is as follows: the 
first agarose spot contain CXCL12 (ligand for CXCR4), the second agarose 
spot contain CCL21 (ligands for CCR7), the third agarose spot contain CCL19 
(ligands for CCR7) and the forth agarose spot contain control, PBS (no 
chemokine). 100 mg of low–melting point agarose was dissolved into 20 ml of 
PBS to make a 0.5% agarose solution. This percentage of the agarose used in 
the assay is very important, higher or lower agarose percentage will make the 
agarose drop harder or softer and will affect the whole process of cell migration. 
The agarose solution was heated until complete dissolution and was left to cool 
down to 40 °C. This temperature is critical, if the temperature was higher than 
this, the agarose drop will melt down quickly on the glass bottom petri dish and 
if the temperature is lower than this, the agarose drop will solidify quickly and 
will not attach properly on the glass bottom petri dish. So once the temperature 
of the agarose solution is at 40 °C, a stock solutions of the known chemokines 
concentrations were prepared and mixed with known amount of agarose 
solution. In this configuration, three different chemokines stock solutions were 
prepared, CXCL12, CCL21 and CCL19 (see experimental) and then mixed with 
known amount of PBS contain melted agarose at 40 °C. The chemokine 
concentration embedded in the agarose spot was optimized by applying 
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different range of concentration dilution mixed with the agarose drop. The 
chemokine ligand concentrations used for the optimization process in this assay 
were 1nM, 100nM, 200nM and 1µM. The optimum results obtained when 
100nM was utilised. Namely, no migration was noticed using the lowest 
concentration, and we observed that the drops “exploded” using the highest 
concentration of 1µM in the majority of occasions. So, the chemokine 
concentration embedded in the agarose spot was used at 100nM for the three 
ligands used. The fourth spot was used as control, PBS was added instead of 
using chemokine ligand. The control spot was used in purpose to compare cells 
migrations between PBS containing spot and chemokine ligands containing 
spots. The spots can be identified by writing on the backside of the glass, using 
a marker pen, a cross was drawn on the back of the plate to form four 
quadrants, one for each of the four spots (Figure 29).  
 
Figure 29 Schematic representations of a glass backed 35 mm petri dish: (A) 
Modifications carried out in this thesis with three agarose drops containing different 
chemoattractant, and one agarose drop as control. (B) A picture of glass back petri 
dish with agarose drops, showing marking. (Picture reproduced courtesy of Dr. Victoria 
Vinader). 
B A 
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The petri dish containing the spots was then cooled for exactly 5 minutes in a 4 
°C fridge to allow the agarose spot to set. Again this step is critical, if the 
agarose spots left in fridge for more than 5 minutes the drop will solidify harder 
and this will make it very difficult for cells to crawl under the spot. Once the 
spots have solidified, 1 ml of cell suspension in 10% FCS media, either 
containing the antagonist, or control (no agent), was plated into the dishes 
which were then incubated at 37 °C to allow the cells to adhere. We started our 
optimization steps using U-87 MG cell line and then different cell lines were 
utilized for our study, this will be highlighted further in this assay. Cells density 
used was optimized at 6.0 x 104/ml as a starting point, but this can be adjusted 
based on cell type. After 4 hours incubation, the culture media was replaced 
with 0.1% FCS, either containing the antagonists or no reagent (as control), and 
the dish was returned to the 37 °C incubator. Initially, we require 10% FCS 
media, to ensure good cell adhesion, however, after 4hrs, we change to 0.1% 
FCS, the purpose of the media change is to ensure no cell proliferation during 
the overnight incubation period, in order to ensure that what we see is cell 
migration, rather than cell number growth. Cells were originally plated in 
medium containing 10% FCS without changing to 0.1% FCS medium and found 
cell number increased tremendously and this would affect the analysis process. 
So, we introduced the 0.1% FCS medium after the cells were attached, but this 
step, inherently includes the extra step of changing the media. We attempted to 
avoid disturbing and moving of petri dish after 4 hour incubation, by plating cells 
in medium containing 0.1% FCS from the beginning; however, analysis after 16 
hours showed that the cells were not properly attached to the plate and this 
affected the cell migration process. In this experiment, we tried different types of 
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disposable glass-bottomed plastic, however 35mm petri dishes with lid from 
iBidi (Glasgow, United Kingdom) were found to be the best for cells to attach 
and migrate toward agarose spots. After 16 h, the agarose spots were analysed 
by counting total number of invading cells using LumaScopes 500. Six fields of 
view of equal size were photographically captured using LumaScopes 500. The 
edges of the spots are clearly discernible in the photographs and the cells 
migrating under the spots are easily distinguishable from those which are not. 
Cells which tend to migrate or travel as group were quantified by measuring the 
percentage of cell-covered area. This is done by measuring the distance 
travelled between migrated cells and the edge on the agarose drop using 
Fiji/ImageJ software 155. In contrast to cells travelling in group, number of cells 
moving individually under the spot was determined using the same software. 
Migrated cells were highlighted and separated from the resting cells using 
segmented line selection tool, the image was then processed by converting it to 
a binary. Cells were counted by an automatic particle analysis. The number of 
cells in each of the six fields were counted and summed up to give the total 
number of cells under the spot. Cells can also be individually counted but we 
found no significant improvement to the results compared with the image 
analysis software. In order to make direct comparison between cells which 
travel as group and cells which travel as individual, we used relative chemotaxis 
index (RCI) of cells. This index provides direct comparison between the 
chemotactic aptitudes towards different chemokines in comparison to the 
chemotactic aptitudes towards CXCL12. A RCI of 1 correlate to cells with 
chemotactic aptitudes similar to that towards CXCL12, whereas RCI of 0 
correlate to cells with low chemotactic aptitudes. We also recorded a time-lapse 
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imaging for cells migrating toward the agarose spot overnight using Nikon 
Eclipse TEZ000-U confocal microscope showing the agarose spot method. 
Images obtained were analysed by Fiji/ImageJ software.  This short film clearly 
shows the cells moving towards the chemokine containing spot and is included 
in a CD attached to the thesis. Data is presented as the mean ±SE of at least 3 
independent experiments. 
3.6.2. Results and Discussions 
In order to compare the chemotactic aptitude of different cell lines towards 
chemoattractant, we required cell lines with contrasting expression of the 
chemokine receptors CXCR4 and CCR7, and responsiveness to their cognate 
ligands. Cells were screened from our cell bank for the expression of 
chemokine receptors CCR7 and CXCR4 using Western blot (Figure 23) and 
flow cytometry (Appendix II). Based on the results obtained, a number of CCR7 
and CXCR4 expressing cell lines were selected and tested under the agarose 
spot assay. Initially, human primary glioblastoma cell line (U-87 MG), human 
colon adenocarcinoma cell line (DLD-1) and human colorectal adenocarcinoma 
cell line (HT-29) cell lines were selected to be used for the agarose spot assay. 
Cells were allowed to migrate under agarose spots contain CXCL12 (ligand for 
CXCR4), CCL21 (ligands for CCR7), CCL19 (ligands for CCR7) and control, 
PBS under identical conditions (Figure 30). The spots were visualized and 
analysed after 16 hours of incubation at 37 °C. 
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(A) U87-MG cells (CCL21 100nM, 16hr) (B) DLD-1 cells (CCL21 100nM, 16hr) 
  
(C)  HT29 cells (CCL21 100nM, 16hr) (D) U87-MG cells (CCL19 100nM, 16hr) 
  
(E) DLD-1 cells (CCL19 100nM, 16hr) (F) HT29 cells (CCL19 100nM, 16hr) 
(G) U87-MG cells (CCL12 100nM, 16hr) (H) DLD-1 cells (CCL12 100nM, 16hr) 
  
(I) HT29 cells (CCL12 100nM, 16hr) (J) U87-MG cells (PBS, 16hr) 
118 
 
  
(K) DLD-1 cells (PBS, 16hr) (L) HT29 cells (PBS, 16hr) 
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Figure 30 Cells migrate under the agarose spot containing a chemokine (A), (B) and 
(C) represent U87-MG, DLD-1 and HT29 cells migrating toward drop containing 
CCL21, 100 nM. (D), (E) and (F) represent U87-MG, DLD-1 and HT29 cells migrating 
toward drop containing CCL19, 100 nM. (G), (H) and (I) represent U87-MG, DLD-1 and 
HT29 cells migrating toward drop containing CXCL12, 100 nM. (J), (K) and (L) 
represent U87-MG, DLD-1 and HT29 cells migrating toward drop containing PBS. (M) 
Relative chemotaxis index of PC-3,DLD-1 and HT29 cells migration under agarose 
spots. Data is presented as the mean ±SE of at least 3 independent experiments. 
With the exception of HT29 cell line, cells migrated under the spots which 
contain the cognate ligands and no migration was observed in the control spot 
which contain PBS. Although, expressing the receptors, U87-MG and DLD-1 
were not included for further investigations. U-87 MG cells are astrocytes and 
were very challenging to count individually, as it is difficult to tell when one cell 
finishes and the next one starts without further staining (eg. using DAPI to stain 
the nuclei) which will inherently include an extra step to the assay. (Figure 30). 
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DLD-1 cells were also excluded from further investigation because we were 
looking for cells which are able to migrate as individual so it would be easier to 
count them. HT29 cell line was also excluded from further investigation because 
no migration was noticed, although they express CCR7 and CXCR4 and this 
suggests that this cell line has too little migratory activity, which was reported in 
literature 156. Further results obtained from our cell bank screen indicated that 
human prostate cancer cell line, PC-3 express high levels of both CCR7 and 
CXCR4 (Appendix II). PC-3 cells also have the ability to travel and evade 
individually and not as group. This will allow us to easily count the cells and 
quantitatively assess the responses for both receptors. In addition, we found 
human colorectal cancer cell line (SW480) do express CXCR4, however their 
expression of CCR7 is low or negligible (Appendix II). Therefore, we set out an 
intracellular calcium mobilisation (calcium flux) assay to assess PC-3 respond 
toward both ligands CCL21, CCL19 and CXCL12 (ligands for CCR7 and 
CXCR4 respectively). PC-3 cells were plated and left to attach to the 96-well 
plate bottom overnight incubation with 10% FCS containing medium. Medium 
was discarded totally the day after, so the ligands will not become diluted, and 
was replaced with Fluo-4 NW dye loading solution and the plate was incubated 
half hour before taking to the Fluoroskan Ascent FL instrument 
(ThermoScientific) to measure fluorescent emitted upon binding ligands with 
their receptors. Each ligand was added separately and washing buffer was used 
to remove any ligand traces before addition of the next one. The fluorescence in 
response to the addition of the chemokine (to give 100nM in-well concentration) 
was measured at room temperature (Ex 485 nm, Em 538 nm). The ligands 
concentration used in this assay was 100nM in the well, same calculation used 
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before in this chapter was applied in this assay.  Figure 31 below illustrates the 
response of CXCR4 and CCR7 receptor upon interaction with their cognate 
ligands.  
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Figure 31 Calcium Flux Mobilization charts comparing response of CXCR4 and CCR7 
receptors toward their cognate ligands using PC-3 cells. Data is presented as the mean 
±SE of at least 3 independent experiments. 
We found that PC-3 cells responded to both CCL21, CCL19 and CXCL12 
(Figure 31). Interestingly, we observed that PC-3 cells responded with high 
fluorescence emitted upon interaction with CXCL12 ligand than the response 
obtained upon interaction cells with CCL21 ligand and the least response was 
noticed upon interaction cells with CCL19 ligand. We thought this might 
correlate to the level of chemokine expression. This was confirmed using flow 
cytometry assay within our research group which revealed higher expression of 
CXCR4 receptor in PC-3 cells than CCR7 receptor (Appendix II). 
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Migration under agarose spot correlates to the expression level of chemokine 
receptor  
As indicated above, PC-3 cell line was shown to respond to calcium flux assay 
for both CXCR4 and CCR7 receptors. Therefore we carried out the agarose 
spot assay experiment with four agarose spots on the same 35-mm dish, with 
one spot as a control (PBS), and the other three spots containing similar 
concentrations of CXCL12, CCL19 and CCL21 each. In this experiment, PC-3 
cells are allowed to migrate toward CXCL12, CCL19 and CCL21 spots under 
identical conditions. This experiment will allow us to assess the chemotactic 
aptitude of PC-3 cells toward different chemokine ligands using same 
experimental conditions. After 16 hour of incubation time, the spots were 
visualized and analysed using LumaScopes 500 (Figure 32). 
 
  
(A) PC-3 cells (CXCL12 100nM, 16hr) (B) PC-3 cells (CCL21 100nM, 16hr) 
  
(C) PC-3 cells (CCL19 100nM, 16hr) 
 
(D) PC-3 cells (PBS 16hr) 
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Figure 32 PC-3 cells which express chemokine receptors CCR7 and CXCR4 migrate 
under agarose spot containing (A) CXCL12 (ligand for CXCR4), and (B) CCL21 and 
(C) CCL19 (ligands for CCR7), but not under agarose spot containing (D) no 
chemokine. (E) Relative chemotaxis index of PC-3 cells migration under agarose spots. 
Data is presented as the mean ±SE of at least 3 independent experiments. 
PC-3 cells do indeed migrate under the agarose spots containing CXCL12, 
CCL19 and CCL21 (Figure 32). However, no migration was observed under the 
agarose spot containing PBS. It was observed number of cells migrated toward 
spot containing CXCL12 is more than number of cells migrated toward spots 
contain CCL21 and CCL19. Interestingly in this experiment, the chemotactic 
aptitude of PC-3 cells, as measured by the number of migrated cells under the 
agarose spot, correlates to the response of the same cells in a calcium 
mobilisation experiment (Figure 31). Since cytoplasmic calcium enables cellular 
motility, this is not surprising. None-the-less, this correlation suggests that the 
agarose spot is a rigorous functional assay. These findings comply with 
previous results obtained from flow cytometry and calcium flux assay which 
indicates availability of high expression level of CXCR4 receptor in PC-3 cells 
than the expression level of CCR7 receptor. In contrast to PC-3 cells, SW480 
cells do not significantly express CCR7, but do express high level of CXCR4. 
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Therefore, we repeated this experiment and allowed SW-480 cells to migrate 
under CXCL12, CCL19 and CCL21 spots under identical conditions (Figure 
33).  
  
(A) SW480 cells (CXCL12 200nM, 16hr) (B) SW480 cells (CCL21 200nM, 16hr) 
  
(C) SW480 cells (CCL19 200nM, 16hr) (D) SW480 cells (PBS 200nM, 16hr) 
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Figure 33 SW480 cells which express chemokine receptor CXCR4 but not CCR7, 
migrate under agarose spot containing (A) CXCL12 (ligand for CXCR4), but not under 
agarose spot containing (B) CCL21 and (C) CCL19 (ligands for CCR7), or agarose 
spot containing (D) no chemokine, (E) Relative chemotaxis index of PC-3 cells 
migration under agarose spots. Data is presented as the mean ±SE of at least 3 
independent experiments. 
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After 16 hours of incubation, we observed migration of SW480 cells under the 
agarose spot containing CXCL12 ligand, but not under agarose spot containing 
CCL19 nor CCL21 ligand. We first started the experiment using 100nM 
concentration of each ligand, however we then increased the concentration of 
each ligands to 200nM to make sure there was no migration under agarose 
spots containing CCL21 or CCL19. This observation is wholly consistent with 
the lack of significant expression of CCR7 in SW480 cells. This was also 
confirmed using scratch assay within our research group (Appendix IV). 
Scratch assay or wound healing assay is an easy-to-perform technique to 
assess cell migration in vitro. The basic steps include making a "scratch" in a 
cell monolayer and then monitoring cell migration by taking images at regular 
intervals and comparing the images to measure the migration rate of the cells. 
170. Wound closure is accelerated over control when PC-3 and SW480 cells are 
treated with CXCL12, showing that activation of the CXCR4 receptor on these 
cells results in increased cell motility. Although wound closure is accelerated 
over control when the PC-3 cells are treated with CCL21 or CCL19, no 
difference was observed when SW480 cells were treated with CCL21 or 
CCL19.  
Cells Migration under agarose spot is monitored by confocal microscope  
In order to demonstrate and describe PC-3 cells migration and movement under 
agarose spot assay is chemoattractant directed, we compiled a cell motility 
short film. Cells were initially incubated with 10% FCS containing medium for 4 
hours. Medium was then replaced with 0.1% FCS containing medium and 
incubated at 37 °C and 5% CO2 atmosphere over 16 hour time. Time-lapse 
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imaging was taken for the cells migrating toward the planar surface overnight 
using Nikon Eclipse TI confocal microscope and cells movement were analysed 
using Fiji/ImageJ software after 16 hours incubation. Figure 34 shows pictures 
which were captured from time-lapse imaging for PC-3 cells migrating toward 
agarose spot containing CCL21 ligand over 16 hours period. ( The time-lapse 
imaging movie is included in a CD attached to this thesis) 
  
(A) PC-3 cells (CCL21 100nM, 4hr) 
 
(B) PC-3 cells (CCL21 100nM, 10hr) 
 
 
(C) PC-3 cells (CCL21 100nM, 16hr) 
 
Figure 34 Migration under agarose spot is monitored by confocal microscopy using 
PC-3 cells;  
After 4 hours of incubation (Figure 34 A), we found that PC-3 cells settled near 
the edge of the agarose spot containing CCL21 chemokine. Cells at this stage 
seem to aggregate near the spot border toward chemoattractant gradient just 
prior to the migration stage. After 10 hours of incubation (B), cells were 
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migrating toward the drop core which contain higher level of the ligand 
concentration. After 16 hours of incubation (C), migrated cells moved much 
further toward the spot core. The key observation in this assay is that we have 
seen that cells were migrating toward the spot containing chemoattractants. 
However, no cells movement was observed in all spots which contain no 
chemoattractants.  
Using Nikon Eclipse TI confocal microscope which detects fluorescently-
labelled molecule, we attempted to determine if the chemokine actually leaves 
the agarose spot. A fluorescently-labelled molecule was embedded in the 
agarose spot under the same conditions of the assay and the decay of 
fluorescence intensity in the spot by fluorescence microscopy was measured. 
As a surrogate for fluorescently labelled CCL21 chemokine, which is 
commercially available, but extremely expensive, blue dextran 10 kDa was 
used, which is similar to the molecular weight of the ligand CCL21, and this was 
tracked using confocal fluorescence microscopy. Unfortunately, the spot did not 
stay attached to the glass bottom although repeated attempting of making many 
different conditions like increasing the solidity of the agarose, going from 0.5% 
to 2%. Cold medium was added to the dextran containing spot in attempt to 
keep spot in a rigid state, however all efforts failed to keep the spot attached to 
the petri dish glassed bottom. This is in contrast to the agarose spot containing 
chemoattractant ligand which properly attached to the glass bottom dish even 
though the medium was exchanged with 0.1% FCS after 4 hour incubation. This 
is probably something to do with the structure of the dextran as a 
polysaccharide which is different from CCL21 ligand as a protein. This 
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experiment will be repeated again using a fluorescent labelled protein that has 
similar molecular structure and weight to the CCL21 ligand. 
Migration under agarose spot is selectively modulated by small molecule 
antagonists  
Our group has previously shown that migration of cells under an agarose spot 
containing CXCL12 can be decreased by an anti-human CXCR4 monoclonal 
antibody (MAB) and small molecule CXCR4 antagonists ICT5040 and 
AMD3100 150. AMD3100 is a selective CXCR4 antagonist and was previously 
shown not to antagonise other chemokine receptors including CCR7 151. In this 
experiment we aimed to demonstrate the suitability of the modified agarose spot 
assay to assess selectivity of small molecule antagonists toward multiple 
chemokine receptors under identical conditions. PC-3 cells were allowed to 
migrate under CXCL12, CCL21, and CCL19 spots in the same petri dish, in the 
presence or absence of CXCR4 antagonist AMD3100 in media. We set out the 
experiment using four petri dishes, each petri dish contain four agarose spots 
which contain CXCL12, CCL21, CCL19 and control. The petri dish was used as 
control in absence of AMD3100 in order to monitor migration of PC-3 cells 
toward different ligands in absence of AMD3100. The rest of the petri dishes 
were used in presence of different concentration of AMD3100 to monitor the 
effect of the antagonist on migration of PC-3 cells toward different receptors. In 
order to have dose dependant response of compound AMD3100, we used 
different concentrations including, 50µM, 100µM and 200µM in medium. All petri 
dishes were prepared at the same time and incubated for 4 hours to make cells 
attach properly to the glass bottom petri dish. Medium was discarded after 4 
hours and replaced with 0.1% FCS and again different concentrations of the 
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antagonist were prepared and applied to medium for overnight incubation. The 
figures obtained below demonstrates effectiveness and selectivity of compound 
AMD3100 against PC-3 cells migration under agarose spot containing CXCL12 
(Figure 35), CCL21 (Figure 36) and CCL19 (Figure 37) chemoattractant. The 
experiment presented herein was repeated at least three times using same 
conditions and results obtained were consistent.    
  
(A) PC-3 cells (CXCL12 100nM, 16hr) 
 
(B) PC-3 cells (CXCL12 100nM, AMD3100 
200 µM, 16hr) 
  
(C) PC-3 cells (CXCL12 100nM, 
AMD3100 100 µM, 16hr) 
(D) PC-3 cells (CXCL12 100nM, AMD3100 
50 µM, 16hr) 
 
 
(E) PC-3 cells (PBS, 16hr) 
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Figure 35 Migration under agarose spot is selectively modulated by small molecule 
antagonists AMD3100. PC-3 cells migration, which express chemokine receptor 
CXCR4, is blocked toward agarose spot containing CXCL12 (ligand for CXCR4) by 
using dose dependant small molecule antagonists AMD3100 (A) CXCL12, (B) 200 uM, 
(C) 100uM, (D) 50 µM of AMD3100, (E) PBS, (F) Relative chemotaxis index of PC-3 
cells migration under agarose spots. Data is presented as the mean ±SE of at least 3 
independent experiments. 
  
(A) PC-3 cells (CCL21 100nM, 16hr) (B) PC-3 cells (CCL21 100nM, AMD3100 
200 µM, 16hr) 
  
(C) PC-3 cells (CCL21 100nM, 
AMD3100 100 µM, 16hr) 
 
(D) PC-3 cells (CCL21 100nM, AMD3100 50 
µM, 16hr) 
 
130 
 
 
 
(E) PC-3 cells (PBS, 16hr) 
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Figure 36 Migration under agarose spot is selectively modulated by small molecule 
antagonists AMD3100. PC-3 cells migration, which express chemokine receptor CCR7, 
is blocked toward agarose spot containing CCL21 (ligand for CCR7) by using dose 
dependant small molecule antagonists AMD3100 (A) CCL21, (B) 200 µM, (C) 100 µM, 
(D) 50 µM of AMD3100, (E) PBS, (F) Relative chemotaxis index of PC-3 cells migration 
under agarose spots. Data is presented as the mean ±SE of at least 3 independent 
experiments. 
  
(A) PC-3 cells (CCL19 100nM, 16hr) (B) PC-3 cells (CCL19 100nM, AMD3100 
200 µM, 16hr) 
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(C) PC-3 cells (CCL19 100nM, 
AMD3100 100 µM, 16hr) 
 
(D) PC-3 cells (CCL19 100nM, AMD3100 50 
µM, 16hr) 
 
 
 
(E) PC-3 cells (PBS, 16hr) 
 
 
(F) 
R
e
la
ti
v
e
 C
h
e
m
o
ta
x
is
 I
n
d
e
x
C
C
L
1
9
 1
0
0
n
M
A
M
D
3
1
0
0
 5
0
µ
M
A
M
D
3
1
0
0
 1
0
0
µ
M
A
M
D
3
1
0
0
 2
0
0
µ
M
P
B
S
0 .0
0 .2
0 .4
0 .6
0 .8
C C L 1 9  1 0 0 n M + n o  A M D 3 1 0 0
C C L 1 9  1 0 0 n M + A M D 3 1 0 0  5 0 µ M
C C L 1 9  1 0 0 n M + A M D 3 1 0 0  1 0 0 µ M
C C L 1 9  1 0 0 n M + A M D 3 1 0 0  2 0 0 µ M
P B S  (s a m e  in  a ll e x p e im e n ts )
***
 
Figure 37 Migration under agarose spot is selectively modulated by small molecule 
antagonists AMD3100. PC-3 cells migration, which express chemokine receptor CCR7, 
is blocked toward agarose spot containing CCL19 (ligand for CCR7) by using dose 
dependant small molecule antagonists AMD3100 (A) CCL19, (B) 200 µM, (C) 100 µM, 
(D) 50 µM of AMD3100, (E) PBS, (F) Relative chemotaxis index of PC-3 cells migration 
under the agarose spots. Data is presented as the mean ±SE of at least 3 independent 
experiments. 
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The figures above indicate the selectivity of the AMD3100 small molecule in 
antagonizing the effect of CXCL12 through CXCR4 receptor. In these figures, 
clearly that show there was a negligible effect on the CCR7. In (Figure 35), we 
can see the selectivity of AMD3100 toward PC-3 migrated cells expressing 
CXCR4 receptor in a dose dependant manner. In the presence of 200µM 
AMD3100, we observed significant reduction of migration of PC-3 cells under 
agarose spot containing CXCL12 ligand. However, no significant reduction of 
migration was observed under the agarose spot containing CCL21 and CCL19 
ligands (Figure 36 and Figure 37 respectively). This observation is consistent 
with our expectation; a selective CXCR4 antagonist does antagonise the 
migration against CXCL12, but does not interfere with the migration against 
CCL19 or CCL21, because it does not antagonise CCR7, the corresponding 
receptor for these two chemokines. There was no migration seen under the 
agarose spots which contain no chemoattractant, this confirms that the 
induction of chemotaxis is caused by the chemoattractant gradient. It was 
mentioned above that the sensitivity of PC-3 cells toward CXCL12 is more likely 
to be higher than the CCL21 or CCL19 due to higher level of CXCR4 receptor 
expressed than the CCR7 receptor. Evidently the migration seen in the images 
above caused by the chemoattractant CCL21 is less than the migration 
obtained from the effect of CXCL12. Figure 38 below shows the direct 
compression between PC-3 cells migration toward their cognate ligands 
CXCL12 (ligand for CXCR4), CCL21 and CCL19 (ligands for CCR7) under 
agarose spot and selectivity of the antagonist AMD3100 toward CXCR4 
receptor but not CCR7 receptor. 
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Figure 38 PC-3 cells migration under agarose spot is selectively modulated by small 
molecule antagonists AMD3100. PC-3 cells migration, which express chemokine 
receptor CXCR4 and CCR7, is blocked toward agarose spot containing CXCL12 
(ligand for CXCR4), but not under agarose spot containing CCL21 and CCL19 (ligands 
for CCR7). Data is presented as the mean ±SE of at least 3 independent experiments. 
In order to study the effectiveness and selectivity of compound 75, we set out a 
parallel experiment to compound AMD3100. PC-3 cells which express both 
receptors were allowed to migrate under agarose spot containing CCL21 
(Figure 39), CCL19 (Figure 40), and CXCL12 (Figure 41) ligands in presence 
or absence of 10 µM CCR7 small molecule antagonist compound 75, ICT13069 
in medium. All spots were in the same petri dish and therefore the experiment 
conditions are identical.  
  
(A) PC-3 cells (CCL21 100nM, 16hr) (B) PC-3 cells (CCL21 100nM, compound 
75 10 µM, 16hr) 
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(C) PC-3 cells (PBS, 16hr)  
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Figure 39 Migration under agarose spot is selectively modulated by small molecule 
antagonists, 75. PC-3 cells migration, which express chemokine receptor CXCR4 and 
CCR7, is allowed to migrate toward agarose spot containing (A) CCL21 (ligand for 
CCR7), (B) 10 µM of compound 75 (C) control (PBS) (D) Relative chemotaxis index of 
PC-3 cells migration toward agarose spots. Data is presented as the mean ±SE of at 
least 3 independent experiments. 
In order to demonstrate the reliability of the newly modified agarose assay, PC-
3 cells were also allowed to migrate toward agarose spot containing CCL19 and 
in presence of 10 µM of CCR7 receptor antagonist, compound 75. Figure 40 
shows modulation of PC-3 cells migration toward CCL19 spot using CCR7 
receptor antagonist. 
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(A) PC-3 cells (CCL19 100nM, 16hr) (B) PC-3 cells (CCL19 100nM, compound 
75 10 µM, 16hr) 
 
 
(C) PC-3 cells (PBS, 16hr) 
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Figure 40 Migration under agarose spot is selectively modulated by small molecule 
antagonists 75. PC-3 cells migration, which express chemokine receptor CXCR4 and 
CCR7, is allowed to migrate toward agarose spot containing (A) CCL19 (ligand for 
CCR7), (B) 10 µM of compound 75 (C) control (PBS), (D) Relative chemotaxis index of 
PC-3 cells migration toward agarose spots. Data is presented as the mean ±SE of at 
least 3 independent experiments. 
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In the same experiment, compound 75 selectivity was determined using 
different spot containing CXCL12 ligand with same experiment conditions. PC-3 
cells were allowed to migrate toward agarose spot containing CXCL12 and in 
different petri dish, same conditions were applied, yet this time in presence of 
10 µM of CCR7 receptor antagonist, compound 75. This was done to find out 
how selective is the newly synthesized molecule is? Figure 41 shows the effect 
of the antagonist against CXCR4 receptor using CXCL12 as a cognate ligand. 
  
(A) PC-3 cells (CXCL12 100nM, 16hr) (B) PC-3 cells (CXCL12 100nM, compound 
75 10 µM, 16hr) 
 
 
(C) PC-3 cells (PBS, 16hr) 
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Figure 41 Migration under agarose spot is selectively modulated by small molecule 
antagonists 75. PC-3 cells migration, which express chemokine receptor CXCR4 and 
CCR7, is allowed to migrate toward agarose spot containing (A) CXCL12 (ligand for 
CXCR4), (B) 10 µM of compound 75 (C) control (PBS), (D) Relative chemotaxis index 
of PC-3 cells migration toward agarose spots. Data is presented as the mean ±SE of at 
least 3 independent experiments. 
Figures above demonstrates effectiveness and selectivity of compound 75 
against PC-3 cells migration under agarose spot containing CXCL12, CCL21 
and CCL19 chemoattractant. In the presence of 10 µM compound 75, migration 
of PC-3 cells under the CCL21 and CCL19 spots was significantly reduced. 
However, the reduction observed with the CXCR4 receptor was not as 
significant as the CCR7 receptor. This observation is consistent with our 
expectation, and correlates with the calcium flux assay results. Figure 42 below 
shows the direct comparison between PC-3 cells migration toward their cognate 
ligands CXCL12 (ligand for CXCR4), CCL21 and CCL19 (ligands for CCR7) 
under agarose spot and selectivity of the antagonist 75 toward CCR7 receptor 
but less toward CXCR4 receptor. 
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Figure 42 Migration under agarose spot is selectively modulated by small molecule 
antagonists 75. PC-3 cells migration, which express chemokine receptor CXCR4 and 
CCR7, is blocked toward agarose spot containing CCL21, CCL19 (ligands for CCR7) 
and CXCL12 (ligand for CXCR4). Data is presented as the mean ±SE of at least 3 
independent experiments. 
For further confirmation to our results obtained from the selectivity of compound 
75 using newly modified agarose spot assay, calcium flux mobilization assay 
was conducted. PC-3 cells were plated in 96-well plate and tested each time 
using the three different ligands, CCL21 and CCL19 (ligands for CCR7) and 
CXCL12 (ligand for CXCR4) without the antagonist to measure the fluorescence 
obtained upon binding of these ligands with their receptors. PC-3 cells 
responded to all ligands and this is obviously because of the expression of 
these receptors in this cell line. Using the same 96-well plate PC-3 cells were 
incubated with the antagonist, 75 and florescence released from the ligands 
interaction with the receptors was measured. Significant reduction in florescent 
was observed in wells which treated with the antagonist and used CCL21 and 
CCL19 as a cognate ligand. However, wells which treated with the antagonist 
and used CXCL12 as cognate ligand showed no significant reduction in the 
amount of florescent released (Figure 43). However, still some effect observed 
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against CXCR4 receptor in compare to the CCR7 receptor. It is also worth to 
mention that in this assay, as illustrated from the figure below, PC-3 cells 
showed response to their cognate ligands in relation to the level of expression 
of these receptors. Fluorescent released upon binding CXCL12 ligand with 
CXCR4 receptor was higher than the fluorescent released upon binding CCL21 
ligand with CCR7 receptor. PC-3 cells showed least release of the fluorescence 
upon binding of CCL19 ligand with CCR7 receptor. These findings correlated 
with the previously mentioned results in Figure 31 regarding chemotactic 
aptitude of PC-3 cells, as measured by the number of migrated cells under the 
agarose spot assay.    
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Figure 43 Inhibition of CCL21, CCL19 (ligands for CCR7) and CXCL12 (ligand for 
CXCR4) mediated response by small molecule antagonists 75 using PC-3 cells. Data 
is presented as the mean ±SE of at least 3 independent experiments. 
Comparison between compound 75 and compound 3 under agarose spot assay 
We have previously shown that migration of PC-3 cells under an agarose spot 
containing CCL21 or CCL19 can be modulated by small molecule CCR7 
antagonist, 75. We have also shown in chapter 2 that compound 75 showed 
higher potency as CCR7 antagonist in the calcium flux assay with IC50 around 
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0.19±0.22 µM than compound 3 which showed activity with IC50 around 10±2.56 
µM. We wanted to draw a direct comparison between assessment of potency 
using calcium flux and agarose spot method. So, the inhibition of PC-3 cells 
migration was compared between compound 75 and much less potent 
compound 3. PC-3 cells were plated in two small petri dish, each contain two 
agarose spots containing CCL21 and CCL19 ligands and two spots containing 
control, PBS. In one petri dish using the same experiment conditions, 
compound 3 was included in the medium and the other petri dish was used as 
control, both petri dishes were incubated overnight to be inspected the following 
day. The concentration of compound 3 used in this experiment is 50 µM which 
is 5 fold higher than the concentration of compound 75, 10 µM, which used 
previously in Figure 39. Figure 44 below shows migration of PC-3 cells toward 
agarose spot containing CCL21 ligand and in presence of small molecule 
compound 3 at concentration 50µM.  
  
(A) PC-3 cells (CCL21 100nM, 16hr) (B) PC-3 cells (CCL21 100nM, compound 3 
50 µM, 16hr) 
 
 
(C) PC-3 cells (PBS, 16hr) 
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Figure 44 Inhibition of PC-3 migration by CCR7 antagonists 3 in an agarose spot 
containing CCL21 ligand: PC-3 cells migration, which express chemokine receptor 
CCR7, is allowed to migrate toward agarose spot containing (A) CCL21 (ligand for 
CCR7), (B) 50 µM of compound 3 (C) control (PBS), (D) Relative chemotaxis index of 
PC-3 cells migration toward agarose spots. Data is presented as the mean ±SE of at 
least 3 independent experiments. 
Figure 45 below shows migration of PC-3 cells toward agarose spot containing 
CCL19 ligand and in presence of small molecule compound 3 at concentration 
50µM.  
  
(A) PC-3 cells (CCL19 100nM, 16hr) (B) PC-3 cells (CCL19 100nM, compound 3 
50 µM, 16hr) 
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(C) PC-3 cells (PBS, 16hr) 
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Figure 45 Inhibition of PC-3 migration by CCR7 antagonists 3 in an agarose spot 
containing CCL19 ligand: PC-3 cells migration, which express chemokine receptor 
CCR7, is allowed to migrate toward agarose spot containing (A) CCL19 (ligand for 
CCR7), (B) 50 µM of compound 3 (C) control (PBS), (D) Relative chemotaxis index of 
PC-3 cells migration toward agarose spots. Data is presented as the mean ±SE of at 
least 3 independent experiments. 
All experiment were performed on the same day using same cell density and 
same conditions. Figure 44 shows migration of PC-3 cells toward agarose spot 
containing CCL21 ligand in presence and absence of compound 3 as 
antagonist. When cells were treated with 50 µM of compound 3, a modest 
reduction in cells migration toward the drop was observed. This is beyond 
comparison with the significant reduction observed when these cells were 
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treated with 10 µM of compound 75 (Figure 39). The figure shows no migration 
in spots containing no chemoattractant, control. Figure 45 shows modest effect 
of compound 3 against PC-3 cells migration toward agarose spot containing 
CCL19 ligand. However, when compound 75 was used in presence of CCL19 
as a ligand, there was a significant decrease in cell numbers (Figure 40). The 
concentration of compound 75 used was 10 µM which is five times less than the 
concentration of compound 3, 50 µM. This indicates the improvement and 
enhancement of the antagonizing activity of compound 75 against CCR7 
receptor which was carried out in our laboratory department.  
To summarize, the modified agarose spot assay described herein provided us 
with opportunity to examine cells movement toward different chemo-attractants 
at the same time. We described how different cells responded to different 
chemo-attractants. Cells are only directing their movement toward agarose spot 
which contain chemo-attractants. The key observation in this newly configured 
technique is that we have seen cell which express chemokine receptors 
migrating toward all the agarose spots which contain chemoattarctants through 
all the experiments. In contrast, we have seen no cells movement toward spots 
which lack chemo-attractants which proves the migration was mediated by the 
presence of ligand. We performed time-lapse imaging to study cells movement 
toward spots contain chemo-attractants, the motility of migrated cells were 
moving toward the agarose spot core contains ligand in progressive way. In 
order to prove that cell migration is in response to the receptor expression, we 
applied this assay using SW480 cells which express only CXCR4 receptor and 
not CCR7 receptor. SW480 cells migrated only toward agarose spot which 
contain CXCL12 (ligand for CXCR4) and we have seen no cell migration toward 
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agarose spots which contain CCL21 and CCL19 (ligands for CCR7). This 
migration toward CXCL12 drop is obviously in response to CXCR4 receptor 
which proved to be expressed in SW480 cells using flow cytometry and western 
blot. We measured and assessed antagonist selectivity between different 
chemokine receptors under identical experimental conditions. The selectivity of 
the small molecule AMD3100 was observed to block CXCR4 receptor but not 
CCR7 receptor. We demonstrated the significant selectivity of compound 75 
against CCR7 receptor over CXCR4 receptor. We also compared effectiveness 
of highly active compound 75 with less active compound 3 against CCR7 
receptor which proved the potency of compound 75 to reduce chemotaxis at a 
given concentration over compound 3. In summary, we established and 
generated rigorous and easy to perform assay, which allow us to analyse and 
assess cells chemotactic aptitude toward multiple chemo-attractants over a 
period of time. The importance of this modification is to analyse cells movement 
and to evaluate antagonist’s activity of small molecules against migration and 
invasion of cells through a planner surface in an identical conditions. Results 
obtained from agarose spot assay was in agreement with results obtained from 
different functional assays like calcium flux assay, flow cytometry and scratch 
assay.  
3.7. Concluding remarks and future works 
The chemokine receptor CCR7 is belonging to the G-protein coupled receptor 
family which is commonly associated in cancer progression and metastasis. 
Blocking the activity of this receptor by a small molecule will eventually reduce 
or prevent cancer growth and metastasis. It is true that blocking the CCR7 
receptor means blocking its normal role in attracting immune cells toward 
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inflammation site. However, there are other types of chemokine receptors and 
cytokines working as chemo-attractants leading to immune cells migration to the 
infection site and cancer is resistant to the immune system 171. Although recent 
studies reported high expression of CCR7 receptor in number of different 
cancer tissues, limited studies explored interfering of the receptor function using 
antibody. However, up to date, there is no small molecule discovered or claimed 
to be an antagonist for this receptor. In this study, we investigated the 
interference between chemokine receptor CCR7 and its ligands using small 
molecule antagonist.  
This receptor was first modelled using a homology modelling which was 
constructed by help of Professor Colin Fishwick at the University of Leeds. 
Compounds obtained from screening library were tested using calcium flux 
assay in our laboratory department and none of these molecules were active 
against CCR7 receptor, so they were excluded from further analysis. Additional 
investigation in literature review, we found a patent describes a technique for 
screening therapeutic compounds which thought to be useful in the methods for 
screening for therapeutic compounds that are useful in the recovery from 
diseases that involves CCL21 and CCR7 interaction. The binding nature of this 
compound remains unknown and not identified and was not claimed as CCR7 
antagonist. We successfully synthesized and characterised this compound in 
our laboratory department and named compound 1, ICT5189. We tested the 
compound using calcium flux assay and confirmed to be an antagonist to the 
CCR7 receptor. Compound 3, ICT5888 was discovered during the synthesis 
process of compound 1 and tested to give activity with comparable result to 
compound 1. Following the biological evaluation of compound 3, different 
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analogues of these compounds have been synthesised and characterised in 
order to look for structure activity relationships and improve their potency as 
antagonists of the CCR7 receptor. Structural activity relationship was carried 
out and determined the most active compound amongst series of many 
compounds. Based on calcium flux assay results obtained, compound 75, 
ICT13069 was identified as the most active compound. It is a novel small 
molecule CCR7 receptor antagonist which is never been synthesised or claimed 
in literature. We evaluated the activity of this compound using different in vitro 
assays like agarose spot assay and scratch assay. The selectivity of the 75 
against CCR7 receptor was determined using PC-3 cells, which express both 
CCR7 and CXCR4. Results obtained showed higher selectivity of the 
compound toward CCR7 receptor than CXCR4. These findings were confirmed 
using calcium flux assay and other biological assays. The structure-activity 
relationship study of compound ICT5888 and development of its analogues has 
afforded greater understanding of the lead compound pharmacophore which is 
responsible for binding to the CCR7 receptor. These findings allowed us to 
identify the important sites in the compound which are amenable to 
modifications. Consequentially, in future, there will be more investigations 
towards compounds which showed comparable activity to the top active 
compound. Compound ICT13069 is now used as a tool to look for a more 
potent compound. Our first objective is to make the reverse sulphonamide of 
compound 75. Also, more studies are required to explore different positions of 
compounds 85, ICT13130, 97, ICT13124 and 49, ICT13063 which were 
synthesised in very late stage of my research. Future analogues will address 
the importance of solubility in an aqueous medium which is an important factor 
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that may improve compounds efficacy and reduce their side effects. This is can 
be done by keeping the right balance between hydrophilicity and lipophilicity of 
the compound. It would also be worth chemically attaching a florescent tag to 
the most active compound in order to aid in tracking down the process of 
blocking the receptor using confocal microscope which detects fluorescently-
labelled molecule. One of the most important considerations which will take 
place in future investigations is the selectivity of the top active compound 
against CCR7 receptor. At this stage, we are looking for a compound that 
blocks this receptor and has no or less effect on other GPCR receptors. We 
investigated the selectivity of compound ICT13069 against CXCR4 receptor, 
which has similar receptor structure, and showed less selectivity. The aim, in 
future, is to synthesise compounds which are highly activity against CCR7 
receptor and send it to companies which target selectivity profiles of any new 
small molecule. The newly top active synthesised compound will be evaluated 
and tested using different preclinical studies including in vitro and in vivo assays 
in order to prove its potency against CCR7 receptor. Future investigation will 
also cover all the biological assays that have to be completed. Table 15 below 
summarises all the cell lines used for each assay in this research, so that future 
work will cover all the gaps required to have a full picture of the research. Once 
all of these studies and investigations have taken place and proved the 
candidate drug as a potent and selective for CCR7 receptor, the next step 
would be to more towards pre-clinical and clinical trials. The clinical trial is 
aimed to evaluate drug efficacy and safety in human and eventually to collect 
data from post marketing.  
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Cell Lines  CCR7 
WB 
CCR7 
FACS 
CXCR4 
FACS 
CCL19 
Agarose 
S. A. 
CCL21 
Agarose 
S. A. 
CXCL12 
Agarose 
S. A. 
CCL19 
Ca2+ Flux 
CCL21 
Ca2+ Flux 
Scratch 
Assay 
SW620          
MDA231          
U87-MG          
DU-145          
PC3          
DLD-1          
MCF-7          
MCF-7  
ADR 
         
HT-29          
HUVEC          
Panc-1          
CCRF-CEM          
OSC-19          
SW480          
Table 15 summary table of all cell lines used for each assay and gaps which will be covered in future investigation. 
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4.1. Experimental Section 
4.1.1. Experimental techniques and materials 
All chemical reagents and starting materials used below were commercially 
available and purchased from Sigma-Aldrich, alfa aesar and tocris. All the 
reagents were used as purchased without any additional purification unless 
otherwise stated. All solvents were of reagent grade, suited for general 
laboratory use. Petroleum ether (PE) refers to the fraction of petroleum spirit 
boiling in the range of 60 to 80 °C. Where stated, mixtures of solvents are 
referred to as volume-to-volume (v/v) ratios. All the compounds made were 
purified by flash chromatography using high-purity silica gel (Merck Grade 
9385), pore size 40-63 µm (CAS Number: 112926-00-8). The analytical thin 
layer chromatography was conducted on Merck silica gel 60 F254 glass backed 
plates (catalogue number 1.05715.0001, Merck Millipore). TLC plates were 
visualised under ultraviolet light lamp (254 nm), or by dipping in basic potassium 
permanganate (KMNO4) solution.  
Hydrogen (1H) Nuclear Magnetic Resonance spectra were recorded in 
deuterated solvents as stated in individual experimental procedures, using 
Bruker AMX400  spectrometer operating at 400 MHz. Carbon (13C) Nuclear 
Magnetic Resonance were performed on the same machines operating at 101 
MHz. Chemical shifts are reported in parts per million (δ, ppm). 1H NMR 
chemical shifts are reported relative to an internal reference (tetramethylsilane) 
or residual proton signals of the solvent. Coupling constants (J) are expressed 
in Hertz (Hz). The splitting patters in NMR spectra are reported with the 
following abbreviations: singlet (s), doublet (d), triplet (t), quartet (q), quintet 
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(quint.), multiplet (m) and broad (br). 13C NMR chemical shifts are reported 
relative to the signal of the solvent. Where necessary, correlation spectroscopy 
(COSY), nuclear Overhauser enhanced spectroscopy (NOESY), heteronuclear 
multiple quantum correlation spectroscopy (HMQC), and distortionless 
enhancement by polarization transfer (DEPT) technique were employed to 
confirm the assignment of NMR spectra. Routine mass spectra was carried out 
at the Analytical Center of the University of Bradford by Mr Andrew Healey and 
were run on a Micromass Quattro Ultima spectrometer in the electron impact 
(EI), chemical ionisation (CI) or positive (+ve) electrospray mode, as stated. All 
high resolution mass spectrometry (HRMS) was carried out at the ESPRC 
National mass spectrometry service centre located in Swansea University.  
Drying oven was used at 140 °C temperature in order to dry all the glassware. 
Reactions sensitive to moisture or air, were carried out under inert atmosphere 
using dry nitrogen or argon. Silicon oil was used to heat up reaction on oil bath 
and place on top of a hot plate stirrer. Mixtures of ice and water were used to 
maintain temperature at 0 °C. 
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4.1.2. Experimental procedures for preparation of chemical compounds 
1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide (5, ICT13001). 
 
Chloromethane sulfonyl chloride (10.0 g, 67.1 mmol) was added dropwise to a 
stirred solution of 2-aminophenol (7.06 g, 64.7 mmol) in anhydrous 
tetrahydrofuran (40 mL) maintained at room temperature under an inert 
atmosphere. After 30 minutes, pyridine (7.30 mL) was added and the resulting 
solution was left stirring overnight at room temperature. Concentrated 
hydrochloric acid (10 mL, 37 %) was added and reaction mixture was extracted 
with ethyl acetate (3 x 150 mL). The combined organic extracts were washed 
with saturated aqueous sodium bicarbonate (200 mL) and brine (200 mL). The 
organic extracts were dried over magnesium sulphate, filtered and concentrated 
in vacuo to give dark red residue. This residue was re-dissolved in methanol 
(100 mL) and solid K2CO3 (26 g) was added to the solution. The solution was 
heated under reflux for 1.5 hr, cooled to room temperature, filtered and 
concentrated to give a black residue. Dichloromethane (3 mL) was added to the 
residue which resulted in precipitation of a solid identified as the title compound 
and supernatant which contained the title compound plus impurities. The 
supernatant was purified by flash column chromatography (EtOAc:PE, 2:8 v/v) 
to give the title compound as a brown solid (combined  7.22 g, 60%); The 
proton and 13C data were in agreement with previously published data 122; m.p. 
123.2-123.9 °C; IR: 3225, 2791,1606, 1591, 1494, 1467, 1429, 1395, 1331, 
153 
 
1314, cm-1; 1H NMR (DMSO-d6) δ 10.59 (s, 1H, NH), 7.07 (d, J =7.1 Hz, 2H, H-
5, H-8), 6.83 (d, J =7.1, Hz, 1H, H-6, H-7), 5.20 (s, 2H, CH2); 13C {1H} NMR 
(DMSO-d6) δ 141.9 (ArC-O), 127.1 (ArC-N), 123.5 (overlapping, C-6, C-8), 
119.9 (C-5), 118.1 (C-7), 76.4 (CH2); LRMS (ESI) m/z: 186.83 (M+H)+; HRMS 
(ESI) m/z calcd. for C7H7O3NNaS [M+Na]+ 208.0036, found: 208.0036. 
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(E)-6-(phenyldiazenyl)-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide. (8, 
ICT13003). 
 
Preparation of benzendiazonium salt: To a stirred solution of aniline (4.29 g, 
46.00 mmol) in water (25 mL), concentrated hydrochloric acid (10 mL, 37 %) 
was added drop wise. The solution was left to cool in an ice bath for 15 minutes 
and then a solution of sodium nitrite (3.32 g) in water (5 mL) was added to give 
benzendiazonium salt as a yellow solution. 
Potassium Carbonate K2CO3 (8.40 g, 60.7 mmol) was added to a stirred 
solution of 1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide 5 (2.80 g, 15.1 mmol) in 
methanol (25 mL). The reaction mixture left to cool in ice bath and then freshly 
prepared solution of benzenediazonium salt was added (35 mL). Hydrochloric 
acid (10 mL, 3M) was then added to the reaction mixture. The mixture was 
filtered and resultant dark red solid was collected and dried. The crude product 
was purified by chromatography (EtOAc:PE, 2:8 v/v) to  the title compound 
(1.38 g, 31% ) as dark brown solid; 1H NMR (DMSO-d6) δ 11.28 (s, 1H, NH), 
7.86 (d, J = 8.0 Hz, 2H, H-14, H-18), 7.67 (dd, J = 8.5, 2.0 Hz, 1H, H-7), 7.59 (d, 
J = 8.0 Hz, 2H, H-15, H-17), 7.56 (d, J = 8.5 Hz, 1H, H-8) 7.00-6.98 (m, 2H, H-
5, H-16), 5.75 (s, 2H, CH2); 13C {1H} NMR (DMSO-d6) δ 151.9 (C-13), 147.1 (C-
10), 143.5 (C-6), 130.1 (C-16), 129.9 (C-9), 128.1 (overlapping C-14, C-18), 
123.4 (overlapping C-15, C-17), 119.0 (C-8), 117.8 (C-7), 108.1 (C-5), 79.4 
(CH2); LRMS (ESI) m/z: 290.1 (M+H)+; 
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6-amino-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide. (3, ICT5888). 
 
From Compound 8: To a stirred solution of compound 8 (0.92 g, 3.17 mmol) in 
ethanol (50 mL), platinum oxide (70.0 mg) was added. The mixture was left 
stirring overnight under hydrogen gas. The reaction mixture was filtered, using 
celite as filtering aid, and concentrated. The product was purified by flash 
column chromatography (EtOAc:PE, 4:6 v/v → neat EtOAc )  to give the title 
compound as light brown solid (0.24 g, 38%); 
From compound 11 (see next experiment): 250 mL flask was charged with -
nitro-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide 11 (0.28 mg, 1.21 mmol) and 
EtOAc (40 mL). Palladium on carbon (10% (w/w), 72 mg) was then added 
carefully. The reaction mixture was stirred at R.T under hydrogen for 24h. The 
mixture was filtered through celite and concentrated to give (0.27 mg, 92%) of 
the title compound as light brown powder; m.p. 175.1-175.7 °C; IR: 3394, 3345, 
3001, 2710, 1624, 1589, 1507, 1423, 1340, 1323 cm-1; 1H NMR (DMSO-d6) δ 
9.50 (s, 1H, NH), 6.54 (d, J = 8.5 Hz, 1H, H-8), 6.26 (dd, J = 8.5, 2.5 Hz, 1H, H-
7), 6.22 (d, J = 2.5 Hz, 1H, H-5), 5.07 (s, 2H, NH2), 5.03 (s, 2H, CH2); 13C {1H} 
NMR (DMSO-d6) δ 148.4 (C-10), 143.6 (C-6), 122.7 (C-9), 114.9 (C-8), 109.6 
(C-7), 102.2 (C-5), 100.8 (CH2); LRMS (ESI) m/z: 201.83 (M+H)+; HRMS (ESI) 
m/z calcd. for C7H9O3N2S [M+H]+: 201.0328, found: 201.0324. 
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6-nitro-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide (11, ICT13031). 
 
To a solution of 1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide 5 (1.00 g, 5.40 mmol) 
in glacial acetic (8 mL) acid, sodium nitrite (0.45 g, 6.53 mmol) was added. 
Solution of concentrated glacial acetic acid (4.5 mL) and nitric acid (0.22 mL) 
was prepared and added drop wise, changes to yellow solution. The reaction 
solution was left stirring at room temperature for 4 hours. The reaction solution 
was then poured into a beaker contain mixture of ice and water (50 mL) and the 
resulted powder was filtered, collected and dried. The crude product was 
separated and purified by chromatography (EtOAc:PE:Acetic Acid, 2:8:3d) to  
give the title compound (0.70 g, 56%) as yellowish white powder; m.p. 170.5-
170.9 °C; IR: 3241, 2947,1935, 1612, 1529, 1478, 1460, 1432, 1348, 1314, cm-
1; 1H NMR (DMSO-d6) δ 7.98 (dd, J = 8.6, 1.8 Hz, 2H, H-7), 7.94 (d, J = 1.8 Hz, 
2H, H-5), 7.01 (d, J = 1.8 Hz, 1H, H-8), 5.42 (s, 2H, CH2); 13C {1H} NMR 
(DMSO-d6) δ 141.8 (C-10), 140.9 (C-6), 134.5 (C-9), 119.7 (C-7), 118.5 (C-5), 
113.9 (C-8), 76.2 (CH2); LRMS (ESI) m/z: 231.4 (M+H)+. 
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(E) & (Z)-3-(2-(triisopropylsilyl)oxazol-5-yl)acrylaldehyde (13, ICT13040, 14, 
ICT13041). 
 
A solution of 2-(triisopropylsilyl) oxazole-5-carbaldehyde 12 (0.90 g, 3.5 mmol) 
in dry toluene (50 mL) was refluxed with 2-(triphenylphosphoranylidene) 
acetaldehyde 15 (3.23 g, 3 eq.) for 3 hours. The solution was allowed to cool to 
room temperature and solvent was then reduced under pressure. The crude 
material was purified by flash chromatography (EtOAc:PE, 1:9 v/v). Which 
yielded two pure isomers, compound 13 (0.60 g, 61%) as yellowish orange solid 
and compound 14 (0.2 g, 20%) as yellow solid; Compound 13; m.p. 145.2-
146 °C; IR: 3404, 3114, 2942, 2865, 2756, 1666, 1624, 1611, 1548, 1463 cm-1; 
1H NMR (CDCl3) δ 9.60 (d, J = 8.0 Hz, 1H, COH), 7.42 (s, 1H, H-4), 7.25 (d, J = 
16.0 Hz, 1H, H-6), 6.57 (dd, J = 16.0, 8.0 Hz, 1H, H-7), 1.36 (m, 3H, C3H 
(CH3)6), 1.08 (d, J = 7.4 Hz, 18H, C3(CH3)6); 13C {1H} NMR (CDCl3) δ 192.7 
(COH), 172.5 (C-2), 149.4 (C-4), 134.5 (C-6), 131.9 (C-5), 128.1 (C-7), 30.8 (C3 
(CH3)6), 18.3 (C(CH3)6); LRMS (ESI) m/z: 280.1 (M+H)+; Compound 14; m.p. 
146.1-146.9 °C; IR: 3405, 3114, 2942, 2866, 2757, 1666, 1624, 1611, 1548, 
1463 cm-1; 1H NMR (CDCl3) δ 9.56 (d, J = 8.0 Hz, 1H, COH), 7.26 (s, 1H, H-4), 
6.82 (d, J = 8.3 Hz, 1H, H-6), 6.24 (dd, J = 8.3, 8.0 Hz, 1H, H-7), 1.26 (m, 3H, 
C3H (CH3)6), 1.04 (d, J = 7.4 Hz, C3(CH3)6); 13C {1H} NMR (CDCl3) δ 193.3 
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(COH), 150.6 (C-2), 132.4 (C-4), 128.7 (C-6), 126.6 (C-5), 125.4 (C-7), 23.3 (C3 
(CH3)6), 17.9 (C (CH3)6); LRMS (ESI) m/z: 280.1 (M+H)+. 
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6-((18-(17-(triisopropylsilyl) oxazol-15-yl) propyl) amino)-1H-benzo[e][1,3,4] 
oxathiazine 2,2-dioxide (17, ICT13042). 
 
A solution of compound 13 (0.50 g, 1.78 mmol) and compound 3 (0.29 g, 1.49 
mmol) in absolute ethanol (9 mL) was left stirring at room temperature 
overnight. Platinum (IV) oxide (18.0 mg) was then added and the resulting 
mixture was left stirring under hydrogen for 5 hours at room temperature. The 
reaction mixture was filtered through celite and concentrated to give dark brown 
oil. The crude material was purified by flash chromatography (EtOAc:PE 3:7 v/v) 
to afford the title compound as dark brown solid (0.39 g, 56 %); m.p. 171.4-
172 °C; 1H NMR (CDCl3) δ 6.78 (s, 1H, H-19), 6.63 (d, J = 8.6 Hz, 1H, H-8), 
6.45 (dd, J = 8.6, 2.4 Hz, 1H, H-7), 6.23 (d, J = 2.4 Hz, 1H, H-5) 4.98 (s, 1H, 
CH2S), 3.06 (t, J = 7.2 Hz, 2H, H-12), 2.72 (t, J = 7.2 Hz, 2H, H-14), 1.88 (m, 
2H, H-13), 1.23 (m, 3H, C3H (CH3)6), 1.10 (d, J = 7.4 Hz, 18H, C3(CH3)6). 13C 
{1H} NMR (CDCl3) δ 167.8 (C-17), 153.7 (C-10), 122.5 (C-15), 122.2 (C-6), 
120.7 (C-19), 116.5 (C-9), 116.2 (C-8)  109.5 (C-7) 104.5 (CH2S), 94.3 (C-5), 
30.9 (C-12), 29.7 (C-14), 23.1 (C-13), 18.4 (C3 (CH3)6), 10.9 (C (CH3)6). LRMS 
(ESI) m/z: 466.7 (M+H)+, HRMS (ESI) m/z calcd. for C22H36N3O4SSi  [M+H]+: 
466.0256, found: 466.0254 
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6-((18-(oxazol-15-yl)propyl)amino)-1H-benzo[e][1,3,4]oxathiazine 2,2-
dioxide (1, ICT5189). 
 
A 1M solution of tetra butylammonium fluoride (TBAF) (0.15 mL, 1 eq) was 
added to a solution of compound 17 (68.3 mg, 0.14 mmol) in THF (7.35 mL) at 
room temperature. The reaction solution was lift stirring under nitrogen for 15 
minutes. The completion of the reaction was monitored by TLC. The reaction 
mixture was directly impregnated on silica and purified by flash chromatography 
(EtOAc:PE, 6:4 v/v) to give the title compound as dark brown solid (41.3 mg, 
95%); m.p. 160.5-161 °C; IR: 3401, 2929, 2852, 1625, 1588, 1509, 1433, 1392, 
1326, 1212 cm-1; 1H NMR (Acetone-d6) δ 7.86 (s, 1H, H-17), 6.71 (s, 1H, H-19), 
6.59 (d, J = 8.6 Hz, 1H, H-8), 6.25 (dd, J = 8.6, 2.4 Hz, 1H, H-7), 6.15 (d, J = 2.4 
Hz, 1H, H-5), 4.87 (s, 2H, CH2S), 3.02 (t, J = 7.6 Hz, 2H, H-12), 2.69 (t, J = 7.6 
Hz, 2H, H-14), 1.82 (m, 2H, H-13); 13C {1H} NMR (Acetone-d6) δ 153.4 (C-17), 
151.4 (C-10), 145.4 (C-10, C-6), 124.5 (C-19), 122.8 (C-8), 116.1 (C-9), 109.3 
(C-7), 101.4 (CH2S), 77.8 (C-5), 43.5 (C-12), 27.9 (C-14), 23.4 (C-13); LRMS 
(ESI) m/z: 310.1 (M+H)+; HRMS (ESI) m/z calcd. for C13H16O4N3S  [M+H]+: 
310.0856, found: 310.0858. 
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15-(tert-butyl)-N-(2,2-dioxido-1H-benzo[e][1,3,4]oxathiazin-6-yl) 
benzenesulfonamide (18, ICT13081). 
 
Round bottom flask was charged with 6-amino-1H-benzo[e][1,3,4]oxathiazine 
2,2-dioxide 3 (0.10 g, 0.50 mmol) and dry prydine (7 mL). The solution was 
treated dropwise with solution of 4-tert-butylbenzenesulfonyl chloride 61 (0.13 g, 
0.60 mmol) in DCM with constant stirring and cooling to 0 °C. After the addition 
was over, the mixture was stirred for 5 hour at R.T and then poured over ice 
and water. The solid was filtered, washed with water and extracted with ethyl 
acetate (3x50 mL). The combined organic extracts were dried over anhydrous 
MgSO4, filtered and the solvent was removed under reduced pressure. The 
resultant material was purified by flash column chromatography (EtOAc:PE, 2:8 
v/v) to give the title compound (0.15 g, 80%) as white powder; m.p: 165.4-165.9 
°C; IR: 3274, 2963, 1593, 1507, 1405, 1329, 1306, 1291, 1255, 1196 cm-1; 1H 
NMR (Acetone-d6) δ 7.67 (d, J = 8.7 Hz, 2H, H-13, H-17), 7.51 (d, J = 8.7 Hz, 
2H, H-14, H-16), 6.83 (dd, J = 8.5, 2.3 Hz, 1H, H-7), 6.81 (d, J = 2.3 Hz, 1H, H-
5), 6.72 (d, J = 8.5 Hz, 1H, H-8), 4.94 (s, 2H, CH2), 1.18 (s, 9H, C(CH3)3); 13C 
{1H} NMR (Acetone-d6) δ 156.9 (C-15), 143.8 (C-10), 137.6 (C-12), 135.2 (C-6), 
127.7 (overlapping C-13, C-17), 126.9 (overlapping C-14, C-16), 124.3 (C-9), 
124.1 (C-8),  122.5 (C-7), 116.6 (CH2), 111.1 (C-5), 76.7 (CH2), 35.6 (C(CH3)3), 
31.2 (C(CH3)3); LRMS (ESI) m/z: 395.98 (M-H)-; HRMS (ESI) m/z calcd. for 
C17H24O5N3S2  [M+NH4]+: 414.1152, found: 414.1149 
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17-((17-(dimethylamino)phenyl)diazenyl)-N-(2,2-dioxido-1H-benzo[e][1,3,4] 
oxathiazin-6-yl)benzenesulfonamide (19, ICT13088). 
 
Compound 6-amino-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide 3 (0.10 g, 0.50 
mmol) in dry prydine (10 mL) was treated dropwise with Dabsyl chloride (0.19 g, 
0.60 mmol) with constant stirring and cooling to 0 °C. After the addition was 
over, the mixture was stirred for 5h at R.T and then poured over ice and water. 
The solid was filtered, washed with water and extracted with ethyl acetate (3x50 
mL). The combined organic extracts were dried over anhydrous MgSO4, filtered 
and the solvent was evaporated under reduced pressure. The resultant material 
was purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the 
title compound (0.13 g, 70 %) as a light red powder; m.p: 171.1-171.6 °C; 1H 
NMR (Acetone-d6) δ 7.77 (d, J = 9.7 Hz, 4H, H-14, H-15, H-22, H-26), 7.73 (d, J 
= 9.2 Hz, 2H, H-13, H-16), 6.85 (d, J = 2.4 Hz, 1H, H-5), 6.81 (dd, J = 8.6, 2.4 
Hz, 1H, H-7), 6.70 (d, J = 8.8 Hz, 3H, H-23, H-25, H-5), 4.88 (s, 2H, CH2), 3.02 
(s, 6H, N(CH3)2); 13C {1H} NMR (Acetone-d6) δ 156.2 (C-18), 153.6 (C-24), 
143.9 (C-10), 143.9 (C-21), 139.7 (C-17), 135.3 (C-9), 128.9 (overlapping C-22, 
C-26), 126.1 (overlapping C-13, C-16), 124.9 (C-6), 123.2 (overlapping C-14, C-
15), 122.2 (H-8), 117.4 (C-7), 112.3 (overlapping C-23, C-25), 112.1 (CH2), 
108.4 (C-5), 40.1 (s, N(CH3)2); LRMS (ESI) m/z: 488.04 (M+H)+; HRMS (ESI) 
m/z calcd. for C21H22O5N5S2  [M+H]+: 488.1057, found: 488.1050. 
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1-methyl-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide (23, ICT13006). 
                   
Potassium carbonate (0.24 g, 1.73 mmol) and methyl iodide (3.41g, 24.0 mmol) 
were added to a solution of compound 5 (0.22 g, 1.18 mmol) in acetone (10 
mL). The reaction mixture was stirred at room temperature for 24 hour. Organic 
components were extracted with DCM (3x50mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered and stripped of solvent 
under reduced pressure to give brown solid. The resultant material was purified 
by flash column chromatography (EtOA:PE, 2:8 v/v) to give the title compound 
as white solid material (160 mg, 68%); m.p. 112.1-112.6 °C; IR: 2923,1583, 
1488, 1429, 1343, 1319, 1297, 1251, 1223, 1202 cm-1; 1H NMR (CDCl3) δ 6.97 
(m, 3H, H5, H-6, H-7), 6.87 (d, J = 7.8 Hz, 1H, H-8), 4.85 (s, 2H, CH2), 3.19 (s, 
3H, CH3); 13C {1H} NMR (CDCl3) δ 143.1 (C-10), 129.9 (C-9), 124.4 (C-7), 
123.9 (C-8), 121.3 (C-6), 118.6 (C-5), 76.8 (CH2), 32.1 (CH3); LRMS (ESI) m/z:  
200.23 (M+H)+; HRMS (ESI) m/z calcd. for C8H9O3NS  [M]+: 199.0296, found: 
199.0295 
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1-methyl-6-nitro-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide (24, ICT13046).  
 
Potassium carbonate (119 mg, 0.86 mmol) and methyl iodate (1.67g, 11.7 
mmol) were added to a solution of 2-nitro-1H-benzooxathiazine 11 (0.1 g, 4.34 
mmol) in acetone (5 mL). The reaction mixture was stirred at room temperature 
for 24 hour. Organic components were extracted with DCM (3x20mL). The 
combined organic extracts were dried over anhydrous MgSO4, filtered and 
stripped of solvent under reduced pressure to give yellow solid. The resultant 
materials was purified by flash column chromatography (EtOA:PE, 2:8 v/v) to 
give the title compound as yellow solid material (0.7 g, 66%); m.p. 165.5-166 °C; 
IR: 3097, 3011, 2923, 2853, 1729, 1577, 1518, 1466, 1371, 1361 cm-1;  1H NMR 
(Acetone-d6) δ 7.72 (dd, J = 8.1, 1.4 Hz, 1H, H-7), 7.52 (d, J = 1.4 Hz, 1H, H-5), 
7.43 (d, J = 8.1, 1H, H-8), 5.48 (s, 2H, CH2), 3.26 (s, 3H, CH3); 13C {1H} NMR 
(Acetone-d6) δ 147.5 (C-10), 146.6 (C-9), 128.7 (C-6), 125.8 (C-5), 123.7 (C-7), 
120.2 (C-8), 73.9 (CH2), 42.5 (CH3); LRMS (ESI) m/z: 245.1 (M+H) +; HRMS 
(ESI) m/z calcd. for C8H9N2O5S  [M+H]+: 245.0490, found: 245.0489 
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6-amino-1-methyl-1H-benzo[e][1,3,4]oxathiazine 2,2-dioxide (20, 
ICT13047). 
 
25 mL flask was charged with compound 24 (70.0 mg, 0.28 mmol) and EtOAc 
(3 mL). Palladium on carbon (10% (w/w), 4.00 mg) was then added carefully. 
The reaction mixture was stirred at R.T under hydrogen for 24h. The mixture 
was filtered through celite and concentrated to give (50.0 mg, 83%) of the title 
compound as yellowish white solid; m.p. 150.9-151.7 °C; IR: 3394, 3345, 3001, 
2710, 1623, 1589, 1507, 1423, 1340, 1320 cm-1; 1H NMR (CDCl3) δ 6.93 (d, J = 
8.3 Hz, 1H, H-8), 6.39 (dd, J = 8.3, 1.2 Hz, 1H, H-7), 6.36 (d, J = 1.2 Hz, 1H, H-
5), 4.95 (s, 2H, CH2), 4.04 – 3.77 (s, 2H, NH2), 3.07 (s, 3H, CH3); 13C {1H} NMR 
(CDCl3) δ 146.9 (C-10), 143.5 (C-6), 128.6 (C-9), 117.5 (C-8), 110.3 (C-7), 
107.7 (C-5), 74.2 (CH2), 39.7 (CH3); LRMS (ESI) m/z: 215.1 (M+H)+; HRMS 
(ESI) m/z calcd. for C8H11N2O3S  [M+H]+: 215.0485, found: 215.0485. 
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7-nitro and 7-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one.  (26, ICT13004), (27, 
ICT13011). 
 
To a solution of 2H-benzo[b] [1,4]oxazin-3(4H)-one 25 (0.90 g, 6.04 mmol) in 
glacial acetic (8 mL) acid, sodium nitrite (0.51 g, 7.39 mmol) was added. 
Solution of glacial acetic acid (5 mL) and concentrated nitric acid (3.5 mL) was 
prepared and added drop wise to the previous solution, the colourless solution 
turned to yellow. The reaction solution was left stirring at room temperature for 4 
h. The solution was then poured into a beaker contain mixture of ice and water 
(50 g) and the precipitate powder filtered, collected and dried. The crude 
product was separated and purified by chromatography (EtOAc:PE, 2:8 v/v) to  
the two isomers. The first isomer, 2-nitro-2H-benzo[b][1,4]oxazin-3(4H)-one 26 
(0.33 g, 28% ) was yellow colour powder. The second isomer, 1-nitro-2H-
benzo[b][1,4]oxazin-3(4H)-one 27 (0.77 g, 66% ) was white powder;  
Synthesis of compound 26 by different route: 500 mL round bottom flask was 
charged with 2-amino-5 nitro phenol (5 g, 32.4 mmol) and 200 mL acetonitrile. 
Sodium bicarbonate (10.9 g, 129 mmol) was added to previous solution and 
was left stirring for 10 minutes. The mixture was put in an ice-salt bath to keep 
the temperature at 0 Co. To this stirring mixture, 2-chloroacetylchloride (4.75 g, 
0.04 mmol) was added dropwise and mixture was left stirring on ice bath for 40 
minutes. The reaction mixture was then refluxed on an oil bath for 2 h. 
Acetonitrile was removed under reduced pressure to obtain yellow colour 
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powder. The product was recrystallized using ethanol:water (1:1) to give the title 
compound ( 4.2 g, 67%); compound 26; the proton and 13C data were in 
agreement with previously published data 157; m.p. 219-220 °C (Lit., 219-222 °C) 
124; IR: 3144, 3081, 2965, 2886, 1794, 1698, 1670, 1601, 1525, 1504 cm-1; 1H 
NMR (DMSO-d6) δ 11.10 (s, 1H, NH), 7.88 (dd, J = 9.1, 2.7 Hz, 1H, H-6), 7.75 
(d, J = 2.7 Hz, 1H, H-8), 7.19 (d, J = 9.1 Hz, 1H, H-5), 4.78 (s, 2H, CH2); 13C 
{1H} NMR (DMSO-d6) δ 163.7 (CO), 148.6 (C-9), 141.7 (C-7), 127.6 (s, C-10), 
119.1 (C-8), 116.5 (C-6), 110.7 (C-5), 66.7 (CH2); LRMS (ESI) m/z: 195.09 
(M+H)+; HRMS (ESI) m/z calcd. for C8H7O4N2 [M+H]+: 195.0400, found: 
195.0397; compound 27; the proton and 13C data were in agreement with 
previously published data 158. m.p. 220.2-223.7 °C (Lit., 219-222 °C)159; IR: 
3134, 3082, 2955, 2872, 1792, 1693, 1672, 1604, 1534, 1523 cm-1; 1H NMR 
(DMSO-d6) δ 11.35 (s, 1H, NH), 7.91 (dd, J = 9.1, 2.7 Hz, 1H, H-7), 7.77 (d, J = 
2.7 Hz, 1H, H-5), 7.06 (d, J = 9.1 Hz, 1H, H-8), 4.76 (s, 2H, CH2); 13C {1H} NMR 
(DMSO-d6) δ 164.7 (CO), 142.8 (C-9), 142.2 (C-6), 133.8 (C-10), 118.7 (C-7), 
115.6 (C-8), 111.4 (C-5,), 66.5 (CH2); LRMS (ESI) m/z: 195.06 (M+H)+; HRMS 
(ESI) m/z calcd. for C8H7O4N2 [M+H]+: 195.0400, found: 195.0397. 
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7-amino-2H-benzo[b][1,4]oxazin-3(4H)-one. (21, ICT13008). 
 
Mixture of compound 26 (0.33 g, 1.70 mmol) and 10% w/w palladium on carbon 
(0.1g) was suspended in ethanol (40 mL). The reaction mixture was left stirring 
under hydrogen overnight. The reaction mixture was filtered, using celite as 
filtering agent, and concentrated to give the title compound (0.26 g, 94%) as 
solid white powder; the proton and 13C data were in agreement with previously 
published data 157; m.p. 213.2-214 °C (Lit., 212-215 °C) 124; IR: 3374, 3315, 
3190, 2985, 2904, 1672, 1614, 1515, 1436, 1405 cm-1;  1H NMR (DMSO-d6) δ 
10.47 (s, 1H, NH), 6.59 (d, J = 8.6 Hz, 1H, H-5), 6.16 (d, J = 2.5 Hz, 1H, H-8), 
6.10 (dd, J = 8.6, 2.5 Hz, 1H, H-6), 4.87 (s, 2H, NH2), 4.27 (s, 2H, CH2); 13C 
{1H} NMR (DMSO-d6) δ 165.6 (CO), 144.2 (C-9), 134.0 (C-7), 127.6 (C-10), 
116.3 (C-5), 108.1 (C-6), 101.3 (C-8), 66.9 (CH2); LRMS (ESI) m/z: 165.01 
(M+H) +. 
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6-amino-2H-benzo[b][1,4]oxazin-3(4H)-one (30, ICT13010). 
 
Mixture of compound 27 (0.40g, 2.06 mmol) and 10% w/w palladium on carbon 
(0.1g) was suspended in ethanol (40 mL). The reaction mixture was left stirring 
under hydrrogen overnight. The reaction mixture was filtered, using celite as 
filtering agent, and concentrated to give the title compound (0.30g, 88%) as a 
pink powder; the proton and 13C data were in agreement with previously 
published data 158; m.p. 232.1-132.6 °C (Lit., ˃228 °C) 159; IR: 3361, 3325, 3204, 
2982, 2912, 1662, 1614, 1525, 1426, 1409 cm-1; 1H NMR (DMSO-d6) δ 10.28 
(s, 1H, NH), 6.84 (d, J = 8.4 Hz, 1H, H-8), 6.56 (d, J = 2.5 Hz, 1H, H-5), 6.17 
(dd, J = 8.4, 2.5 Hz, 1H, H-7), 4.89 (s, 2H, NH2), 4.41 (s, 2H, CH2); 13C {1H} 
NMR (DMSO-d6) δ 206.5 (CO), 163.8 (C-9), 145.0 (C-6), 144.1 (C-10), 116.2 
(C-8), 107.8 (C-7), 101.8 (C-5), 66.7 (CH2); LRMS (ESI) m/z: 165.01 (M+H)+. 
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6-(benzylamino)-2H-benzo[b][1,4]oxazin-3(4H)-one (34, ICT13012). 
 
To a solution of 6-amino-(2H-benzo[b][1,4]oxazin-3(4H)-one) 27 (0.40 g, 2.43 
mmol) in dichloromethane (50 mL), 3 equivalent of  benzaldehyde 31 ( 0.65 g, 
6.12 mmol) was added. The reaction mixture was left stirring over moderate 
speed for 48 hours. Small amount from the reaction mixture enough to run 
proton NMR was taken and dried to monitor formation of the imine, compound 
32. 1H NMR (DMSO) δ 10.80 (s, 1H, NH), 8.64 (s, 1H, CHN), 7.91 (d, J = 7.0, 
Hz, 2H, H-14, H-18), 7.79 (d, J = 2.9 Hz, 1H, H-5), 7.51 (dd, J = 7.8, 2.7 Hz, 3H, 
H-15, H-16, H-17), 6.98 (d, J = 8.2 Hz, 1H, H-8), 6.96 (dd, J = 8.2, 2.9 Hz, 1H, 
H-7), 4.60 (s, 2H, CH2O). Half equivalent of sodium borohydride (70.0 mg, 1.85 
mmol) was added to the reaction mixture and was left stirring over moderate 
speed, 24 hours. The mixture then concentrated to give yellow solid materials. 
The solid product was purified by flash column chromatography (EtOAc:PE, 2:8 
v/v) to give the title compound as brown solid (0.48 g, 78% ); m.p. 160.5-
160.9 °C; 1H NMR (CDCl3) δ 9.08 (s, 1H, NH), 7.24 (m, 5H, H-14, H-15, H-16, 
H-17, H-18), 6.58 (d, J = 8.3 Hz, 1H, H-8), 6.20 (d, J = 2.4 Hz, 1H, H-5), 6.16 
(dd, J = 8.3, 2.4 Hz, 1H, H-7), 4.47 (s, 2H, CH2O), 4.20 (s, 2H, CH2N); 13C {1H} 
NMR (CDCl3) δ 165.5 (CO), 145.5 (C-13), 144.8 (C-9), 139.0 (C-6), 128.7 
(overlapping C-15, C-17), 127.4 (overlapping C-16, C-18), 127.8 (C-14). 116.8 
(C-10), 111.2 (C-7), 105.3 (C-8), 107.1 (C-5), 71.3 (CH2), 48.5 (CH2N); LRMS 
(ESI) m/z: 255.14 (M+H) +. 
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7-(benzylamino)-2H-benzo[b][1,4]oxazin-3(4H)-one (35, ICT13016). 
 
250 mL round bottom flask was charged with 7-amino-(2H-benzo[b][1,4]oxazin-
3(4H)-one) 26 (0.38g, 2.32mmol) and dichloromethane (50 mL). One equivalent 
of benzaldehyde 31 (0.65 g, 6.12 mmol) was then added to previously stirring 
solution. The reaction mixture was left stirring over moderate speed 48 hours at 
room temperature under nitrogen condition. Small amount from the reaction 
mixture enough to run proton NMR was taken and dried to monitor formation of 
the imine, compound 33. 1H NMR (CDCl3) δ 10.84 (s, 1H, NH), 8.66 (s, 1H, 
CHN), 7.95 (d, J = 7.0, Hz, 2H, H-14, H-18), 7.81 (d, J = 2.9 Hz, 1H, H-8), 7.52 
(m, 3H, H-15, H-16, H-17), 7.08 (d, J = 8.2 Hz, 1H, H-5), 6.96 (dd, J = 8.2, 2.9 
Hz, 1H, H-7), 4.60 (s, 2H, CH2). Half equivalent of sodium borohydride (70.0 
mg, 1.85 mmol) was added and the mixture was left stirring over moderate 
speed for 24 hours. The reaction mixture then concentrated to give yellow solid 
materials. The solid product was purified by flash column chromatography 
(EtOAc:PE, 2:8 v/v) to give the title compound as brown solid (0.40 g, 67% ); 
m.p. 139.1-139.9 °C (Lit., 138-140 °C) 124; 1H NMR (CDCl3) δ 8.08 (s, 1H, NH), 
7.23 (m, 5H, H-14, H-15, H-16, H-17, H-18), 6.81 (d, J = 8.3 Hz, 1H, H-5), 6.18 
(d, J = 2.4 Hz, 1H, H-8), 6.13 (dd, J = 8.3, 2.4 Hz, 1H, H-6), 4.79 (s, 2H, CH2O), 
4.30 (s, 2H, CH2N);13C {1H} NMR (CDCl3) δ 168.1 (CO), 153.1 (C-9), 144.0 (C-
7), 139.9 (overlapping C-14, C-18), 128.5 (C-13), 126.9 (overlapping C-15, C-
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17), 126.3 (C-16), 123.3 (C-5), 115.2 (C-10), 110.1 (C-6), 96.5 (C-8), 69.3 
(CH2), 48.2 (CH2N); LRMS (ESI) m/z: 255.14 (M+H) +. 
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N-(2-methoxy-4-nitrophenyl)methanesulfonamide (38, ICT13019).  
 
Solution of 2-methoxy-4-nitroaniline 37 (1.00 g, 5.94 mmol) in dry pyridine (5 
mL) was treated dropwise with methanesulfonyl chloride 36 (0.55 mL, 7.13 
mmol) with stirring and cooling to 0 C˚. After the addition was over, the mixture 
was stirred for 5h at R.T and then poured over ice and water. The solid fomed 
was filtered, washed with water and recrystallized from acetone-hexane to give 
the title compound (1.20 g, 82%) as yellow powder; m.p.  146.7-147 °C (Lit., 
146 °C) 160; IR: 3257, 3119, 3028, 2937, 1588, 1530, 1495, 1450, 1417, 1350 
cm-1; 1H NMR (CDCl3) δ 7.95 (d, J = 2.5 Hz, 1H, H-3) 7.92 (dd, J = 8.6, 2.5 Hz, 
1H, H-5), 7.49 (d, J = 8.6 Hz, 1H, H-6), 7.28 (s, 1H, NH) 3.96 (s, 3H, OCH3), 
3.16 (s, 3H, SCH3). 13C {1H} NMR (CDCl3) δ 157.8 (C-2), 149.8 (C-4), 133.1 (C-
6), 128.4 (C-1), 116.3 (C-5), 107.8 (C-3), 56.9 (OCH3), 43.7 (SCH3); LRMS 
(ESI) m/z: 247.2 (M+H) +. 
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N-(4-amino-2-methoxyphenyl)methanesulfonamide (22, ICT13029). 
 
250 mL flask was charged with N-(2-methoxy-4-nitrophenyl) 
methanesulfonamide 38 (0.67 g, 2.72 mmol) and MeOH (20 mL). Palladium on 
carbon (10% (w/w), 67 mg) was then added carefully. The reaction mixture was 
stirred at R.T under hydrogen for 24h. The mixture was filtered through celite 
and concentrated. The residue was then purified by crystallization EtOAc-PE to 
give (0.50 g, 85%) of the title compound; m.p. 193.7-194 °C (Lit., 193-194 °C) 
161; IR: 3447, 3369, 2931, 1629, 1588, 1530, 1495, 1450, 1417, 1350 cm-1; 1H 
NMR (CDCl3) δ 7.19 (s, 1H, NH), 6.94 (d, J = 9.2 Hz, 1H, H-6), 6.19 (dd, J = 
9.2, 2.4 Hz, 1H, H-5), 6.15 (d, 2.4 Hz, 1H, H-3) 3.81 (s, 3H, OCH3), 3.31 (s, 3H, 
SCH3); 13C {1H} NMR (CDCl3) δ 157.4 (C-2), 150.1 (C-4), 132.9 (C-6), 112.2 
(C-1), 107.2 (C-5), 98.8 (C-3), 55.8 (OCH3), 43.4 (SCH3); LRMS (ESI) m/z: 
217.0 (M+H)+. 
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Chloro-N-(2-methoxy-4-nitrophenyl)methanesulfonamide (41, ICT13018). 
 
To solution of 2-methoxy-4-nitroaniline 37 (1.00 g, 5.94 mmol) in dry prydine (5 
mL), chloromethanesulfonyl chloride (0.64 mL, 7.13 mmol) was added drop 
wise. The mixture was then stirred and cooled 0 C˚. After the addition was over, 
the mixture was stirred for 5h at R.T and then poured over ice and water. The 
solid was filtered, washed with water and recrystallized from acetone-hexane to 
give the title compound (1.50 g, 90%) as yellow crystals; m.p. 171.2-171.7 °C; 
IR: 3255, 3096, 3016, 2956, 1592, 1525, 1499, 1454, 1434, 1393 cm-1; 1H NMR 
(CDCl3) δ 7.85 (dd, J = 8.7, 2.4 Hz, 1H, H-5), 7.74 (d, J = 2.4 Hz, 1H, H-3), 7.65 
(d, J = 8.7 Hz, 1H, H-6), 7.40 (s, 1H, NH), 4.53 (s, 2H, CH2), 3.97 (s, 3H, 
OCH3); 13C {1H} NMR (CDCl3) δ 148.1 (C-2), 144.6 (C-4), 131.7 (C-1), 117.5 
(C-6), 117.3 (C-5), 106.2 (C-3), 56.7 (CH2), 54.5 (CH3); LRMS (ESI) m/z: 281.2 
(M+H)+. 
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N-(2-methoxy-4-nitrophenyl)butanesulfonamide (42, ICT13022). 
 
To a stirred solution of 2-methoxy-4-nitroaniline 37 (1.00 g, 5.94 mmol) in dry 
prydine (5 mL) was treated dropwise with butane-1-sulfonyl chloride (0.92 mL, 
7.13 mmol) with stirring and cooling to 0 C˚. After the addition was over, the 
mixture was stirred for 5h at R.T and then poured over ice and water. The solid 
was filtered, washed with water and recrystallized from acetone-hexane to give 
the title compound (1.20 g, 70%) as brown solid; m.p. 98.3-98.9 °C; IR: 3475, 
3319, 3095, 2924, 2871, 1732, 1621, 1594, 1499, 1466 cm-1; 1H NMR (CDCl3) δ 
7.85 (dd, J = 8.8, 2.4 Hz, 1H. H-5), 7.71 (d, J = 2.4 Hz, 1H, H-3), 7.58 (d, J = 8.8 
Hz, 1H, H-6), 7.15 (s, 1H, NH), 3.94 (s, 3H, OCH3), 3.09 (t, J = 7.9 Hz, 2H, H-7), 
1.73 (m, 2H, H-8), 1.36 (m, 2H, H-9), 0.84 (t, J = 7.4 Hz, 3H, H-10); 13C {1H} 
NMR (CDCl3) δ 147.4 (C-2), 143.6 (C-4), 133.0 (C-1), 117.7 (C-6), 116.1 (C-5), 
106.0 (C-3), 56.5 (OCH3), 52.2 (C-8), 25.4 (C-7), 21.3 (C-9), 13.4 (C-10); LRMS 
(ESI) m/z: 289.3 (M+H)+. 
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N-(4-amino-2-methoxyphenyl)butanesulfonamide (48, ICT13036). 
 
100 mL flask was charged with N-(2-methoxy-4-nitrophenyl) butane-1-
sulfonamide 42 (0.5 g, 1.73 mmol) and ethyl acetate (20 mL). Palladium on 
carbon (10% (w/w) (10.4 mg, 0.037 mmol) was then added carefully. The 
reaction mixture was stirred at R.T under hydrogen for 24h. The mixture was 
filtered through celite and concentrated to give the title compound as yellow 
solid (0.40 g, 89%); m.p. 180.2-180.9 °C; IR: 3436, 3364, 3293, 3259, 2962, 
2933, 1635, 1613, 1592, 1512 cm-1;  1H NMR (CDCl3) δ 7.19 (d, J = 8.7 Hz, 1H, 
H-6), 6.29, (s, 1H, NH), 6.19 (dd, J = 8.7, 2.5 Hz, 1H, H-5), 6.18 (d, J = 2.5 Hz, 
1H, H-3), 3.74 (s, 3H, OCH3), 2.92 (t, J = 8.0 Hz, 2H, H-7), 1.69 (m, 2H, H-8), 
1.30 (m, 2H, H-9), 0.81 (t, J = 7.4 Hz, 3H, H-10); 13C {1H} NMR (CDCl3) δ 151.8 
(C-2), 145.6 (C-4), 125.0 (C-6), 116.4 (C-1), 107.3 (C-5), 98.4 (C-3), 55.5 (C-8), 
50.4 (OCH3), 25.3 (C-7), 21.5 (C-9), 13.8 (C-10); LRMS (ESI) m/z: 259.4 
(M+H)+; HRMS (ESI) m/z calcd. for C11H19N2O3S  [M+H]+: 259.1111, found: 
259.1113. 
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Trifluoro-N-(2-methoxy-4-nitrophenyl)methanesulfonamide (43, ICT13060). 
 
To a stirred suspension of 2-methoxy-4-nitroaniline 37 (0.50 g, 2.97 mmol) and 
sodium bicarbonate (124 mg, 1.47 mmol) in dichloromethane (10 mL), 
maintained at 0 °C under nitrogen atmosphere was added 
trifluoromethanesulfonic anhydride (0.49 mL, 2.97 mmol). The reaction mixture 
was brought to room temperature and was stirred for 6 h.  Hydrochloric acid 
solution (10 mL, 2M) was added to the reaction mixture. Organic components 
were extracted with DCM (3x50mL). The combined organic extracts were dried 
over anhydrous MgSO4, filtered and stripped of solvent under reduced 
pressure. The residue was purified by flash column chromatography 
(EtOAc:PE, 2:8 v/v) to give the title compound as yellow needles (0.70 g, 78%); 
m.p: 105.2-105.6 °C (Lit., 103-105 °C)1; IR: 3471, 3381, 3257, 2923, 1592, 
1501, 1446, 1417, 1377, 1328 cm-1; 1H NMR (CDCl3) δ 7.86 (dd, J = 8.7, 2.4 
Hz, 1H, H-5), 7.75 (d, J = 2.4 Hz, 1H, H-3), 7.63 (d, J = 8.7 Hz, 1H, H-6), 7.43 
(S, 1H, NH), 3.98 (s, 3H, OCH3); 13C {1H} NMR (CDCl3) δ 148.6 (C-2), 145.3 
(C-4), 129.7 (C-1), 124.5 (q, JF = 298.9 Hz, CF3), 118.7 (C-6), 117.2 (C-5), 
106.2 (C-3), 56.8 (OCH3); LRMS (ESI) m/z: 301.2 [M+H]+; HRMS (ESI) m/z 
calcd. For C8H8F3N2O5S [M+H]+: 301.0101, found: 301.0104. 
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Trifluoro-N-(4-amino-2-methoxyphenyl)methanesulfonamide (49, 
ICT13063). 
 
Palladium on carbon 10% w/w (0.10 g) was added to a solution of compound 43 
(0.20 g, 0.66 mmol) in ethanol (20 mL). The reaction mixture was left stirring 
under hydrogen overnight. The reaction mixture was filtered, using celite as 
filtering agent, and concentrated to give the title compound (0.16 g, 89 %) as 
brown solid; m.p: 123.3-124.7 °C (Lit., 123-124 °C)2; IR: 3494, 3443, 3393, 
3276, 2950, 2845, 1609, 1593, 1513, 1470 cm-1; 1H NMR (CDCl3) δ 7.19 (s, 1H, 
NH), 7.14 (d, J = 8.9 Hz, 1H, H-6), 6.17 (dd, J = 8.9, 2.4 Hz, 1H, H-5), 6.15 (d, J 
= 2.4 Hz, 1H, H-3), 3.74 (s, 3H, OCH3); 13C {1H} NMR (CDCl3) δ 153.5 (C-2), 
147.2 (C-4), 126.6 (C-6), 120.0 (q, JF = 298.9 Hz, CF3), 113.9 (C-1), 106.9 (C-
5), 98.3 (C-3), 55.5 (OCH3); LRMS (ESI) m/z: 271.1 (M+H)+; HRMS (ESI) m/z 
calcd. for C8H10F3N2O3S[M+H]+: 271.0359 found: 271.0361. 
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N-(2-methoxy-4-nitrophenyl)benzenesulfonamide (44, ICT13021). 
 
A 250 size flask was charged with 2-methoxy-4-nitroaniline 37 (1.00 g, 5.94 
mmol) and dry prydine (5 mL). The solution was treated dropwise with 
benzenesulfonyl chloride (0.90 mL, 7.13 mmol) with constant stirring and 
cooling to 0 C˚. After the addition was over, the mixture was stirred for 5h at R.T 
and then poured over ice and water. The solid was filtered, washed with water 
and recrystallized from acetone-cyclo-hexane to give the title compound (1.50 
g, 81%) as pale yellow crystals; m.p. 181.1-182 °C; IR: 3284, 3237, 3067, 2939, 
1592, 1518, 1496, 1447, 1396, 1355 cm-1; 1H NMR (CDCl3) δ 7.89 (d, J = 7.3, 
2H, H-8, H-12), 7.86 (dd, J = 9.1, 2.4 Hz, 1H, H-5), 7.67 (d, J = 2.4 Hz, 1H, H-
3), 7.64 (d, J = 9.1, Hz, 1H, H-6), 7.60 (d, J = 7.3, Hz, 1H, H-10), 7.52 (d, J = 7.4 
Hz, 2H, H-9, H-11), 7.28 (s, 1H, NH), 3.91 (s, 3H, OCH3); 13C {1H} NMR (CDCl3) 
δ 147.8 (C-2), 143.9 (C-7), 138.7 (C-4), 133.7 (C-10), 132.5 (C-1), 129.3 
(overlapping C-8, C-12), 127.1 (overlapping C-9, C-11), 117.4 (C-6), 117.2 (C-
5), 105.9 (C-3), 56.4 (OCH3); LRMS (ESI) m/z: 309.3 (M+H)+. 
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N-(4-amino-2-methoxyphenyl)benzenesulfonamide (50, ICT13035). 
 
100 mL flask was charged with N-(2-methoxy-4-nitrophenyl) 
benzenesulfonamide 44 (0.50 g, 1.62 mmol) and ethyl acetate (20 mL). 
Palladium on carbon (10% (w/w) (8.0 mg, 0.03 mmol) was then added carefully. 
The reaction mixture was stirred at R.T under hydrogen for 24h. The mixture 
was filtered through celite and concentrated to give the title compound as brown 
solid (0.40 g, 88%); m.p. 173-173.9 °C; IR: 3436, 3364, 3291, 3060, 2935, 
1646, 1615, 1595, 1511, 1472 cm-1; 1H NMR (CDCl3) δ 7.58 (d, J = 8.0 Hz, 2H, 
H-8, H-12), 7.40 (d, J = 7.6 Hz, 1H, H-10), 7.31 (d, J = 8.0 Hz, 2H, H-9, H-11), 
7.24 (d, J = 8.6 Hz, 1H, H-6), 6.43 (s, 1H, NH), 6.17 (dd, J = 8.6, 2.4 Hz, 1H, H-
5), 5.94 (d, J = 2.4 Hz, 1H, H-3), 3.29 (s, 3H, OCH3); 13C {1H} NMR (CDCl3) δ 
152.4 (C-2), 145.8 (C-4), 139.2 (C-7), 132.4 (C-10), 128.3 (overlapping C-9, C-
11), 127.3 (overlapping C-8, C-12), 126.1 (C-6), 116.1 (C-1), 107.2 (C-5), 98.3 
(C-3), 55.1 (OCH3); LRMS (ESI) m/z: 279.3 (M+H)+; HRMS (ESI) m/z calcd. for 
C13H15N2O3S  [M+H]+: 279.0798, found: 279.0801. 
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N-(2-methoxy-4-nitrophenyl)-4-methylbenzenesulfonamide (45, ICT13020). 
 
To solution of 2-methoxy-4-nitroaniline 37 (1.00 g, 5.94 mmol) in dry prydine (5 
mL), 4-methylbenzene-1-sulfonyl chloride (1.35 g, 7.13 mmol) was added drop 
wise. The mixture was then stirred and cooled 0 C˚. After the addition was over, 
the mixture was stirred for 5h at R.T and then poured over ice and water. The 
solid was filtered, washed with water and recrystallized from ethanol-hexane to 
give the title compound (1.20 g, 62%) as brown powder; m.p. 175-175.6 °C; IR: 
3284, 2941, 1593, 1525, 1496, 1444, 1397, 1356, 1341, 1323 cm-1; 1H NMR 
(CDCl3) δ 7.75 (dd, J = 8.8, 2.4 Hz, 1H, H-5), 7.69 (d, J = 7.6, 2H, H-8, H-12), 
7.58 (d, J = 2.4 Hz, 1H, H-3), 7.52 (d, J = 8.8 Hz, 1H, H-6), 7.39 (s, 1H, NH), 
7.20 (d, J = 7.6 Hz, 2H, H-9, H-11), 3.82 (s, 3H, OCH3), 2.32 (s, 3H, Ar-CH3); 
13C {1H} NMR (CDCl3) δ 147.7 (C-2), 144.73 (C-4), 143.69 (C-10), 135.72 (C-
7), 132.65 (C-1), 129.92 (overlapping C-8, C-12), 127.2 (overlapping C-9, C-
11), 117.4 (C-6), 116.8 (C-5), 105.8 (C-3), 56.4 (OCH3), 21.6 (Ar-CH3); LRMS 
(ESI) m/z: 323.2 (M+H)+. 
 
 
 
183 
 
N-(4-amino-2-methoxyphenyl)-4-methylbenzenesulfonamide (51, 
ICT13034). 
 
100 mL flask was charged with N-(2-methoxy-4-nitrophenyl)-4-
methylbenzenesulfonamide 45 (0.50 g, 1.55 mmol) and ethyl acetate (20 mL). 
Palladium on carbon (10% (w/w) (8.0 mg, 0.03 mmol) was then added carefully. 
The reaction mixture was stirred at R.T under hydrogen for 24h. The mixture 
was filtered through celite and concentrated to give the title compound as yellow 
needles (0.38 g, 83%); m.p: 172.8-173 °C; IR: 3467, 3377, 3261, 1615, 1595, 
1512, 1453, 1439, 1401, 1329 cm-1; 1H NMR (CDCl3) δ 7.47 (d, J = 8.2 Hz, 2H, 
H-8, H-12), 7.21 (d, J = 8.3 Hz, 1H, H-6), 7.09 (d, J = 8.2 Hz, 2H, H-9, H-11), 
6.44 (s, 1H, NH), 6.16 (dd, J = 8.3, 2.3 Hz, 1H, H-5), 5.96 (d, J = 2.3 Hz, 1H, H-
3), 3.33 (s, 3H, OCH3), 2.28 (s, 3H, Ar-CH3); 13C {1H} NMR (CDCl3) δ 151.1 (C-
2), 144.5 (C-10), 142.1 (C-7), 135.2 (C-4), 127.9 (overlapping C-8, C-12), 126.3 
(overlapping C-9, C-11), 126.2 (C-6), 115.4 (C-1), 106.2 (C-5), 97.3 (C-3), 54.1 
(OCH3), 20.4 (Ar-CH3); LRMS (ESI) m/z: 293.34 (M+H) + 
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N-(4-nitro-2-methoxyphenyl)-1-(tert-butyl)benzenesulfonamide (40, 
ICT13062). 
 
A solution of 2-methoxy-4-nitroaniline 37 (0.25 g, 1.48 mmol) and 4-tert-
butylbenzenesulfonyl chloride 61 (0.41 g, 1.77 mmol) in pyridine (10 mL) was 
added dropwise at 0 °C, and mixture kept stirring under nitrogen at room 
temperature for 6 h. Hydrochloric acid solution (10 mL, 2M) was added to the 
solution mixture. The organic components were then extracted with ethyl 
acetate (3x50mL). The combined organic extracts were dried over anhydrous 
MgSO4, filtered and the solvent was removed under reduced pressure. The 
crude was purified by using flash column chromatography (EtOAc:PE, 2:8 v/v) 
to give the title compound as a light yellow needles (0.42 g, 77%); m.p: 135.0-
135.2 °C; IR: 3265, 2966, 1593, 1514, 1438, 1402, 1357, 1335, 1289, 1253 cm-
1; 1H NMR (CDCl3) δ 7.86 (dd, J = 8.9, 2.4 Hz, 1H, H-5), 7.82 (d, J = 8.6, 2H, H-
8, H-12), 7.68 (d, J = 2.4 Hz, 1H, H-3), 7.63 (d, J = 8.9 Hz, 1H, H-6), 7.51 (d, J = 
8.6, 2H, H-9, H-11), 7.47 (s, 1H, NH), 3.92 (s, 3H, OCH3), 1.33 (s, 9H, (CH3)3); 
13C {1H} NMR (CDCl3)  δ 157.6 (C-10), 147.7 (C-2), 144.7 (C-4), 135.7 (C-7), 
132.7 (C-1), 127.0 (overlapping C-8, C-12), 126.3 (overlapping C-9, C-11), 
117.5 (C-6), 116.6 (C-5), 105.8 (C-3), 56.4 (OCH3), 35.2 (C(CH3)3), 30.9 
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(C(CH3)3); LRMS (ESI) m/z: 365.1 (M+H)+; HRMS (ESI) m/z calcd. for 
C17H21N2O5S [M+H]+: 365.1166, found: 365.1168. 
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N-(4-amino-2-methoxyphenyl)-1-(tert-butyl)benzenesulfonamide (52, 
ICT13070). 
 
Palladium on carbon (10% (w/w), 67.0 mg) was added to a solution of 
compound 40 (54.0 mg, 0.15 mmol) in ethanol (10 mL). The reaction mixture 
was left stirring under hydrogen overnight. The mixture was filtered through 
celite and concentrated. The residue was then purified by flash column 
chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (37.0 mg, 73%) 
as brownish white powder; m.p: 150.0-150.6 °C; IR: 3475, 3378, 3235, 2955, 
1614, 1594, 1509, 1469, 1456, 1440 cm-1; 1H NMR (CDCl3) δ 7.49 (d, J = 8.6 
Hz, 2H, H-8, H-12), 7.30 (d, J = 8.6 Hz, 2H, H-9, H-11), 6.41 (d, J = 8.4 Hz, 1H, 
H-6), 6.17 (dd, J = 8.4, 2.4 Hz, 1H, H-5), 5.95 (d, J = 2.4 Hz, 1H, H-3), 3.26 (s, 
3H, OCH3), 1.22 (s, 9H, C(CH3)3); 13C {1H} NMR (CDCl3) δ 156.1 (C-10), 152.4 
(C-2), 145.7 (C-4), 136.2 (C-7), 126.6 (overlapping C-8, C-12), 126.1 (C-6), 
125.3 (overlapping C-9, C-11), 116.3 (C-1), 107.2 (C-5), 98.2 (C-3), 55.2 
(OCH3), 35.0 (C(CH3)3), 31.0 (C(CH3)3); LRMS (ESI) m/z: 335.2 (M+H)+; HRMS 
(ESI) m/z calcd. for C17H23N2O3S [M+H]+: 335.1424, found: 335.1426. 
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N-(4-amino-2-phenoxyphenyl)methanesulfonamide (58, ICT13050). 
 
100 mL flask was charged with N-(4-nitro-2-phenoxyphenyl) methane- 
sulphonamide 57 (0.20 g, 0.64 mmol) and ethyl acetate (20 mL). Palladium on 
carbon (10% (w/w) was then added carefully. The reaction mixture was stirred 
at R.T under hydrogen for 24h. The mixture was filtered through celite and 
concentrated to give the title compound as brown solid (0.16 g, 92%); m.p. 
198.1-198.8 °C (Lit., 198 °C) 162; 1H NMR (CDCl3) δ 7.44 (d, J = 8.4 Hz, 2H, H-8, 
H-12), 7.15 (d, J = 8.4 Hz, 2H, H-9, H-11), 7.10 (d, J = 8.3 Hz, 1H, H-10), 6.30 
(d, J = 2.1 Hz, 1H, H-6), 6.12 (dd, J = 9.1, 2.1 Hz, 1H, H-5),  6.03 (d, J = 9.1 Hz, 
1H, H-3), 2.94 (s, 3H, CH3); 13C {1H} NMR (CDCl3) δ 154.5 (C-7), 141.4 (C-2), 
140.6 (C-4), 125.7 (overlapping C-8, C-12), 121.9 (C-10), 121.0 (C-1), 119.5 
(overlapping C-9, C-11), 118.4 (C-6), 110.9 (C-5), 103.2 (C-3), 42.8 (CH3); 
LRMS (ESI) m/z: 279.4 (M+H)+ 
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Methyl 2-amino-5-nitrobenzoate (60, ICT13064). 
 
Round bottom flask was charged with 2-amino-5-nitrobenzoic acid 59 (0.20 g, 
1.09 mmol) and 20 mL of methanol. The reaction solution was treated with 
thionyl chloride (0.23 mL, 3.27 mmol) dropwise and refluxed overnight. After 
cooling to room temperature, water was added and extracted with ethyl acetate 
(3x50 mL). The combined organic extracts were dried over anhydrous MgSO4, 
filtered and the solvent was evaporated under reduced pressure to give the title 
compound (0.19 mg, 88%). as yellow needles;m.p: 167.1-167.0 °C (Lit., 167-
169 °C) 163; IR: 3470, 3357, 2964, 1703, 1624, 1597, 1563, 1510, 1483, 1433 
cm-1; 1H NMR (Acetone-d6) δ 8.72 (d, J = 2.7 Hz, 1H, H-6), 8.12 (dd, J = 9.2, 2.7 
Hz, 1H, H-4), 7.56 (s, 2H, NH2), 6.97 (d, J = 9.2 Hz, 1H, H-3), 3.92 (s, 3H, 
OCH3); 13C {1H} NMR (Acetone-d6) δ 168.6 (CO2CH3), 157.2 (s, C-2), 138.3 (C-
5), 129.4 (C-4), 129.1 (C-6), 116.8 (C-3), 110.4 (C-1), 52.4 (OCH3); LRMS (ESI) 
m/z: 197.1 (M+H)+; HRMS (ESI) m/z calcd. for C8H9N2O4 [M+H]+: 197.0557, 
found: 197.0555. 
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Methyl 2-(4-(tert-butyl)phenylsulfonamido)-5-nitrobenzoate (62, ICT13067). 
 
To stirred solution of methyl 2-amino-5-nitrobenzoate 60 (0.10 g, 0.51 mmol) in 
THF (5 mL), two equivalent of sodium hydride as a 65% dispersion in mineral oil 
(24.0 mg, 1.0 mmol) was added in portions at room temperature over 20 min. 4-
tert-butylbenzenesulfonyl chloride 61 (0.14 g, 0.61 mmol) was then added 
dropwise, and the mixture was left stirring overnight at room temperature. The 
reaction mixture was poured into hydrochloric acid (10 mL, 2M) and reaction 
mixture was extracted with ethyl acetate (3x50 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered and the solvent was 
removed under reduced pressure. The crude material was purified by flash 
column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.15 g, 
75%) as yellow powder; m.p: 161.3-161.5 °C; IR: 2958, 1695, 1612, 1588, 
1520, 1489, 1438, 1408, 1335, 1262 cm-1; 1H NMR (Acetone-d6) δ 11.02 (s, 1H, 
NH), 8.63 (d, J = 2.5 1H, H-6), 8.25 (dd, J = 9.2, 2.5 Hz, 1H, H-4), 7.83 (d, J = 
8.6 Hz, 2H, H-8, H-12), 7.76 (d, J = 9.2 Hz, 1H, H-3), 7.53 (d, J = 8.6 Hz, 2H, H-
9, H-11), 3.94 (s, 3H, OCH3), 1.16 (s, 3H, C(CH3)3); 13C {1H} NMR (Acetone-d6) 
δ 167.6 (CO2CH3), 158.8 (C-10), 146.3 (C-2), 142.4 (C-5), 137.0 (C-7), 130.1 
(C-4), 128.0 (overlapping C-8, C-12), 127.8 (C-6), 127.5 (overlapping C-9, C-
11), 118.6 (C-3), 115.6 (C-1), 53.7 (OCH3), 35.8 (C(CH3)3), 31.1 (C(CH3)3); 
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LRMS (ESI) m/z: 393 (M+H)+; HRMS (ESI) m/z calcd. for C18H24O6N3S 
[M+NH4]+: 410.1380, found: 410.1374 
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2-(4-(tert-butyl)phenylsulfonamido)-5-nitrobenzoic acid (63, ICT13074). 
 
Solution of Sodium hydroxide (10 mL, 3M) was added to compound 62 (0.15 g, 
0.38 mmol) and was reflux heated for 1 h. hydrochloric acid (10 mL, 2M) was 
added and reaction mixture was extracted with ethyl acetate ( 3x50 mL ). The 
combined organic extracts were dried over anhydrous MgSO4, filtered and the 
solvent was evaporated under reduced pressure to give the title compound 
(0.13 g, 90%) as whitish yellow powder; m.p: 115.3-115.9 °C; 1H NMR 
(Acetone-d6) δ 8.72 (d, J = 2.4 Hz, 1H, H-6), 8.40 (dd, J = 9.1, 2.4 Hz, 1H, H-4), 
7.94 (d, J = 8.6 Hz, 2H, H-8, H-12), 7.83 (d, J = 9.1, 1H, H-3), 7.68 (d, J = 8.6 
Hz, 2H, H-9, H-11), 1.12 (s, 9H, C(CH3)3); 13C {1H} NMR (Acetone-d6) δ 177.7 
(CO2H), 169.7 (C-10), 167.4 (C-2), 157.2 (C-7), 128.5 (C-5), 127.1 (C-6), 126.3 
(overlapping C-8, C-12 ), 125.6 (overlapping C-9, C-11), 116.9 (C-4), 116.1 (C-
3), 112.0 (C-1), 35.0 (C(CH3)3), 29.5 (C(CH3)3); LRMS (ESI) m/z: 377.86 (M-H)-; 
HRMS (ESI) m/z calcd. for C18H22O6N3S [M+NH4]+: 393.1115, found: 393.1115. 
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Methyl 5-amino-2-(4-(tert-butyl)phenylsulfonamido)benzoate (64, 
ICT13089). 
 
Round bottom flask was charged with compound 62 (20.0 mg, 0.05 mmol) and 
EtOAc (30 mL). Palladium on carbon (10% (w/w) was then added carefully. The 
reaction mixture was stirred at R.T under hydrogen for 24h. The mixture was 
filtered through celite and concentrated to give (15.0 mg 82%) of the title 
compound as yellow crystals; m.p: 110.2-110.7 °C; IR: 3478, 3361, 3008, 2948, 
1678, 1628, 1591, 1575, 1519, 1469 cm-1; 1H NMR (Acetone-d6) δ 9.46 (s, 1H, 
NH), 7.44 (d, J = 8.6 Hz, 2H, H-8, H-12), 7.39 (d, J = 8.6 Hz, 2H, H-9, H-11), 
7.30 (d, J = 8.9 Hz, 1H, H-3), 6.99 (d, J = 2.8 Hz, 1H, H-6), 6.79 (dd, J = 8.9, 2.8 
Hz, 1H, H-4), 4.69 (s, 2H, NH2), 3.60 (s, 3H, OCH3), 1.24 (s, 9H, (CH3)3); 13C 
{1H} NMR (Acetone-d6) δ 156.3 (CO2CH3), 155.8 (C-10), 142.3 (C-5), 138.5 (C-
7), 127.4 (C-2), 125.4 (overlapping C-8, C-12), 125.3 (C-3), 125.2 (overlapping 
C-9, C-11), 120.7 (C-4), 119.6 (C-6), 114.4 (C-1), 51.6 , (OCH3), 51.3 (C(CH3)3), 
34.3 (C(CH3)3)); LRMS (ESI) m/z: 363.07 (M+H)+; HRMS (ESI) m/z calcd. for 
C18H23O4N2S  [M+H]+: 363.1373, found: 363.1374 
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Methyl 2-amino-5-methoxybenzoate (67, ICT13093). 
 
 
 Round bottom flask was charged with 2-amino-5-methoxybenzoic acid 68 (0.20 
g, 1.19 mmol) and 20 mL of methanol. The reaction solution was treated with 
thionyl chloride (0.10 mL, 3.57 mmol) dropwise and refluxed overnight. After 
cooling to room temperature, the reaction was with water and extracted with 
ethyl acetate (3x50 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and the solvent was evaporated under reduced 
pressure to give the title compound (0.19 mg, 88%) as black solid; m.p: 37.1-
37.8 °C (Lit., 37-38 °C) 164; 1H NMR (Acetone-d6) δ 7.15 (d, J = 1.4 Hz, 1H, H-
6), 6.82 (dd, J = 8.9, 1.4 Hz, 1H, H-4), 6.64 (d, J = 8.9 Hz, 1H, H-3), 5.94 (s, 2H, 
NH2), 3.69 (s, 3H, OCH3), 3.57 (s, 3H, CO2CH3); 13C {1H} NMR (Acetone-d6) δ 
168.8 (CO2CH3), 150.8 (C-5), 147.2 (C-2), 124.0 (C-4), 119.1 ( C-3), 113.4 (C-
6), 110.2 (C-1), 55.9 (OCH3), 51.8 (CO2CH3); LRMS (ESI) m/z: 182.0 (M+H)+; 
HRMS (ESI) m/z calcd. for C9H12NO3  [M+H]+: 182.1511, found: 182.1522 
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Methyl 2-(4-(tert-butyl)phenylsulfonamido)-5-methoxybenzoate (66, 
ICT13108). 
 
To solution of methyl 2-amino-5-methoxybenzoate 67 (0.10 g, 0.55 mmol) in 
pyridine (10 mL), solution of 4-tert-butylbenzenesulfonyl chloride 61 (0.15 g, 
0.66 mmol) in DCM was added dropwise at 0 °C. The solution was left stirring at 
room temperature for 5 h. 2M hydrochloric acid (10 mL, 2M) was added and 
reaction solution was extracted with ethyl acetate (3x50 mL). The combined 
organic extracts were dried over anhydrous MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The resultant material was purified by 
flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound 
(0.15 g, 72%) as brownish red solid; m.p: 146.4-146.8 °C; 1H NMR (CDCl3) δ 
9.89 (s, 1H, NH), 7.59 (d, J = 8.3 Hz, 2H, H-8, H-12), 7.33 (d, J = 8.3 Hz, 2H, H-
9, H-11), 7.28 (d, J = 3.2 Hz, 1H, H-6), 6.99 (dd, J = 9.1, 1.4 Hz, 1H, H-4), 6.88 
(dd, J = 9.1, 1.4 Hz, 1H, H-3), 3.79 (s, 3H, OCH3), 3.59 (s, 3H, CO2CH3), 1.20 
(s, 9H, C(CH3)3); 13C {1H} NMR (CDCl3) δ 156.9 (CO2CH3), 155.8 (C-10), 136.6 
(C-5), 133.8 (C-2), 127.0 (overlapping C-8, C-12), 125.8 (overlapping C-9, C-
11), 123.6 (C-7), 122.7 (C-1), 120.9 (C-4), 118.6 (C-3), 114.7 (C-6), 55.6 ( 
OCH3), 52.4 (CO2CH3), 35.8 (C(CH3)3), 31.0 (C(CH3)3); LRMS (ESI) m/z: 
378.18.0 (M+H)+; HRMS (ESI) m/z calcd. for C19H24O5NS  [M+H]+: 378.1370, 
found: 378.1371. 
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N-(4-bromo-2-methoxyphenyl)-4-(tert-butyl)benzenesulfonamide (70, 
ICT13122). 
 
Solution of 4-bromo-2-methoxyaniline 69 (0.10 g, 0.49 mmol) in dry pyridine (10 
mL) was treated dropwise with solution of 4-(tert-butyl) benzene-1-sulfonyl 
chloride 61 (88.6 mg, 0.59 mmol) in DCM. The reaction mixture was left stirring 
for 5h. Hydrochloric acid (10 mL, 2M) was added and mixture reaction was 
extracted with ethyl acetate (3x50 mL). The combined organic extracts were 
dried over anhydrous MgSO4, filtered and the solvent was stripped off under 
reduced pressure. The resultant material was purified by flash column 
chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.12 g, 61 %) 
as white crystals; m.p: 112.2-112.7 °C; 1H NMR (Acetone-d6) δ 8.08 (s, 1H, 
NH), 7.60 (d, J = 8.6 Hz, 2H, H-8, H-12), 7.45 (d, J = 8.6 Hz, 2H, H-9, H-11), 
7.30 (d, J = 8.4 Hz, 1H, H-6), 6.95 (dd, J = 8.4, 1.8 Hz, 1H, H-5), 6.91 (d, J = 1.8 
Hz, 1H, H-3), 3.47 (s, 3H, OCH3), 1.21 (s, 9H, C(CH3)3); 13C {1H} NMR 
(Acetone-d6) δ 157.2 (C-10), 152.7 (C-2), 138.1 (C-7), 127.8 (overlapping C-8, 
C-12), 126.7 (C-4), 126.6 (overlapping C-9, C-11), 124.8 (C-6), 124.3 (C-5), 
118.7 (C-1), 115.5 (C-3), 56.4 (OCH3), 34.9 (C(CH3)3), 31.3 (C(CH3)3); LRMS 
(ESI) m/z: 399.87 (M+H)+; HRMS (ESI) m/z calcd. for C17H21O3NBrS: 398.0420, 
found: 398.0421 and 400.041 50:50 [M+H]+ 
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N-(2-methoxyphenyl)tert-butylbenzenesulfonamide (71, ICT13078). 
 
To solution of 2-methoxyaniline 72 (50.0 mg, 0.40 mmol) in dry prydine (5 mL), 
solution of 4-tert-butylbenzenesulfonyl chloride 61 (0.11 g, 0.48 mmol) in DCM 
was added dropwise at 0 °C. The mixture was stirred under nitrogen for 5h at 
R.T and then poured over ice and water. The solid was filtered, washed with 
water and extracted with ethyl acetate (3x50 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The resultant crude material was purified 
by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound 
(0.10 mg, 78%) as grey crystals; m.p: 172.9-173.3 °C; IR: 3252, 2962, 2927, 
2866, 1637, 1595, 1547, 1498, 1466, 1444 cm-1; 1H NMR (CDCl3) δ 7.60 (d, J = 
8.8 Hz, 2H, H-8, H-12), 7.45 (dd, J = 7.7, 1.5 Hz, 1H, H-6), 7.33 (d, J = 8.8 Hz, 
2H, H-9, H-11), 6.97 (dt, J=7.7, 1.5 Hz, 1H, H-4), 6.91 (s, 1H, NH), 6.83 (td, 
J=7.7, 1.0 Hz, 1H, 1H, H-5), 6.66 (dd, J = 8.1, 0.8 Hz, 1H, H-3), 3.54 (s, 3H, 
OCH3), 1.23 (s, 9H, C(CH3)3); 13C {1H} NMR (CDCl3) δ 155.5 (C-10), 148.5 (C-
2), 135.3 (C-7), 126.0 (overlapping C-8, C-12), 125.0 ( C-1), 124.6 (overlapping 
C-9, C-11), 124.2 (C-6), 120.1 (C-4), 120.1 (C-5), 109.5 (C-3), 54.5 (OCH3), 
34.0 (C(CH3)3), 30.0 (C(CH3)3); LRMS (ESI) m/z: 320.1 (M+H)+; HRMS (ESI) 
m/z calcd. for C17H22O3N2S [M+NH4]+: 320.1315, found: 320.1316 
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Methyl 4-amino-3-methoxybenzoate (74, ICT13084). 
 
Round bottom flask was charged with 4-amino-3-methoxybenzoic acid 73 (0.30 
g, 1.79 mmol) and 20 mL of methanol. The reaction solution was treated with 
thionyl chloride (0.23 mL, 5.37 mmol) dropwise and refluxed overnight. After 
cooling to room temperature, water was added and extracted with ethyl acetate 
(3x50 mL). The combined organic extracts were dried over anhydrous MgSO4, 
filtered and the solvent was evaporated under reduced pressure to give to give 
the title compound (0.24 g, 73%) as brown powder; m.p: 127.6-128.2 °C (Lit., 
127-129 °C) 165; 1H NMR (Acetone-d6) δ 7.33 (dd, J = 8.2, 1.8 Hz, 1H, H-6), 7.26 
(d, J = 1.8 Hz, 1H, H-2), 6.59 (d, J = 8.2 Hz, 1H, H-5), 5.05 (s, 2H, NH2), 3.75 
(s, 3H, CO2CH3), 3.68 (s, 3H, OCH3); 13C {1H} NMR (Acetone-d6) δ 165.3 ( 
CO2CH3), 144.5 (C-3), 141.6 (C-4), 122.7 (C-6), 116.5 (C-1), 111.0 (C-5), 109.5 
(C-2), 53.7 (CO2CH3), 49.5 (OCH3); LRMS (ESI) m/z: 182.8 (M+H)+; HRMS 
(ESI) m/z calcd. for C9H12NO3  [M+H]+: 182.1913, found: 181.1901. 
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Methyl 4-(4-(tert-butyl)phenylsulfonamido)-3-methoxybenzoate (75, 
ICT13069). 
 
To solution of methyl 4-amino-3-methoxybenzoate 74 (0.50 g, 2.75 mmol) in 
pyridine (10 mL), solution of 4-tert-butylbenzenesulfonyl chloride 61 (0.76 g, 
3.26 mmol) in DCM was added dropwise at 0 °C. The mixture was left stirring at 
room temperature for 5 h. Hydrochloric acid (10 mL, 2M) was added and 
reaction mixture was extracted with ethyl acetate (3x50 mL). The combined 
organic extracts were dried over anhydrous MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The resultant material was purified by 
flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound 
(0.80 g, 77%) as yellow crystals; m.p: 155.3-155.8 °C; IR: 3364, 3212, 2964, 
1706, 1672, 1609, 1592, 1508, 1468, 1443 cm-1;  1H NMR (CDCl3) δ 7.68 (d, J 
= 8.7 Hz, 2H, H-8, H-12), 7.54 (dd, J = 8.6, 1.5 Hz, 1H, H-6), 7.48 (d, J = 8.6 Hz, 
1H, H-5), 7.38 (d, J = 8.7 Hz, 2H, H-9, H-11), 7.36 (d, J = 1.5 Hz, 1H, H-2), 7.25 
(s, 1H, NH), 3.80 (s, 3H, CO2CH3), 3.72 (s, 3H, OCH3), 1.22 (s, 9H, C(CH3)3); 
13C {1H} NMR (CDCl3) δ 166.5 (CO2CH3), 157.1 (C-10), 147.9 (C-3), 136.0 (C-
7), 130.7 (C-4), 127.0 (overlapping C-8, C-12), 126.0 (overlapping C-9, C-11), 
125.8 (C-1), 123.1 (C-6), 117.8 (C-5), 111.3 (C-2), 55.9 (OCH3), 52.2 (CO2CH3), 
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35.1 (C(CH3)3), 31.0 (C(CH3)3); LRMS (ESI) m/z: 378.1 (M+H)+; HRMS (ESI) 
m/z calcd. for C19H24NO5S [M+H]+: 378.1371, found: 378.1370 
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Ethyl 4-amino-3-methoxybenzoate (77, ICT13111). 
 
Round bottom flask was charged with methyl 4-amino-3-methoxybenzoic acid 
73 (0.50 g, 2.98 mmol) and 30 mL of ethanol. The reaction solution was treated 
with thionyl chloride (0.61 mL, 8.91 mmol) dropwise and refluxed overnight. 
After cooling to room temperature, the reaction was with water and extracted 
with ethyl acetate (3x50 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and the solvent was evaporated under reduced 
pressure to give the title compound (0.48 g, 82%) as a brown solid; m.p: 84.0-
84.7 °C (Lit., 84-85 °C) 166; 1H NMR (CDCl3) δ 7.47 (dd, J = 8.4, 1.7 Hz, 1H, H-
6), 7.37 (d, J = 1.7 Hz, 1H, H-2), 6.57 (d, J = 8.4 Hz, 1H, H-5), 4.24 (q, J = 7.1 
Hz, 2H, CH2), 4.14 (s, 2H, NH2), 3.80 (s, 3H, OCH3), 1.28 (t, J = 7.1 Hz, 3H, 
CH2CH3); 13C {1H} NMR (CDCl3) δ 166.9 (CO2CH3), 146.1 (C-3), 141.1 (C-4), 
124.0 (C-6), 119.8 (C-1), 113.0 (C-5), 111.1 (C-2), 60.4 (CH2), 55.5 (OCH3), 
14.5 (CH2CH3); LRMS (ESI) m/z: 196 (M+H)+; HRMS (ESI) m/z calcd. for 
C10H14NO3  [M+H]+: 196.2112, found: 196.2105. 
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Ethyl 4-(4-(tert-butyl)phenylsulfonamido)-3-methoxybenzoate (76, 
ICT13113). 
 
Solution of ethyl 4-amino-3-methoxybenzoate 77 (0.15 g, 0.76 mmol) in pyridine 
(15 mL) was treated dropwise with solution of 4-tert-butylbenzenesulfonyl 
chloride 61 (0.21 g, 0.92 mmol) in DCM at 0 °C. The solution was left stirring at 
room temperature for 5 h. 2M hydrochloric acid (10 mL) was added to reaction 
mixture. Organic components were then extracted with ethyl acetate (3x50 mL). 
The combined organic extracts were dried over anhydrous MgSO4, filtered and 
the solvent was removed under reduced pressure. The resultant material was 
purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title 
compound (0.25 g, 84 %) as yellowish white solid; m.p: 129.3-129.8 °C; IR: 
3354, 3252, 2961, 1712, 1672, 1606, 1592, 1507, 1462, 1433 cm-1; 1H NMR 
(Acetone-d6) δ 7.68 (d, J = 8.6 Hz, 2H, H-8, H-12), 7.50 (dd, J = 8.3, 1.5 Hz, 1H, 
H-6), 7.47 (d, J = 8.3 Hz, 1H, H-5), 7.45 (d, J = 8.6 Hz, 2H H-9, H-11), 7.33 (d, J 
= 1.5 Hz, 1H, H-2), 4.17 (q, J = 7.1 Hz, 2H, CH2), 3.63 (s, 3H, OCH3), 1.19 (t, J 
= 7.2 Hz, 3H, CH2CH3), 1.16 (s, 9H, C(CH3)3); 13C {1H} NMR (Acetone-d6) δ 
166.1 (CO2CH2), 157.5 (C-10), 150.2 (C-3), 138.1 (C-7), 132.0 (C-4), 127.9 
(overlapping C-8, C-12), 127.5 (overlapping C-9, C-11), 126.8 (C-1), 123.2 (s, 
C-6), 120.1 (s, C-5), 112.4 (s, C-2), 61.5 (CH2), 56.3 (OCH3), 35.7 (C(CH3)3), 
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31.2 (C(CH3)3), 14.5 (CH2CH3); LRMS (ESI) m/z: 392.1 (M+H)+; HRMS (ESI) 
m/z calcd. for C20H26O5NS  [M+H]+: 392.1526, found: 392.1522 
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4-(4-(tert-butyl)phenylsulfonamido)-3-methoxybenzoic acid (78, ICT13072). 
 
Solution of Sodium hydroxide (10 mL, 3M) was added to compound 75 (0.40 g, 
1.06 mmol) and was reflux heated for 1h. Hydrochloric acid (10 mL, 2M) was 
added and reaction mixture was extracted with ethyl acetate (3x50 mL). The 
combined organic extracts were dried over anhydrous MgSO4, filtered and the 
solvent was evaporated under reduced pressure to give the title compound 
(0.28 g, 72 %) as wheat brown powder; m.p: 175.1-175.6 °C; IR: 2963, 1692, 
1607, 1593, 1528, 1465, 1445, 1399, 1347, 1325 cm-1; 1H NMR (Acetone-d6) δ 
7.68 (d, J = 7.4 Hz, 2H, H-8, H-12), 7.48 (dd, J = 8.8, 1.4 Hz, 1H, H-6), 7.46 (d, 
J = 8.8 Hz, 1H, H-5), 7.43 (d, J = 7.4 Hz, 2H, H-9, H-11), 7.35 (d, J = 1.4 Hz, 
1H, H-2), 3.64 (s, 3H, OCH3), 1.17 (s, 9H, C (CH3)3); 13C {1H} NMR (Acetone-
d6) δ 170.5 (CO2CH3), 164.3 (C-10), 152.5 (C-3), 145.0 (C-7), 137.8 (C-4), 
131.6 (C-8, C-12), 127.8 (C-9, C-11), 126.8 (C-1), 123.6 (C-6), 120.2 (C-5), 
112.7 (C-2), 56.3 (OCH3), 55.4 (C(CH3)3), 35.7 (C(CH3)3); LRMS (ESI) m/z: 
364.1 (M+H)+; HRMS (ESI) m/z calcd. for C18H25O5N2S [M+NH4]+: 381.1479, 
found: 381.1478 
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N-(4-(hydroxymethyl)-2-methoxyphenyl) tert-butylbenzenesulfonamide 
(79, ICT13091). 
 
Under nitrogen atmosphere compound 75 (0.10 g, 0.26) was dissolved in dry 
THF (10 mL). The temperature was cooled to -78 using dry ice and acetone. 1.2 
equivalent of Lithium triethylborohydride (super hydride) in THF (0.36 mL, 0.31 
mmol) was added carefully and mixture was left stirring for 5 h until the reaction 
completed. The reaction was then warmed to room temperature and quenched 
with methanol and water and then was extracted over ice and water. The solid 
was filtered, washed with water and extracted with ethyl acetate (3x50 mL). The 
combined organic extracts were dried over anhydrous MgSO4, filtered and the 
solvent was evaporated under reduced pressure. The resultant material was 
purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title 
compound (80.0 mg, 88%) as yellow powder; m.p: 130.0-130.6 °C; IR: 3254, 
2963, 2870, 1595, 1509, 1462, 1432, 1394, 1365, 1336 cm-1; 1H NMR (CDCl3) δ 
7.61 (d, J = 8.7 Hz, 2H, H-8, H-12), 7.40 (d, J = 8.3, 1H, H-6), 7.34 (d, J = 8.7 
Hz, 2H, H-9, H-11), 7.19 (s, 1H, OH), 6.94 (s, 1H, NH), 6.79 (dd, J = 8.3, 1.8 Hz, 
1H, H-5), 6.73 (d, J = 1.8, 1H, H-3), 4.54 (s, 2H, CH2), 3.56 (s, 3H, CH3), 1.20 
(s, 9H, (CH3)3); 13C {1H} NMR (CDCl3) δ 156.6 (C-10), 149.5 (C-2), 138.0 (C-7), 
136.2 (C-1), 127.0 (overlapping C-8, C-12), 125.8 (overlapping C-9, C-11), 
125.3 (C-4), 120.8 (C-6), 119.4 (C-5), 109.2 (C-3), 64.6 (CH2), 55.0 (OCH3), 
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35.0 (C(CH3)3), 32.2 (C(CH3)3); LRMS (ESI) m/z: 350.1 (M+H)+; HRMS (ESI) 
m/z calcd. for C18H24O4NS  [M+H]+: 350.1421, found: 350.1424. 
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4-(4-(tert-butyl)phenylsulfonamido)-3-methoxybenzamide (80, ICT13092). 
 
Under nitrogen atmosphere compound 75 (0.20 g, 0.52 mmol) was dissolved in 
Ammonium hydroxide (50mL, 35%) and mixture was left stirring at room 
temperature for 5 days. The reaction mixture was then washed with water and 
extracted with ethyl acetate (3x50 mL). The combined organic extracts were 
dried over anhydrous MgSO4, filtered and the solvent was evaporated under 
reduced pressure. The resultant material was purified by flash column 
(EtOAc:PE, 2:8 v/v) to give the title compound (0.15 g, 79 %) as white crystals; 
m.p: 115.4-115.9 °C; IR: 3460, 3216, 2966, 1665, 1606, 1573, 1513, 1453, 
1389, 1336 cm-1; 1H NMR (CDCl3) δ 7.65 (d, J = 8.5 Hz, 2H, H-8, H-12), 7.45 
(d, J = 8.4 Hz, 1H, H-5), 7.37 (d, J = 8.5 Hz, 2H, H-9, H-11), 7.28 (d, J = 1.5 Hz, 
1H, H-2), 7.23 (dd, J = 8.4, 1.5 Hz, 1H, H-6), 3.66 (s, 3H, OCH3), 1.20 (s, 9H, 
C(CH3)3); 13C {1H} NMR (CDCl3) δ 168.9 (CONH2), 157.1 (C-10), 148.7 (C-3), 
135.9 (C-7), 129.6 (C-4), 129.5 (C-1), 126.9 (overlapping C-8, C-12), 126.0 
(overlapping C-9, C-11), 119.8 (C-6), 118.5 (C-5), 110.3 (C-2), 56.0 (d, J = 21.8 
Hz, OCH3), 35.1 (C(CH3)3), 30.9 (C(CH3)3); LRMS (ESI) m/z: 363.1 (M+H)+; 
HRMS (ESI) m/z calcd. for C18H23O4N2S  [M+H]+: 363.1373, found: 363.1380 
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Methyl 3-methoxy-4-(methylsulfonamido)benzoate (81, ICT13073). 
 
To solution of methyl 4-amino-3-methoxybenzoate 74 (0.20 g, 1.10 mmol) in 
pyridine (10 mL), methylsulfonyl chloride (0.15 g, 1.32 mmol) was added 
dropwise at 0 °C. The mixture was left stirring at room temperature for 5 h. 
Hydrochloric acid (10 mL, 2M) was added and reaction mixture was extracted 
with ethyl acetate (3x50 mL). The combined organic extracts were dried over 
anhydrous MgSO4, the mixture was filtered and the solvent was evaporated 
under reduced pressure. The resultant crude materials was purified by flash 
column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.21 g, 
73 %) as white powder; m.p: 124.8-125.0 °C; IR: 3267, 3014, 2933, 1715, 1604, 
1594, 1508, 1472, 1451, 1433 cm-1; 1H NMR (Acetone-d6) δ 7.66 (dd, J = 8.3, 
1.8 Hz, 1H, H-6), 7.61 (d, J = 1.8 Hz, 1H, H-2), 7.59 (d, J = 8.3 Hz, 1H, H-2), 
3.98 (s, 3H, OCH3), 3.89 (s, 3H, CO2CH3), 3.10 (s, 3H, SO2CH3); 13C {1H} NMR 
(Acetone-d6) δ 166.8 (CO2CH3), 150.0 (C-3), 132.6 (C-4), 127.0 (C-6), 123.5 (C-
1), 119.6 (C-5), 112.5 (C-2), 56.5 (OCH3), 52.3 (CO2CH3), 40.1 (s, SO2CH3); 
LRMS (ESI) m/z: 258.93.1 (M-H)-; HRMS (ESI) m/z calcd. for C10H14O5NS 
[M+H]+: 260.0587, found: 260.0589. 
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Methyl 4-(4-((4-(dimethylamino)phenyl)diazenyl)phenylsulfonamido)-3-
methoxybenzoate (82, ICT13085). 
 
To solution of methyl 4-amino-3-methoxybenzoate 74 (0.10 g, 0.55 mmol) in 
pyridine (8 mL), Dabsyl chloride (0.21 g, 0.66 mmol) was added dropwise at 0 
°C. The solution was left stirring at room temperature for 5 h. Hydrochloric acid 
(10 mL, 2M) was added and reaction mixture was extracted with ethyl acetate 
(3x50 mL). The combined organic extracts were dried over anhydrous MgSO4, 
filtered and the solvent was evaporated under reduced pressure. The resultant 
material was purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to 
give the title compound (0.23 g, 89 %) as a light red crystals; m.p: 114.7-114.9 
°C; 1H NMR (Acetone-d6) δ 7.91 (d, J = 8.9 Hz, 2H, H-8, H-12), 7.72 (d, J = 8.9 
Hz, 2H, H-9, H-11) 7.70 (d, J = 8.6 Hz, 2H, H-14, H-18), 7.33 (dd, J = 8.4, 1.8 
Hz, 1H, H-6), 7.27 (d, J = 8.4 Hz, 1H, H-5), 7.24 (d, J = 1.8 Hz, 1H, H-2), 6.75  
(d, J = 8.6 Hz, 2H, H-15, H-17), 3.68 (s, 3H, OCH3), 3.64 (s, 3H, CO2CH3), 
2.99 (s, 6H, N(CH3)2); 13C {1H} NMR (Acetone-d6) δ 164.6 (CO2CH3), 155.5 (C-
10), 154.4 (C-16), 151.3 (C-3), 144.0 (C-13), 142.5 (C-7), 128.7 (overlapping C-
8, C-12,), 128.4 (C-4), 126.1 (overlapping C-9, C-11), 125.8 (C-1), 123.6 (C-6), 
122.2 (overlapping C-14, C-18), 117.4 (C-5) 112.3 (overlapping C-15, C-17), 
111.8 (C-2), 55.3 (OCH3), 51.3 (CO2CH3), 40.0 (N(CH3)2); LRMS (ESI) m/z: 
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469.13 (M+H)+; HRMS (ESI) m/z calcd. for C23H23O5N4S  [M-H]-: 467.1395, 
found: 467.1388. 
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3-methoxy-4-(methylsulfonamido)benzoic acid (83, ICT13071). 
 
Solution of Sodium hydroxide (10 mL, 3M) was added to methyl 3-methoxy-4-
(methylsulfonamido)benzoate 81 (0.30 g, 1.15 mmol) and was reflux heated for 
1 h. Hydrochloric acid (10 mL, 2M)  was added and reaction mixture was 
extracted with ethyl acetate (3x50 mL). The combined organic extracts were 
dried over anhydrous MgSO4, filtered and the solvent was evaporated under 
reduced pressure to give the title compound (0.23 g, 93%) as white powder. 
The proton NMR data was in agreement with previously published data 167; m.p: 
185.0-185.6 °C; IR: 3237, 2928, 1676, 1608, 1591, 1510, 1467, 1431, 1393, 
1329 cm-1; 1H NMR (Acetone-d6) δ 7.70 (dd, J = 8.3, 1.7 Hz, 1H, H-6), 7.64 (d, J 
= 1.7 Hz, 1H, H-2), 7.60 (d, J = 8.3 Hz, 1H, H-5), 3.97 (s, 3H, OCH3), 3.08 (s, 
3H, SO2CH3); 13C {1H} NMR (Acetone-d6) δ 165.8 (CO2H), 149.8 (C-3), 131.6 
(C-4), 127.0 (C-6), 123.8 (C-1), 119.7 (C-5), 112.7 (C-2), 56.5 (OCH3), 40.0 
(SO2CH3); LRMS (ESI) m/z: 246.02 (M+H)+; HRMS (ESI) m/z calcd. for 
C9H15O5N2S [M+NH4]+: 263.0696, found: 263.0699 
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Ethyl 4-(4-((4-(dimethylamino)phenyl)diazenyl)phenylsulfonamido)-3-
methoxybenzoate (84, ICT13114). 
 
Round bottom flask was charged with ethyl 4-amino-3-methoxybenzoate 77 
(0.10 g, 0.51 mmol) in presence of pyridine (15 mL). Dabsyl chloride (0.19 g, 
0.61 mmol) dissolved in DCM was added dropwise at 0 °C to the reaction 
solution. The solution was left stirring at room temperature for 5h. 2M 
hydrochloric acid (10 mL, 2M) was added and reaction mixture was extracted 
with ethyl acetate (3x50 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and the solvent was stripped of under reduced 
pressure. The resultant material was purified by flash column chromatography 
(EtOAc:PE, 2:8 v/v) to give the title compound (0.15 g, 60 %) as dark red 
crystals; m.p: 176.1-176.3 °C; IR: 3225, 2854, 1696, 1601, 1586, 1547, 1524, 
1446, 1413, 1348 cm-1; 1H NMR (Acetone-d6) δ 8.52 (s, 1H, NH), 7.85 (d, J = 
8.4 Hz, 2H, H-8, H-12), 7.74 (d, J = 8.4 Hz, 2H, H-9, H-11), 7.70 (d, J = 8.4 Hz, 
2H, H-14, H-18). 7.49 (dd, J = 8.2, 1.2 Hz, 1H, H-6), 7.38 (d, J = 8.2 Hz, 1H, H-
5), 7.33 (d, J = 1.2 Hz, 1H, H-2), 6.75  (d, J = 8.4 Hz, 2H, H-15, H-17), 4.23 (q, 
J=7.0 Hz, 2H, CH2), 3.64 (s, 3H, OCH3), 3.01 (s, 6H, N(CH3)2), 1.18 (s, 3H, 
CH2CH3); 13C {1H} NMR (Acetone-d6) δ 166.9 (CO2CH2), 166.7 (C-10), 146.7 
(C-16), 143.3 (C-3), 125.5 (C-13), 124.8 (C-7), 124,6 (overlapping C-8, C-12), 
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124.4 (C-1), 123.0 (C-4), 119.3 (overlapping C-9, C-11), 113.2 (C-6), 113.1 
(overlapping C-14, C-18) 111.8 (C-5), 111.7 (overlapping C-15, C-17), 111.6 (C-
2), 60.4 (CH2), 56.4 (OCH3), 55.7 (N(CH3)2), 15.2 (CH2CH3); LRMS (ESI) m/z: 
483.3 (M+H)+; HRMS (ESI) m/z calcd. for C24H27O5N4S  [M+H]+: 483.1697, 
found: 483.1685 
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Ethyl 4-(5-(dimethylamino)naphthalene-1-sulfonamido)-3-
methoxybenzoate (85, ICT13130). 
 
Ethyl 4-amino-3-methoxybenzoate 77 (0.10 g, 0.51 mmol) was dissolved in dry 
pyridine (10 mL). The reaction temperature was brought to 0 °C and solution of 
dansyl chloride (0.16 g, 0.59 mmol) in DCM was added dropwise and was left 
stirring for 5 h. Hydrochloric acid (10 mL, 2M) was added and the reaction 
solution was extracted with ethyl acetate (3x50 mL). The combined organic 
extracts were dried over anhydrous MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The resultant material was purified by 
flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title compound 
(0.21 g, 96 %) as brown solid; m.p: 142.0-142.6 °C; IR: 3269, 2927, 2852, 1708, 
1605, 1588, 1574, 1507, 1461, 1433 cm-1; 1H NMR (CDCl3) δ 8.42 (d, J = 8.8 
Hz, 1H, H-8), 8.25 (d, J = 8.8 Hz, 1H, H-15), 8.17 (d, J = 7.3, Hz, 1H, H-10), 
7.52 (dd, J = 7.3, 8.8 Hz, 1H, H-14), 7.48 (s, 1H, NH), 7.44 (dd, J = 8.4, 1.6 Hz, 
1H, H-6), 7.41 (d J = 8.4, 1H, H-5), 7.36 (dd, J = 7.3, 8.8 Hz, 1H, H-9), 7.25 (d, J 
= 1.6 Hz, 1H, H-2), 7.10 (d, J = 7.3 Hz, 1H, H-13), 4.21 (q, J = 7.1 Hz, 2H, CH2), 
3.56 (s , 3H, OCH3), 2.78 (s, 6H, N(CH3)2), 1.26 (t, J = 7.1 Hz, 3H, CH2CH3); 13C 
{1H} NMR (CDCl3) δ 166.0 (CO2CH2), 152.0 (C-12), 147.9 (C-7), 133.8 ( C-3), 
131.1 (C-8), 130.6 (C-4), 130.3 (C-10), 129.8 (C-16), 129.5 (C-1), 128.4 (C-14), 
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126.1 (C-5), 122.9 (C-6), 118.5 (C-15), 117.7 (C-9), 115.2 (C-13), 112.3 (C-11), 
111.2 (C-2), 61.0 (CH2), 55.8 (OCH3), 45.4 (N(CH3)2), 14.3 (CH2CH3); LRMS 
ESI (-ve) m/z: 427.03 (M-H)-; HRMS (ESI) m/z calcd. for C22H25O5N2S  [M+H]+: 
429.1479, found: 429.1473. 
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Ethyl 4-([1,1'-biphenyl]-4-ylsulfonamido)-3-methoxybenzoate (86, 
ICT13126). 
 
Round bottom flask was charged with ethyl 4-amino-3-methoxybenzoate 77 
(0.10 g, 0.51 mmol) in presence of pyridine (15 mL). Solution of [1,1’-biphenyl]-
4-sulfonyl chloride (15.0 mg, 0.0.59 mmol) in DCM was added dropwise at 0 °C 
to the reaction solution. The solution was left stirring at room temperature for 
5h. Hydrochloric acid (10 mL, 2M) was added and the reaction mixture was 
extracted with ethyl acetate (3x50 mL). The combined organic extracts were 
dried over anhydrous MgSO4, filtered and the solvent was evaporated under 
reduced pressure. The resultant material was purified by flash column 
chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.20 g, 95%) 
as yellow crystals; m.p: 120.8-121.0 °C; IR: 3213, 2977, 2940, 1697, 1601, 
1565, 1506, 1480, 1462, 1438 cm-1; 1H NMR (CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H, 
H-8, H-12), 7.59–7.52 (m, 4H, H-9, H-11, H-15, H-17), 7.48 (d, J = 1.5 Hz, 1H, 
H-2), 7.44 (d, J = 8.1, 1.5 Hz, 1H, H-6) 7.39 – 7.32 (m, 3H, H-14, H-16, H-18), 
7.30 (d, J = 8.1 Hz, 1H, H-5), 7.28 (s, 1H, NH), 4.26 (q, J = 7.1 Hz, 2H, CH2), 
3.73 (s, 3H, OCH3), 1.28 (t, J = 7.1 Hz, 3H, CH2CH3); 13C {1H} NMR (CDCl3) δ 
166.0 (CO2CH2), 148.1 (C-3), 146.1 (C-13), 139.0 (C-7), 137.4 (C-10), 130.3 (C-
4), 129.0 (overlapping C-15, C-17), 128.6 (C-16), 127.7 (overlapping C-14, C-
18), 127.6 (overlapping C-8, C-12), 127.2 (overlapping C-9, C-11), 126.6 (C-1), 
123.1 (C-6), 118.2 (C-5), 111.3 (C-2), 61.1 (CH2), 56.0 (OCH3), 14.3 (CH2CH3); 
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LRMS (ESI) m/z: 410.95 (M-H)-; HRMS (ESI) m/z calcd. for C22H22O5NS  
[M+H]+: 412.1213, found: 412.1211. 
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Propyl 4-amino-3-methoxybenzoate (ICT13142). 
 
Round bottom flask was charged with 4-amino-3-methoxybenzoic acid 73 (0.10 
g, 0.59 mmol) and 30 mL of propanol. The reaction solution was treated with 
thionyl chloride (0.12 mL, 1.77 mmol) dropwise and refluxed overnight. After 
cooling to room temperature, acidic water was added and extracted with ethyl 
acetate (3x50 mL). The combined organic extracts were dried over anhydrous 
MgSO4, filtered and the solvent was evaporated under reduced pressure to give 
to give the title compound (95.0 mg, 76 %) as brown solid; m.p: 39.6-40.4 °C; 
IR: 3416, 3039, 2844, 2599, 1713, 1623, 1537, 1503, 1456, 1419 cm-1; 1H NMR 
(Acetone-d6) δ 7.80 (dd, J = 8.4, 1.4 Hz, 1H, H-6), 7.78 (d, J = 1.4 Hz, 1H, H-2), 
7.53 (d, J = 8.4 Hz, 1H, H-5), 4.32 (t, J = 6.6 Hz, 2H, OCH2), 4.03 (s, 3H, 
OCH3), 1.80 (m, 2H, CH2CH3), 1.03 (t, J = 7.4 Hz, 3H, CH2CH3); 13C {1H} NMR 
(Acetone-d6) δ 165.5 (CO2CH2), 147.4 (C-3), 137.8 (C-4), 123.2 (C-6), 121.3 (C-
1), 116.0 (C-5), 111.1 (C-2), 65.5 (OCH2), 55.6 (OCH3), 21.6 (CH2CH3), 10.3 
(CH2CH3); LRMS (ESI) m/z: 210 (M+H)+; HRMS (ESI) m/z calcd. for C11H16NO3  
[M+H]+: 210.1034, found: 210.1012 
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Propyl 4-(5(dimethylamino) naphthalene-1-sulfonamido)-3-
methoxybenzoate (87, ICT13143). 
 
Propyl 4-amino-3-methoxybenzoate (0.10 g, 0.47 mmol) was dissolved in dry 
pyridine (10 mL). The reaction temperature was brought to 0 °C and dansyl 
chloride (0.15 g, 0.57 mmol) was then added dropwise and solution was left 
stirring for 5h. Hydrochloric acid (10 mL, 2M) was added and reaction mixture 
was extracted with ethyl acetate (3x50 mL). The combined organic extracts 
were dried over anhydrous MgSO4, filtered and the solvent was evaporated 
under reduced pressure. The resultant material was purified by flash column 
chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.19 g, 91 %) 
as yellowish green crystals; m.p: 161.2-162 °C; IR: 3267, 2937, 2788, 1708, 
1606, 1588, 1574, 1507, 1455, 1433 cm-1; 1H NMR (CDCl3) δ 8.43 (d, J = 8.8 
Hz, 1H, H-8), 8.25 (d, J = 8.8 Hz, 1H, H-15), 8.17 (d, J = 7.3 Hz, 1H, H-10), 7.53 
(dd, J = 7.3, 8.8 Hz, 1H, H-14), 7.49 (s, 1H, NH), 7.46 (dd, J = 8.4, 1.6 Hz, 1H, 
H-6), 7.38 (d, J = 8.4 Hz, 1H, H-5), 7.35 (dd, J = 7.3, 8.8 Hz, 1H, H-9), 7.25 (d, J 
= 1.6 Hz, 1H, H-2), 7.10 (d, J = 8.3 Hz, 1H, H-13), 4.12 (t, J = 6.7 Hz, 2H, 
OCH2), 3.56 (s, 3H, OCH3), 2.78 (s, 6H, N(CH3)2), 1.65 (m, 2H, CH2CH3), 0.90 
(t, J = 7.4 Hz, 3H, CH2CH3); 13C {1H} NMR (CDCl3) δ 166.0 (CO2CH2), 152.0 
(C-12), 147.9 (C-7), 133.9 (C-3), 131.1 (C-8), 130.6 (C-4), 130.3 (C-10), 129.8 
(C-16), 129.5 (C-1), 128.4 (C-14), 126.1 (C-5), 122.9 (C-6), 118.5 (C-15), 118.3 
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(C-9), 115.2 (C-13), 112.1 (C-11), 111.2 (C-2), 66.5 (OCH2), 55.8 (OCH3), 45.4 
(N(CH3)2), 22.0 (CH2CH3), 10.4 (CH2CH3); LRMS (ESI) m/z: 443.01 (M+H)+; 
HRMS (ESI) m/z calcd. for C23H27O5N2S  [M+H]+: 443.1635, found: 443.1628. 
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Propyl 4-(4-((4-(dimethylamino)phenyl)diazenyl)phenylsulfonamido)-3-
methoxybenzoate (88, ICT13144). 
 
Round bottom flask was charged with propyl 4-amino-3-methoxybenzoate (0.10 
g, 0.47 mmol) in presence of pyridine (15 mL). Solution of dabsyl chloride (0.18 
g, 0.57 mmol) in DCM was added dropwise at 0 °Cto the reaction solution. The 
solution was left stirring at room temperature for 5h. Hydrochloric acid (10 mL, 
2M) was added and reaction mixture was extracted with ethyl acetate (3x50 
mL). The combined organic extracts were dried over anhydrous MgSO4, filtered 
and the solvent was evaporated under reduced pressure. The resultant material 
was purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the 
title compound (0.20 g, 85%) as dark red solid;  m.p: 145.5-145.9 °C; IR: 3260, 
2930, 2780, 1736, 1643, 1601, 1527, 1413, 1330, 1220 cm-1; 1H NMR 
(Acetone-d6) δ 8.58 (s, 1H, NH), 7.86 (d, J = 8.4 Hz, 2H, H-8, H-12), 7.79 (d, J = 
8.4 Hz, 2H, H-9, H-11), 7.76 (d, J = 8.4 Hz, 2H, H-14, H-18). 7.50 (dd, J = 8.2, 
1.2 Hz, 1H, H-6), 7.49 (d, J = 8.2 Hz, 1H, H-5), 7.34 (d, J = 1.2 Hz, 1H, H-2), 
6.83  (d, J = 8.4 Hz, 2H, H-15, H-17), 4.07 (t, J = 6.6 Hz, 2H, OCH2), 3.65 (s, 
3H, OCH3), 3.08 (s, 6H, N(CH3)3), 1.61 (m, 2H, CH2CH3), 0.85 (t, J = 7.4 Hz, 
3H, CH2CH3); 13C {1H} NMR (Acetone-d6) δ 166.3 (CO2CH2), 153.8 (C-10), 
144.2 (C-16), 140.4 (C-3), 131.9 (C-13), 129.3 (C-7), 128.2 (overlapping C-8, C-
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12), 128.0 (C-1), 127.4 (C-4), 123.2 (overlapping C-9, C-11), 122.5 (overlapping 
C-14, C-18), 120.8 (C-6), 114.3 (C-5), 113.5 (overlapping C-15, C-17), 112.4 
(C-2), 67.0 (OCH2), 56.4 (OCH3), 40.9 (N(CH3)3), 22.7 (CH2CH3), 10.7 
(CH2CH3); LRMS (ESI) m/z: 497.02 (M+H)+; HRMS (ESI) m/z calcd. for 
C25H29O5N4S  [M+H]+: 497.1853, found: 497.1842. 
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Methyl 2-(4-(tert-butyl)phenylsulfonamido)-4,5-dimethoxybenzoate (90, 
ICT13068).  
 
To solution of methyl 2-amino-4, 5-dimethoxybenzoate 91 (0.10 g, 0.47 mmol) 
in dry prydine (10 mL), solution of 4-tert-butylbenzenesulfonyl chloride 61 (0.13 
g, 0.56 mmol) in DCM was added dropwise at 0 °C. The mixture was left stirring 
at R.T for 5 h. Hydrochloric acid solution (10 mL, 2M) was added to the reaction 
mixture. Organic components were extracted with ethyl acetate (3x50 mL). The 
combined organic extracts were dried over anhydrous MgSO4, filtered and the 
solvent was evaporated under reduced pressure. The resultant material was 
purified by flash column chromatography (EtOAc:PE, 2:8 v/v) to give the title 
compound (0.15 g, 78 %) as brown crystals; m.p: 144.7-144.9 °C; IR: 2967, 
1672, 1618, 1592, 1518, 1466, 1438, 1402, 1359, 1256 cm-1; 1H NMR (CDCl3) δ 
10.38 (s, 1H, NH), 7.63 (dd, J = 8.6, 2.0 Hz, 2H, H-8, H-12), 7.34 (dd, J = 8.6, 
2.0 Hz, 2H, H-9, H-11), 7.24 (d, J = 5.9 Hz, 2H, H-3, H-6), 3.85 (s, 3H, 
CO2CH3), 3.75 (s, 6H, O(CH3)2), 1.21 (s, 9H, C(CH3)3); 13C {1H} NMR (CDCl3) δ 
167.8 (CO2CH3), 156.7 (C-5), 153.9 (C-10), 144.6 (C-1), 136.2 (C-4), 136.0 (C-
7) 127.0 (overlapping C-8, C-12), 125.9 (overlapping C-9, C-11), 112.0 (C-3), 
108.2 (C-2), 103.2 (C-6), 56.1 (O(CH3)2), 52.2 ( CO2CH3), 35.1 (C(CH3)3), 31.0 
223 
 
(C(CH3)3); LRMS (ESI) m/z: 408.1 (M+H)+; HRMS (ESI) m/z calcd. for 
C20H26O6NS [M+H]+: 408.1475, found: 408.1469 
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N-(4-(tert-butyl)phenyl)-2,4-dimethoxybenzenesulfonamide (95, ICT13121). 
 
2,4-dimethoxybenzene-1-sulfonyl chloride 93 (0.19 g, 0.80 mmol) was first 
dissolved in THF (15 mL) and was left stirring over 15 minutes. 4-(tert-butyl) 
aniline 94 (0.10 g. 0.67 mmol) was added dropwise to the solution and mixture 
was left stirring under nitrogen for 5h. Hydrochloric acid (10 mL, 2M) was added 
and extracted with ethyl acetate (3x50 mL). The combined organic extracts 
were dried over anhydrous MgSO4, filtered and the solvent was removed under 
reduced pressure. The crude material was purified by flash column 
chromatography (EtOAc:PE, 2:8 v/v) to give the title compound (0.20 g, 85%) 
as white powder; m.p: 188.5-188.9 °C; IR: 3258, 2961, 1598, 1576, 1511, 1465, 
1439, 1419, 1396, 1364 cm-1; 1H NMR (CDCl3) δ 7.67 (d, J = 8.5 Hz, 1H, H-6), 
7.16 (J = 8.6 Hz, 2H, H-8, H-12), 6.93 (s, 1H, NH), 6.92 (J = 8.6 Hz, 2H, H-9, H-
11), 6.40 (d, J = 2.1 Hz, 1H, H-3), 6.38 (dd, J = 8.5, 2.1 Hz, 1H, H-5), 3.91 (s, 
3H, OCH3), 3.72 (s, 3H, OCH3), 1.14 (s, 9H, C(CH3)3); 13C {1H} NMR (CDCl3) δ 
164.9 (C-4), 157.7 (C-2), 148.0 (C-10), 134.2 (C-7), 132.7 (C-6), 126.0 
(overlapping C-8, C-10), 121.1 (overlapping C-9, C-11), 118.7 (C-1), 104.4 (C-
5), 99.3 (C-3), 56.3 (OCH3), 55.7 (OCH3), 34.2 ( C(CH3)3), 31.2 (C(CH3)3); 
LRMS (ESI) m/z: 350.98 (M+H)+; HRMS (ESI) m/z calcd. for C18H24O4NS  
[M+H]+: 350.1421, found: 350.1422 
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4.1.3. Experimental procedures for Western blot 
All general chemicals, media and media supplements were obtained from 
Sigma-Aldrich (Poole, UK) unless otherwise specified. Rabbit Monoclonal 
antibody anti CCR7 [Y59], Abcam (Massachusetts, USA), Polyclonal goat anti 
rabbit linked to horseradish peroxidise conjugated secondary antibody (Dako, 
Ely, United Kingdom), Mouse monoclonal antibody anti-β-actin (Sigma Aldrich), 
polyclonal rabbit anti mouse linked to horseradish peroxidise (Dako), 
Nitrocellulose membrane and Amersham Hyper-film enhanced 
chemiluminescence detection reagent were obtained from GE Healthcare Life 
Sciences. 
Cells and cell culture 
All cell lines were obtained from the American Type Culture Collection (ATCC, 
Middlesex, UK), except for MCF-7 AND MCF-7 ADR were purchased from NCI. 
The cells were cultured in 75 cm2 cell culture flasks (T-75) as monolayers in 
10% Foetal Calf Serum (FCS), sodium pyruvate (1 mM) and L-glutamine (2 
mM) RPMI-1640 medium (Sigma-Aldrich), at 37 °C , 95% air and 5% CO2 
atmosphere. 
Determination of protein concentration  
The Bradford assay was used to determine the protein concentration in each 
sample solution 168. Serial dilutions started from 1 mg/ml, 0.5 mg/ml, 0.25 
mg/ml, 0.125 mg/ml and 0.0625 mg/ml of BSA and blank dissolved in distilled 
water were prepared to create a standard curve of absorbance. Dilution of the 
protein samples were prepared to have 50 µL in total. 1.5 ml of the Bradford 
reagent was added to each 50 µL tube containing BSA, blank and samples 
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dilutions and the tubes were vortex mixed and allowed to stand for 15 minutes 
at room temperature to give enough time for the Coomassie Brilliant Blue dye to 
conjugate with the protein. The BSA standard concentration was analysed using 
a spectrophotometer (Cary 50 BIO UV-Visible) at a wavelength of 595nm. 
Results obtained from samples were calculated from the standard curve to get 
the protein concentration. 
Method:  
A panel of 10 cell pellets were first harvested from different cell lines which 
believed to have expression of CCR7 receptor based on literature review. Each 
pellet obtained is collection of three 75% confluent T-75 flasks. Cells were first 
washed with 10 ml of HBSS and collected in an Eppendorf tube, cell 
suspension was centrifuged at a speed of 13,000 rcf for 5 minutes at 22 ˚C to 
obtain the pellet and discard liquid layer. Pellets were then suspended in 2 X 
volume of protein extraction buffer. After the protein concentration was 
determined for each cell pellet, specific amount of protein was mixed with buffer 
solution and vortex mixed, centrifuged and heated in water bath for 10 minutes 
at 60 ˚C. 5 µl of PageRuler™ Plus Prestained Protein Ladder (Thermo 
Scientific) and the desired concentration of proteins were loaded on a 12% 
polyacrylamide gel for 20 min at 80 V and then 1 hour at 160 V constant 
voltage. The voltage was stopped when the dye reached 1 cm from the bottom 
of the gel. Transfer membrane and all pads and filters were soaked in the 
transfer buffer making sure that no bubbles are formed.   
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Blotting 
The protein was transferred from polyacrylamide gel to nitrocellulose membrane 
(GE Healthcare Life Sciences) in presence of transfer buffer, the whole stack 
including transfer paper, gel and blotting papers were held vertically in the 
transfer buffer and the tank was connected to a power supply at 58 mA for 2 
hours on ice. The membrane was placed in blocking solution (Marvel skimmed 
milk) on a rocker platform for one hour at room temperature. The membrane 
was then incubated with diluted rabbit monoclonal antibody anti CCR7 [Y59] 
(Abcam) primary antibody on the plate overnight at 4 ˚C. The membrane was 
washed with wash solution (0.5 % Tween PBS) for 15 minutes three times, 
washed solution was discarded. The membrane was incubated with the diluted 
horseradish peroxidise conjugated secondary antibody (Dako) in blocking 
solution for about one hour at room temperature on the rocker plate. Again, the 
membrane was washed three times and the washing solution was discarded.  
The final step was to detect CCR7 protein availability on these cell lines by 
using the reporter enzyme which linked to the antibody which gives colorimetric 
reaction during exposing to the appropriate substrate.  The CCR7 protein was 
detected by incubating membrane with Amersham Hyper-film enhanced 
chemiluminescence (ECL) for about 10 minutes. The film was then developed in 
Multigrade Paper Developer solution (Ilford), washed with water and fixed in 
Rapid Film and Paper Fixer solution (Ilford) for 2 minutes and left to dry. 
Because the molecular weight of the ligand is close to the molecular weight of 
beta actin, the blots were stripped using stripping buffer (15 g glycine, 1 g SDS, 
10 ml Tween20, Adjust pH to 2.2 Bring volume up to 1 L with ultrapure water) 
for 1 hour at 25 ˚C and re-probed with mouse monoclonal anti-β-actin (Sigma 
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Aldrich), which recognize proteins with band size 42 kDa to assess loading 
density. The primary antibody was incubated overnight at 4°C and same steps 
used in detecting the CCR7 receptor were repeated.  
4.1.4. Experimental procedure for calcium flux assay 
Chemicals and biologicals 
All general chemicals, media and media supplements were obtained from 
Sigma-Aldrich unless otherwise specified. Recombinant CCL19 (and CCL21 
were purchased from R&D Systems (Abingdon,  UK). CCR7 antagonists were 
synthesised at the Institute of Cancer Therapeutics (University of Bradford, UK). 
Fluo-4 NW dye mix (Catalogue number F36206), (Component A), Probenecid, 
water soluble (Component B) and Assay buffer (1X HBSS, 20 mM HEPES) 
(Component C, included in starter pack only) were purchased from life 
technologies, UK. 96-well black-wall, flat bottom, microtiter plate (catalogue 
number 27614033) were purchased from Costar (Massachusetts, USA). 
Cells and cell culture 
Human glioblastoma-astrocytoma, epithelial-like cell line (U-87-MG), human T 
cell lymphoblast-like cell line (CCRF-CEM), human pancreatic carcinoma 
epithelial-like cell line (Panc-1) were obtained from the American Type Culture 
Collection (ATCC, Middlesex, UK). Human oral squamous cell carcinoma 
(OSC-19) was a generous gift from Dr Faye Johnson, MD Anderson Cancer 
Centre, Houston, USA. OSC-19 cell line was chosen because it was reported 
within our research group to have high expression of CCR7. CCRF and Panc-1 
cell lines were chosen because they were reported in literature to have high 
expression of CCR7 receptor. U-87-MG cell line is a cell line amongst panel of 
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cell lines which showed remarkable expression on western blot assay. The cells 
were cultured in 75 cm2 cell culture flasks (T-75) as monolayers in 10% Foetal 
Calf Serum (FCS), sodium pyruvate (1 mM) and L-glutamine (2 mM) RPMI-
1640 medium (Sigma-Aldrich), at 37 °C , 95% air and 5% CO2 atmosphere. 
Method 
Cells were seeded into each well of 96-well black-wall, flat bottom, microtiter 
plate at a density of 5 x 104 cells per well. After 24 h, the growth medium was 
replaced with 100μl of the dye loading solution (Molecular Probes™ Fluo-4 NW 
(no wash), Invitrogen F36206). The plates were incubated at 37 °C for 30 
minutes and at room temperature for an additional 30 minutes. 20μL of a given 
concentration of the antagonist in medium, or plain medium as control, was 
added to each well and the plate was incubated at 37 °C for 15 minutes and at 
room temperature for an additional 30 minutes. The plate was transferred into a 
Fluoroskan Ascent FL instrument (ThermoScientific) and the fluorescence in 
response to the addition of 20μl chemokine (to give 100 nM in-well 
concentration) was measured at room temperature (Ex 485 nm, Em 538 nm). 
IC50 is calculated as the concentration of the antagonist required to half the 
maximal response to chemokine using Prism software. Data is presented as the 
mean ±SE of at least 3 independent experiments. 
Making the reagents 
Following the manufacturing instructions, 1 ml of the assay buffer (component 
C) was added to the container labelled as component B (probenecid) and vortex 
mix in order to make a 250 mM stock solution of probenecid. 10 ml of the assay 
buffer (component C) and 100µl of the probenecid solution (component B) was 
added to the component A (containing the Fluo-4 NW dye). The mixture was 
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shaked well for 2 minutes in the vortex mixer to make sure the dye dissolved 
properly. This dye loading solution is sufficient for one 96-well microplate as 
100µl of the dye is loaded to each well. 
Preparation of ligands CCL21 and CCL19 
Both ligands are prepared the same way considering the differences in 
molecular weight. For example, 25µg lyophilized CCL21 (MW = 12 kDa) was 
reconstituted by adding 100μL of sterile phosphate-buffered-saline solution 
(PBS) containing 0.1% BSA to afford 100µL of 2.083 x 10-5 M stock solution. 
First, both ligand were used to determine the concentration to be used in the 
assay, so serial dilutions were taken place. The first dilution was prepared by 
adding 100µL of stock solution to 900µL of assay buffer (without probenecid) to 
afford 2.083 x 10-6 M solution (1000µL). If 20µL of this solution is added to 
100µL of assay buffer (120µL), the final concentration of CCL21 is 3.47x10-7. 
Taking into account the 700µl which is used to purge the system and number of 
wells repeated in each assay (75µL for 3 runs and 225µL is left for next 
dilutions). CCl21 showed better activity, so 100 nM of CCL21 was conducted 
from the EC50 curve to be used for the whole assay. Taking into account the 
dead volume of pipes in the fluoroskan, 700µL, and number of wells used in 
each run, CCL21 is calculated to make 100nm in the wells (140µL total volume).  
Preparation of antagonist solutions 
A stock solution of each compound was prepared by dissolving known amount 
of compound in 100 µl DMSO, to generate 100mM stock solution. The first top 
concentration was made by adding 2 µL of the stock solution to an Eppendorf 
tube containing 198 µL of assay buffer without probenecid to give a 1mM 
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solution (containing 1% DMSO v/v). When the 20µL of first dilution solution is 
added directly to the well (total volume 140µL: 100µl loading dye mixture + 20µl 
ligand + 20µl antagonist) the final concentration of the molecule in cell 
suspension is 142uM, containing 0.14% DMSO.   
4.1.5. Experimental procedure for Agarose Spot Method. 
Chemicals and biologicals 
Recombinant CXCL12, CCL19  and CCL21 were purchased from R&D 
Systems. UltrapureTM low-melting agarose  was purchased from Invitrogen 
(Paisley, UK). CXCR4 antagonist AMD3100 (catalogue number 3299) 169, was 
purchased from Tocris Biosciences (Westwoods Business Park, Ellisville, 
Missouri USA). CCR7 antagonist compound 75 and compound 3 were 
synthesised at the Institute of Cancer Therapeutics (University of Bradford, UK). 
Cells and cell culture 
Human primary glioblastoma cell line (U87-MG), human colon adenocarcinoma 
cell line (DLD-1), human colorectal adenocarcinoma cell line (HT-29) human 
prostate PC-3 and colorectal SW-480 adenocarcinoma cell lines were obtained 
from the American Type Culture Collection (ATCC). The cells were cultured in 
75 cm2 cell culture flasks (T-75) as monolayers in 10% Foetal Calf Serum 
(FCS), sodium pyruvate (1 mM) and L-glutamine (2 mM) RPMI-1640 medium 
(Sigma-Aldrich), at 37 °C , 95% air and 5% CO2 atmosphere. 
Equipment 
Disposable glass-bottomed plastic 35mm petri dishes with lid  were purchased 
from iBidi (Glasgow, United Kingdom). These dishes have a usable glass 
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surface area with a 20 mm diameter. Images were observed using LumaScopes 
500 (Etaluma, Inc. Carlsbad, CA) with 20x objectives. A Nikon Eclipse TI 
confocal microscope was used to record a movie of cells migration.  
Method 
100 mg of low–melting point agarose was placed into a 100-mL beaker and 
dissolved into 20 mL PBS to make a 0.5% agarose solution. This was heated 
until boiling on a hot plate, and swirled to facilitate complete dissolution. Once 
all agarose particles were dissolved, the beaker was taken off of the heat and 
cooled down to 40 °C. Stock solutions of the appropriate cheomkines were 
prepared as following. For example, 10µg lyophilized CXCL12 (MW = 8004 Da) 
was reconstituted by adding 100μL of sterile phosphate-buffered-saline solution 
(PBS) containing 0.1% BSA to afford a 12.5 μM stock solution. To prepare a 
100 nM CXCL12/agarose solution, 1.6 μL of the CXCL12 stock solution was 
mixed with 18.4 μL of PBS. The resulting 20μL was then mixed with 180 μL of 
0.5% agarose solution at 40 °C. To prepare CCL21 (MW = 12 kDa) is prepared 
as: 25ug lyophilized CCL21 is reconstituted by adding 100µL of sterile 
phosphate-buffered- saline solution containing 0.1% BSA. This affords a stock 
solution of 20.83uM. To prepare a 100 nM CCL21/agarose solution, 0.96 μL of 
the CCL21 stock solution was mixed with 19.03 μL of PBS. The resulting 20μL 
was then mixed with 180 μL of 0.5% agarose solution at 40 °C. To prepare 
CCL19 (MW = 8800 D) is prepared as: 25ug lyophilized CCL19 is reconstituted 
by adding 100µL of sterile phosphate-buffered-saline solution containing 0.1% 
BSA. This affords a stock solution of 28.41uM. To prepare a 100 nM 
CCL19/agarose solution, 0.70 μL of the CCL19 stock solution was mixed with 
19.29 μL of PBS. The resulting 20μL was then mixed with 180 μL of 0.5% 
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agarose solution at 40 °C. To prepare the control agarose solution, 20μl of PBS 
was placed in an Eppendorf tube and mixed with 180 μL of 0.5% agarose 
solution at 40oC. Stock solutions of the appropriate antagonists were prepared 
as following. To prepare AMD3100, 100mM stock solution of AMD3100 was 
prepared by dissolving 7.945 mg of the drug (MW= 794.5) into 100μL of 
deionized water (stock solution). This stock solution was aliquoted according to 
experiment need and stored at -20 C˚. Stock solution (100mM) was further 
diluted to 1mM (10μL stock + 990μL medium, 1mL total) in separate eppendorf 
tube (1mL is needed because medium containing drug is discarded after 
incubation for 4 hours to change the 0.1% medium). Then serial dilutions were 
prepared as follow, to make 200μM AMD3100, 800μL medium containing cells 
+ 200μL of 1mM AMD3100 solution (1mL total). To make 100μM AMD3100, 
add 900μL medium containing cells to 100μL of 1mM AMD3100 solution (1mL 
total). To make 50μM AMD3100, add 950μL medium containing cells to 50μL of 
1mM AMD3100 solution (1mL total). To prepare compound 75, 100mM stock 
solution of compound 75 was prepared by dissolving 3.7745 mg of the drug 
(MW= 377.45) into 100μL of DMSO (stock solution). To prepare compound 3, 
100mM stock solution of compound 75 was prepared by dissolving 2.00 mg of 
the drug (MW= 200.22) into 100μL of DMSO (stock solution). These stock 
solutions were aliquoted according to experiment need and stored at -20 C˚. 
The required diluted concentrations were then prepared the same way as 
shown in AMD3100 compound.  
The ends of 200μl pipette tips (catalogue number 70.760.211; Sarstedt, 
Leicester, UK) were cut with scissors by about 2 mm in order to facilitate the 
transfer of the viscous agarose solution and the formation of the spot. Using 
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these cut pipette tips, 10μl drops of agarose solution (either control containing 
only PBS, or containing chemokine) were applied onto each of the quadrants of 
the petri dish. Depending on the purpose of the experiment, spots containing 
the same chemokine (to allow the results to be obtained in duplicate or 
triplicate) or different chemokines (to allow comparison) can be applied for each 
dish. If required, the spots can be identified by writing on the backside of the 
glass. The petri dish containing the spots was then cooled for exactly 5 minutes 
in a 4 °C fridge to allow the agarose spot to set. 1 ml of cell suspension in 10% 
FCS media, either containing the antagonist(s), or control (no agent), was 
plated into the dishes which were then incubated at 37 °C, 5% CO2 to allow the 
cells to adhere. The cell density was about 6.0 x 104/ml, after 4 hours, the 
culture media was replaced with 0.1% FCS. After 16 h, the agarose spots were 
analysed by counting total number of invading cells using a microscope. A 
movie was taken for the cells migrating using Nikon Eclipse TEZ000-U confocal 
microscope. Images obtained were analysed by Fiji/ImageJ software. Data is 
presented as the mean ±SE of at least 3 independent experiments.  
 
 
 
 
 
 
 
 
  
235 
 
5. References 
1. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment. Blood. 2006;107(5):1761-7. 
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. 
Cell. 2011;144(5):646-74. 
3. Yokota J. Tumor progression and metastasis. Carcinogenesis. 
2000;21(3):497-503. 
4. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors 
in cancer metastasis and cancer cell‐derived chemokines in host immune 
response. Cancer science. 2007;98(11):1652-8. 
5. Tannock IF, Hill RP. The basic science of oncology. New York: McGraw-
Hill; 1998. 
6. Murakami T, Cardones AR, Hwang ST. Chemokine receptors and 
melanoma metastasis. Journal of dermatological science. 2004;36(2):71-8. 
7. Foon KA. Biological therapy of cancer. Breast cancer research and 
treatment. 1986;7(1):5-14. 
8. Hassan S, Baccarelli A, Salvucci O, Basik M. Plasma Stromal Cell–
Derived Factor-1: Host Derived Marker Predictive of Distant Metastasis in 
Breast Cancer. Clinical cancer research. 2008;14(2):446-54. 
9. Pienta KJ, Robertson BA, Coffey DS, Taichman RS. The Cancer 
Diaspora: Metastasis beyond the seed and soil hypothesis. Clinical cancer 
research. 2013;19(21):5849-55. 
10. Miyazaki H, Takabe K, Yeudall WA. Chemokines, chemokine receptors 
and the gastrointestinal system. World j gastroenterol. 2013;19(19):2847. 
236 
 
11. Janeway C, Travers P, Hunt S. Immunobiology: the immune system in 
health and disease: Current Biology; 1996. 
12. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano‐Cabral F. CB2 
receptors in the brain: role in central immune function. British journal of 
pharmacology. 2008;153(2):240-51. 
13. Fu H, Karlsson J, Bylund J, Movitz C, Karlsson A, Dahlgren C. Ligand 
recognition and activation of formyl peptide receptors in neutrophils. Journal of 
leukocyte biology. 2006;79(2):247-56. 
14. Murdoch C, Finn A. Chemokine receptors and their role in inflammation 
and infectious diseases. Blood. 2000;95(10):3032-43. 
15. Locati M, Bonecchi R, Corsi MM. Chemokines and Their Receptors 
Roles in Specific Clinical Conditions and Measurement in the Clinical 
Laboratory. American Journal of Clinical Pathology Pathology Patterns 
Reviews. 2005;123(Suppl 1):S82-S95. 
16. Vaddi K, Keller M, Newton M. The Chemokine Factsbook: Ligands and 
Receptors: Academic Press; 1997. 
17. Ali S, Lazennec G. Chemokines: novel targets for breast cancer 
metastasis. Cancer and Metastasis Reviews. 2007;26(3-4):401-20. 
18.  Lolis E, Murphy JW. The Structural Biology of Chemokines. In: Harrison 
JK, Lukacs NW, editors. The Chemokine Receptors. Totowa, NJ: Humana 
Press; 2007. p. 9-30. 
19. Hattermann K, Holzenburg E, Hans F, Lucius R, Held-Feindt J, Mentlein 
R. Effects of the chemokine CXCL12 and combined internalization of its 
receptors CXCR4 and CXCR7 in human MCF-7 breast cancer cells. Cell Tissue 
Res. 2014;357(1):253-66. 
237 
 
20. Shim H, Oishi S, Fujii N, editors. Chemokine receptor CXCR4 as a 
therapeutic target for neuroectodermal tumors. Seminars in cancer biology; 
2009: Elsevier. 
21. Chung ACK, Lan HY. Chemokines in renal injury. Journal of the 
American Society of Nephrology. 2011;22(5):802-9. 
22. de Munnik SM, Smit MJ, Leurs R, Vischer HF. Modulation of cellular 
signaling by herpesvirus-encoded G protein-coupled receptors. Frontiers in 
pharmacology. 2015;6. 
23. Struyf S, Gouwy M, Dillen C, Proost P, Opdenakker G, Van Damme J. 
Chemokines synergize in the recruitment of circulating neutrophils into inflamed 
tissue. European journal of immunology. 2005;35(5):1583-91. 
24. Zou Y-R, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of 
the chemokine receptor CXCR4 in haematopoiesis and in cerebellar 
development. Nature. 1998;393(6685):595-9. 
25. Lazennec G, Richmond A. Chemokines and chemokine receptors: new 
insights into cancer-related inflammation. Trends Mol Med. 2010;16(3):133-44. 
26. Rossi D, Zlotnik A. The biology of chemokines and their receptors. 
Annual review of immunology. 2000;18(1):217-42. 
27. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. 
Annual review of pharmacology and toxicology. 2002;42(1):469-99. 
28. Ransohoff RM, Suzuki K, Proudfoot AEI, Hickey WF, Harrison JK. 
Universes in Delicate Balance: Chemokines and the Nervous System: 
Chemokines and the Nervous System: Elsevier; 2002. 
29. Herndon RM. Multiple sclerosis: immunology, pathology, and 
pathophysiology: Demos Medical Publishing; 2003. 
238 
 
30. Xing YN, Xu XY, Nie XC, Yang X, Yu M, Xu HM, et al. Role and 
clinicopathologic significance of CXC chemokine ligand 16 and chemokine (C-
X-C motif) receptor 6 expression in gastric carcinomas. Hum Pathol. 
2012;43(12):2299-307. 
31. Harrison JK, Lukacs NW. The chemokine receptors: Springer; 2007. 
32. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in 
prostate cancer. Endocrine-related cancer. 2009;16(3):663-73. 
33. Karnoub AE, Weinberg RA. Chemokine networks and breast cancer 
metastasis. Breast disease. 2007;26(1):75-85. 
34. Gangur V, Birmingham NP, Thanesvorakul S. Chemokines in health and 
disease. Veterinary immunology and immunopathology. 2002;86(3):127-36. 
35. Rosenkilde MM, Schwartz TW. The chemokine system–a major regulator 
of angiogenesis in health and disease. Apmis. 2004;112(7‐8):481-95. 
36. Foti M, Granucci F, Aggujaro D, Liboi E, Luini W, Minardi S, et al. Upon 
dendritic cell (DC) activation chemokines and chemokine receptor expression 
are rapidly regulated for recruitment and maintenance of DC at the inflammatory 
site. International immunology. 1999;11(6):979-86. 
37. Esche C, Stellato C, Beck LA. Chemokines: key players in innate and 
adaptive immunity. Journal of investigative dermatology. 2005;125(4):615-28. 
38. Robertson MJ. Role of chemokines in the biology of natural killer cells. 
Journal of leukocyte biology. 2002;71(2):173-83. 
39. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer 
metastasis. Journal of leukocyte biology. 2006;79(4):639-51. 
239 
 
40. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. 
Involvement of chemokine receptors in breast cancer metastasis. Nature. 
2001;410(6824):50-6. 
41. Johnson Z, Power CA, Weiss C, Rintelen F, Ji H, Ruckle T, et al. 
Chemokine inhibition-why, when, where, which and how? Biochemical Society 
Transactions. 2004;32(2):366-77. 
42. Crane IJ, Wallace CA, McKillop‐Smith S, Forrester JV. Control of 
chemokine production at the blood–retina barrier. Immunology. 
2000;101(3):426-33. 
43. Xiang Z-l, Zeng Z-c, Tang Z-y, Fan J, Zhuang P-y, Liang Y, et al. 
Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients 
increases the risk of bone metastases and poor survival. BMC Cancer. 
2009;9(1):176. 
44. Yu Y, Sweeney MD, Saad OM, Crown SE, Handel TM, Leary JA. 
Chemokine-Glycosaminoglycan Binding SPECIFICITY FOR CCR2 LIGAND 
BINDING TO HIGHLY SULFATED OLIGOSACCHARIDES USING FTICR 
MASS SPECTROMETRY. Journal of Biological Chemistry. 
2005;280(37):32200-8. 
45. Kim B-T, Kitagawa H, Tamura J-i, Saito T, Kusche-Gullberg M, Lindahl 
U, et al. Human tumor suppressor EXT gene family members EXTL1 and 
EXTL3 encode α1, 4-N-acetylglucosaminyltransferases that likely are involved 
in heparan sulfate/heparin biosynthesis. PNAS. 2001;98(13):7176-81. 
46. Yan D, Lin X. Shaping morphogen gradients by proteoglycans. Cold 
Spring Harbor perspectives in biology. 2009;1(3). 
47. Linkes W. Progress in Chemokine Research: Nova Publishers; 2007. 
240 
 
48. Mellado M, Rodríguez-Frade JM, Mañes S, Martínez-A C. Chemokine 
signaling and functional responses: the role of receptor dimerization and TK 
pathway activation. Annu Rev Immunol. 2001;19:397-421. 
49. Richmond A. NF-κB, chemokine gene transcription and tumour growth. 
Nature Reviews Immunology. 2002;2(9):664-74. 
50. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. JAK/STAT Pathways in 
Cytokine Signaling and Myeloproliferative Disorders Approaches for Targeted 
Therapies. Genes & cancer. 2010;1(10):979-93. 
51. Stadtmann A, Zarbock A. CXCR2: from bench to bedside. Frontiers in 
immunology. 2015;3:263. 
52. Owen JL, Mohamadzadeh M. Macrophages and chemokines as 
mediators of angiogenesis. Frontiers in Physiology.4:159. 
53. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer 
development. Molecular Cancer Research. 2006;4(4):221-33. 
54. Peddareddigari VG, Wang D, DuBois RN. The tumor microenvironment 
in colorectal carcinogenesis. Cancer Microenvironment. 2010;3(1):149-66. 
55. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, 
Naeem R, et al. Stromal fibroblasts present in invasive human breast 
carcinomas promote tumor growth and angiogenesis through elevated SDF-
1/CXCL12 secretion. Cell. 2005;121(3):335-48. 
56. Koontongkaew S. The Tumor Microenvironment Contribution to 
Development, Growth, Invasion and Metastasis of Head and Neck Squamous 
Cell Carcinomas. Journal of Cancer. 2013;4(1):66. 
241 
 
57. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, et 
al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node 
metastasis in T1 breast cancer. Clin Cancer Res. 2005;11(16):5686-93. 
58. Segerer S, Nelson PJ, SchlÖNdorff D. Chemokines, chemokine 
receptors, and renal disease: from basic science to pathophysiologic and 
therapeutic studies. Journal of the American Society of Nephrology. 
2000;11(1):152-76. 
59. Kawaguchi M, Kokubu F, Matsukura S, Ieki K, Odaka M, Watanabe S, et 
al. Induction of CXC chemokines, growth-related oncogene α expression, and 
epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17F) 
involves activation of raf1-mitogen-activated protein kinase kinase-extracellular 
signal-regulated kinase 1/2 pathway. Journal of Pharmacology and 
Experimental Therapeutics. 2003;307(3):1213-20. 
60. Luster AD. Chemokines--chemotactic cytokines that mediate 
inflammation. New England journal of medicine. 1998;338(7):436-45. 
61. Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S, et al. Blockade of SDF-
1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via 
inactivation of canonical Wnt pathway. British journal of cancer. 
2008;99(10):1695-703. 
62. Schwiebert LM. Chemokines, Chemokine Receptors and Disease: Elsevier; 
2005. 
63. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment. Blood. 2006;107(5):1761-7. 
64. Stein JV, Nombela‐Arrieta C. Chemokine control of lymphocyte 
trafficking: a general overview. Immunology. 2005;116(1):1-12. 
242 
 
65. Weng AP, Shahsafaei A, Dorfman DM. CXCR4/CD184 immunoreactivity 
in T-cell non-Hodgkin lymphomas with an overall Th1–Th2+ immunophenotype. 
American journal of clinical pathology. 2003;119(3):424-30. 
66. Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of 
B16 tumor cells to endothelial cells in vitro and in vivo via β1 integrin. Cancer 
research. 2003;63(20):6751-7. 
67. McGrath KE, Koniski AD, Maltby KM, McGann JK, Palis J. Embryonic 
expression and function of the chemokine SDF-1 and its receptor, CXCR4. 
Developmental biology. 1999;213(2):442-56. 
68. Takabatake Y, Sugiyama T, Kohara H, Matsusaka T, Kurihara H, Koni 
PA, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of 
renal vasculature. Journal of the American Society of Nephrology. 
2009;20(8):1714-23. 
69. Fulton AM. Chemokine Receptors in Cancer: Springer; 2009. 
70. Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunological 
reviews. 2000;177(1):175-84. 
71. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions 
between hematopoietic and bone marrow stromal cells regulate human stem 
cell migration and development in NOD/SCID chimeric mice. Experimental 
hematology. 2006;34(8):967-75. 
72. Zoughlami Y, Voermans C, Brussen K, van Dort KA, Kootstra NA, 
Maussang D, et al. Regulation of CXCR4 conformation by the small GTPase 
Rac1: implications for HIV infection. Blood. 2012;119(9):2024-32. 
243 
 
73. Chen S, Lin F, Shin ME, Wang F, Shen L, Hamm HE. RACK1 regulates 
directional cell migration by acting on Gβγ at the interface with its effectors 
PLCβ and PI3Kγ. Molecular biology of the cell. 2008;19(9):3909-22. 
74. Alblas J, Ulfman L, Hordijk P, Koenderman L. Activation of Rhoa and 
ROCK are essential for detachment of migrating leukocytes. Molecular biology 
of the cell. 2001;12(7):2137-45. 
75. Furusato B, Mohamed A, Uhlén M, Rhim JS. CXCR4 and cancer. 
Pathology international. 2010;60(7):497-505. 
76. Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new 
target therapeutic for non-small cell lung cancer. J Thorac Oncol. 
2008;3(12):1379-83. 
77. Hunter K, Welch DR, Liu ET. Genetic background is an important 
determinant of metastatic potential. Nature genetics. 2003;34(1):23-4. 
78. Choi HY, Saha SK, Kim K, Kim S, Yang GM, Kim B, et al. G protein-
coupled receptors in stem cell maintenance and somatic reprogramming to 
pluripotent or cancer stem cells. BMB Rep. 2015;48(2):68-80. 
79. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine 
receptor superfamilies and their molecular evolution. Genome biology. 
2006;7(12):243. 
80. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, et al. Correlation effect of EGFR 
and CXCR4 and CCR7 chemokine receptors in predicting breast cancer 
metastasis and prognosis. J Exp Clin Cancer Res. 2010;29(1):16. 
81. Scholten DJ. Chemokine Receptors CXCR3 and CXCR7: Allosteric 
Ligand Binding, Biased Signaling, and Receptor Regulation [PhD]. Amsterdam: 
Vrije Universiteit; 2012. 
244 
 
82. Noor S, Wilson EH. Role of CC chemokine receptor type 7 and its 
ligands during neuroinflammation. Age. 2012;15:17. 
83. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, Van Waes C, 
et al. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-κB and 
activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and 
neck (SCCHN). Journal of Biological Chemistry. 2012;287(5):3581-90. 
84. Love M, Sandberg JL, Ziarek JJ, Gerarden KP, Rode RR, Jensen DR, et 
al. Solution structure of CCL21 and identification of a putative CCR7 binding 
site. Biochemistry. 2012;51(3):733-5. 
85. Pease JE, Williams TJ. The attraction of chemokines as a target for 
specific anti‐inflammatory therapy. British journal of pharmacology. 
2006;147(S1):S212-S21. 
86. Otero C, Groettrup M, Legler DF. Opposite fate of endocytosed CCR7 
and its ligands: recycling versus degradation. Journal of Immunology. 
2006;177(4):2314-23. 
87. Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing 
immunity and tolerance. Nature Reviews Immunology. 2008;8(5):362-71. 
88. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, et al. 
Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that 
is a specific functional ligand for EBI1, CCR7. J Biol Chem. 
1997;272(21):13803-9. 
89. Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, Förster R, et al. Balanced 
responsiveness to chemoattractants from adjacent zones determines B-cell 
position. Nature. 2002;416(6876):94-9. 
245 
 
90. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, Ludewig B, et al. 
CCL19/CCL21-triggered signal transduction and migration of dendritic cells 
requires prostaglandin E2. Blood. 2004;103(5):1595-601. 
91. Nicolson GL. Autocrine and paracrine growth mechanisms in cancer 
progression and metastasis. In: JR B, editor. Encyclopedia of Cancer. 2nd ed. 
San Diego: Elsevier Science; 2002. p. 165-77. 
92 Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing 
immunity and tolerance. Nature Reviews Immunology. 2008;8(5):362-71. 
93. Okada T, Cyster JG. CC chemokine receptor 7 contributes to Gi-
dependent T cell motility in the lymph node. Journal of Immunology. 
2007;178(5):2973-8. 
94. Yamashita N, Tashimo H, Matsuo Y, Ishida H, Yoshiura K, Sato K, et al. 
Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific 
murine asthmatic model. Journal of allergy and clinical immunology. 
2006;117(5):1040-6. 
95. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is 
required for the in vivo function of CD4+ CD25+ regulatory T cells. Journal of 
experimental medicine. 2007;204(4):735-45. 
96. Yang B-G, Tanaka T, Jang MH, Bai Z, Hayasaka H, Miyasaka M. Binding 
of lymphoid chemokines to collagen IV that accumulates in the basal lamina of 
high endothelial venules: its implications in lymphocyte trafficking. Journal of 
Immunology. 2007;179(7):4376-82. 
97. Zidar DA, Violin JD, Whalen EJ, Lefkowitz RJ. Selective engagement of 
G protein coupled receptor kinases (GRKs) encodes distinct functions of biased 
ligands. PNAS. 2009;106(24):9649-54. 
246 
 
98. Riol-Blanco L, Sánchez-Sánchez N, Torres A, Tejedor A, Narumiya S, 
Corbí AL, et al. The chemokine receptor CCR7 activates in dendritic cells two 
signaling modules that independently regulate chemotaxis and migratory speed. 
Journal of Immunology. 2005;174(7):4070-80. 
99. Verzijl D, Ijzerman AP. Functional selectivity of adenosine receptor 
ligands. Purinergic signalling. 2011;7(2):171-92. 
100. Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. 
A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 
chemokine axis in the adaptive immune system. Cytokine & growth factor 
reviews. 2013. 
101. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. β-arrestins and cell 
signaling. Annu Rev Physiol. 2007;69:483-510. 
102. Nandagopal S, Wu D, Lin F. Combinatorial guidance by CCR7 ligands 
for T lymphocytes migration in co-existing chemokine fields. PloS one. 
2011;6(3):e18183. 
103. Allaire M-A, Dumais N. Involvement of the MAPK and RhoA/ROCK 
pathways in PGE< sub> 2</sub>-mediated CCR7-dependent monocyte 
migration. Immunology Letters. 2012;146(1):70-3. 
104. Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uenosono Y, Arigami T, et 
al. Prognostic value of CCR7 expression in gastric cancer. 
Hepatogastroenterology. 2007;54(76):1025-8. 
105. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC 
chemokine receptor-7 and regional lymph node metastasis of B16 murine 
melanoma. J Natl Cancer Inst. 2001;93(21):1638-43. 
247 
 
106. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling 
networks: emerging paradigms. Trends Pharmacol Sci. 2001;22(7):368-76. 
107. Fang L, Hwang ST. Roles for CCR7 in cancer biology.  Chemokine 
receptors in cancer: Springer; 2009. p. 93-108. 
108. Sánchez-Sánchez N, Riol-Blanco L, de la Rosa G, Puig-Kröger A, 
García-Bordas J, Martín D, et al. Chemokine receptor CCR7 induces 
intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 
2004;104(3):619-25. 
109. Palmqvist C, Wardlaw AJ, Bradding P. Chemokines and their receptors 
as potential targets for the treatment of asthma. British journal of pharmacology. 
2007;151(6):725-36. 
110. Vinader V, Afarinkia K. A beginner's guide to chemokines. Future Med 
Chem. 2012;4(7):845-52. 
111. Ott TR, Lio FM, Olshefski D, Liu XJ, Struthers RS, Ling N. Determinants 
of High-Affinity Binding and Receptor Activation in the N-Terminus of CCL-19 
(MIP-3β). Biochemistry. 2004;43(12):3670-8. 
112. Ott TR, Lio FM, Olshefski D, Liu X-J, Ling N, Struthers RS. The N-
terminal domain of CCL21 reconstitutes high affinity binding, G protein 
activation, and chemotactic activity, to the C-terminal domain of CCL19. 
Biochemical and biophysical research communications. 2006;348(3):1089-93. 
113. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist 
of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the 
development of chronic graft-versus-host disease in mice. Journal of 
Immunology. 2003;170(1):588-96. 
248 
 
114. Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS. Identification of 
CC chemokine receptor 7 residues important for receptor activation. Journal of 
Biological Chemistry. 2004;279(41):42383-92. 
115. Otero C, Eisele PS, Schaeuble K, Groettrup M, Legler DF. Distinct motifs 
in the chemokine receptor CCR7 regulate signal transduction, receptor 
trafficking and chemotaxis. Journal of Cell Science. 2008;121(16):2759-67. 
116. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. 
Differential desensitization, receptor phosphorylation, β-arrestin recruitment, 
and ERK1/2 activation by the two endogenous ligands for the CC chemokine 
receptor 7. Journal of Biological Chemistry. 2004;279(22):23214-22. 
117. Proudfoot AEI, Power CA, Rommel C, Wells TNC, editors. Strategies for 
chemokine antagonists as therapeutics. Seminars in immunology; 2003: 
Elsevier. 
118. Carter PH. Chemokine receptor antagonism as an approach to anti-
inflammatory therapy:‘just right’or plain wrong? Current opinion in chemical 
biology. 2002;6(4):510-25. 
119. Koopmann W, Ediriwickrema C, Krangel MS. Structure and function of 
the glycosaminoglycan binding site of chemokine macrophage-inflammatory 
protein-1β. Journal of Immunology. 1999;163(4):2120-7. 
120. Chen G, Chen S-M, Wang X, Ding X-F, Ding J, Meng L-H. Inhibition of 
chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis 
(CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of 
rapamycin (mTOR) pathway in human gastric carcinoma cells. Journal of 
Biological Chemistry. 2012;287(15):12132-41. 
249 
 
121. Gladue RPPGR, Martin WHPGR, Poss CSPGR. Treatment of T-cell 
mediated diseases. Google Patents; 2002. 
122. Grombein CM, Hu Q, Rau S, Zimmer C, Hartmann RW. Heteroatom 
insertion into 3, 4-dihydro-1H-quinolin-2-ones leads to potent and selective 
inhibitors of human and rat aldosterone synthase. European journal of medicinal 
chemistry. 2015;90:788-96. 
123. Zhang L, Liu W, Mao F, Zhu J, Dong G, Jiang H, et al. Discovery of 
Benzylidene Derivatives as Potent Syk Inhibitors: Synthesis, SAR Analysis, and 
Biological Evaluation. Archiv der Pharmazie. 2015;348(7):463-74. 
124. Piao Z-T, Guan L-P, Zhao L-M, Piao H-R, Quan Z-S. Synthesis of novel 
7-benzylamino-2H-1, 4-benzoxazin-3 (4H)-ones as anticonvulsant agents. 
European journal of medicinal chemistry. 2008;43(6):1216-21. 
125. Mierke DF, Giragossian C. Peptide hormone binding to G‐protein‐
coupled receptors: Structural characterization via NMR techniques. Medicinal 
research reviews. 2001;21(5):450-71. 
126. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled 
receptors and Src family kinases. Oncogene. 2004;23(48):7969-78. 
127. Medler KF. Calcium signaling in taste cells: regulation required. Chemical 
senses. 2010;35(9):753-65. 
128. Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, 
et al. Calcium signaling around mitochondria associated membranes (MAMs). 
Cell Communication and Signaling. 2011;9(1):1. 
129. Lodish H, Berk A, Zipursky S. Molecular cell biology. 4th ed. New York: 
WH Freeman; 2000. 
250 
 
130. Jensen EC. The basics of western blotting. The anatomical record. 
2012;295(3):369-71. 
131. Shuyi Y, Juping D, Zhiqun Z, Qiong P, Wuyang J, Ting L, et al. A critical 
role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in 
vitro and in vivo. Cancer biology & therapy. 2008;7(7):1037-43. 
132. Tutunea-Fatan E, Majumder M, Xin X, Lala PK. The role of CCL21/CCR7 
chemokine axis in breast cancer-induced lymphangiogenesis. Molecular cancer. 
2015;14(1):1. 
133. Chen L, Liu X, Zhang H-Y, Du W, Qin Z, Yao Y, et al. Upregulation of 
chemokine receptor CCR10 is essential for glioma proliferation, invasion and 
patient survival. Oncotarget. 2014;5(16):6576-83. 
134. Peng C, Zhou K, An S, Yang J. The effect of CCL19/CCR7 on the 
proliferation and migration of cell in prostate cancer. Tumor Biology. 
2015;36(1):329-35. 
135. Chi B-J, Du C-L, Fu Y-F, Zhang Y-N, Wang RW. Silencing of CCR7 
inhibits the growth, invasion and migration of prostate cancer cells induced by 
VEGFC. International journal of clinical and experimental pathology. 
2015;8(10):12533. 
136. Na IK, Busse A, Scheibenbogen C, Ghadjar P, Coupland SE, Letsch A, 
et al. Identification of truncated chemokine receptor 7 in human colorectal 
cancer unable to localize to the cell surface and unreactive to external ligands. 
International Journal of Cancer. 2008;123(7):1565-72. 
137. Cunningham HD, Shannon LA, Calloway PA, Fassold BC, Dunwiddie I, 
Vielhauer G, et al. Expression of the CC chemokine receptor 7 mediates 
251 
 
metastasis of breast cancer to the lymph nodes in mice. Translational oncology. 
2010;3(6):354-61. 
138. Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 
expression by breast tumor cells via endothelin receptor A and hypoxia-
inducible factor-1. Cancer research. 2006;66(24):11802-7. 
139. Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, 
Wilsberg V, et al. Effect of chemokine receptors CXCR4 and CCR7 on the 
metastatic behavior of human colorectal cancer. Clinical Cancer Research. 
2005;11(5):1743-50. 
140. Cai W, Tao J, Zhang X, Tian X, Liu T, Feng X, et al. Contribution of 
homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to 
coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 
2014;34(9):1933-41. 
141. Ramirez PW, Famiglietti M, Sowrirajan B, DePaula-Silva AB, Rodesch C, 
Barker E, et al. Downmodulation of CCR7 by HIV-1 Vpu results in impaired 
migration and chemotactic signaling within CD4+ T cells. Cell reports. 
2014;7(6):2019-30. 
142. Fisher T. Fluo-4 NW Calcium Assay Kit Catalog number F36205: Thermo 
Fisher; 2006 [Available from: 
https://www.thermofisher.com/order/catalog/product/F36205. 
143. Bruserud Ø. The chemokine system in experimental and clinical 
hematology. Preface. Curr Top Microbiol Immunol. 2010;341:v-vi. 
144. Horuk R. Chemokine receptor antagonists: overcoming developmental 
hurdles. Nat Rev Drug Discov. 2009;8(1):23-33. 
252 
 
145. Hulkower KI, Herber RL. Cell migration and invasion assays as tools for 
drug discovery. Pharmaceutics. 2011;3(1):107-24. 
146. Zigmond SH. Ability of polymorphonuclear leukocytes to orient in 
gradients of chemotactic factors. J Cell Biol. 1977;75(2 Pt 1):606-16. 
147. Zicha D, Dunn GA, Brown AF. A new direct-viewing chemotaxis 
chamber. J Cell Sci. 1991;99 ( Pt 4):769-75. 
148. Muinonen-Martin AJ, Veltman DM, Kalna G, Insall RH. An improved 
chamber for direct visualisation of chemotaxis. PLoS One. 2010;5(12):e15309. 
149. Wiggins H, Rappoport J. An agarose spot assay for chemotactic 
invasion. Biotechniques. 2010;48(2):121-4. 
150. Vinader V, Al-Saraireh Y, Wiggins HL, Rappoport JZ, Shnyder SD, 
Patterson LH, et al. An agarose spot chemotaxis assay for chemokine receptor 
antagonists. J Pharmacol Toxicol Methods. 2011;64(3):213-6. 
151. Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, et al. 
Characterization of the molecular pharmacology of AMD3100: a specific 
antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem 
Pharmacol. 2006;72(5):588-96. 
152. Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, et al. 
Association of CXCR4 and CCR7 chemokine receptor expression and lymph 
node metastasis in human cervical cancer. Ann Oncol. 2007;18(1):70-6. 
153. Wagner PL, Moo TA, Arora N, Liu YF, Zarnegar R, Scognamiglio T, et al. 
The chemokine receptors CXCR4 and CCR7 are associated with tumor size 
and pathologic indicators of tumor aggressiveness in papillary thyroid 
carcinoma. Ann Surg Oncol. 2008;15(10):2833-41. 
253 
 
154. Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M, et 
al. CCR7 and CXCR4 expression predicts lymph node status including 
micrometastasis in gastric cancer. Int J Oncol. 2009;35(1):19-24. 
155. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years 
of image analysis. Nat Meth. 2012;9(7):671-5. 
156. Schreiner C, Bauer J, Margolis M, Juliano RL. Expression and role of 
integrins in adhesion of human colonic carcinoma cells to extracellular matrix 
components. Clin Exp Metastasis. 1991;9(2):163-78. 
157. Argade A, Bhamidipati S, Li H, Sylvain C, Clough J, Carroll D, et al. 
Design, synthesis of diaminopyrimidine inhibitors targeting IgE-and IgG-
mediated activation of Fc receptor signaling. Bioorganic & medicinal chemistry 
letters. 2015;25(10):2122-8. 
158. Verho O, Gustafson KP, Nagendiran A, Tai CW, Bäckvall JE. Mild and 
Selective Hydrogenation of Nitro Compounds using Palladium Nanoparticles 
Supported on Amino‐Functionalized Mesocellular Foam. ChemCatChem. 
2014;6(11):3153-9. 
159. Shridhar D, Gandhi S, Rao KS. A Facile synthesis of 2-alkyl (aryl)-6-and-
7-nitro-3-oxo-3, 4-dihydro-2H-1, 4-benzoxazines. Synthesis. 
1982;1982(11):986-7. 
160. Hanson JR, Saberi H. Comparative orienting effects of the 
methanesulfonamide group in aromatic nitration. Journal of Chemical Research. 
2004;2004(7):460. 
161. Cain BF, Atwell GJ, Denny WA. Potential antitumor agents. 16. 4'-
(Acridin-9-ylamino) methanesulfonanilides. Journal of medicinal chemistry. 
1975;18(11):1110-7. 
254 
 
162. Pericherla S, Mareddy J, Rani D, Gollapudi PV, Pal S. Chemical 
modifications of nimesulide. Journal of the Brazilian Chemical Society. 
2007;18(2):384-90. 
163. O'Rand M, inventor; University of North Carolina at Chapel Hill, assignee. 
Small molecules for inhibiting male fertility patent WO/2015/138919. 2015. 
164. Kovács D, Molnár-Tóth J, Blaskó G, Fejes I, Nyerges M. Synthesis of 
New Pyrazolo [1, 5-α] quinazoline Derivatives. Synth Comm. 2015;45(14):1675-
80. 
165. Macielag M, Greco M, Zhang YM, Teleha C, inventors; Janssen 
Pharmaceutica Nv, assignee. Quinoline derivatives useful as cb-1 inverse 
agonists patent WO2015130444 A1. 2015. 
166. Tang PC, Zhang N, Zhang B, Wang W, Zheng H, Wu L, inventors; 
shanghai hengrui pharmaceutical co., ltd, assignee. Dihydropteridinone 
derivatives, preparation process and pharmaceutical use thereof patent 
WO/2011/035534. 2014. 
167. Ayesa S, Lindquist C, Agback T, Benkestock K, Classon B, Henderson I, 
et al. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors 
of cathepsin S: effect of sulfonamides P3 substituents on potency and 
selectivity. Bioorganic & medicinal chemistry. 2009;17(3):1307-24. 
168. Kruger NJ. The Bradford method for protein quantitation. Basic protein 
and peptide protocols. 1994:9-15. 
169. De Clercq E. The bicyclam AMD3100 story. Nature Reviews Drug 
Discovery. 2003;2(7):581-7. 
255 
 
170. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and 
inexpensive method for analysis of cell migration in vitro. Nat Protoc. 
2007;2(2):329-33. 
171. Stein JV, Nombela-Arrieta C. Chemokine control of lymphocyte 
trafficking: a general overview. Immunology. 2005;116(1):1-12. 
 
 
 
  
256 
 
Appendix I Evaluating activity of Different compounds using calcium 
flux assay. 
 
1. Dose Dependant Response (IC50) curves for CCR7 receptor 
antagonists using OSC-19 cell line. 
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2. Evaluating activity of different compound using two different 
concentration. 
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Figure 46 (A) Different compound 3 (ICT5888) analogues were tested using two 
different concentration, (B) Activity of the analogues were assessed by calcium flux 
assay. 
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Figure 47 (A) number of different compound 3, ICT5888 analogues were tested using 
two different concentration (B) Activity of these analogues were assessed by calcium 
flux assay. 
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Figure 48 (A) number of different analogues were tested using two different 
concentration (B) Activity of different molecules were assessed by calcium flux assay. 
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Appendix II CCR7 and CXCR4 membranous receptor expression using 
flow cytometry assay 
 
Figure 49 CCR7 and CXCR4 membranous protein expression: (A) CCR7 is expressed 
in all cell lines (the pink curve). The more shifted the unfilled curve (CCR7 stained) 
from the filled curve (isotype control), the higher the expression. (B) CXCR4 is 
expressed in 6 cell lines the unfilled curve (CXCR4 stained). (This work was conducted 
by Mrs. Haneen Bashir) 
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CXCR4 expression on SW480 cells CCR7 expression on SW480 cells 
  
CXCR4 expression on PC-3 cells CCR7 expression on PC-3 cells 
Figure 50 Expression of CCR7 and CXCR4 receptor in SW48 and PC-3 cells using 
flow cytometry. High expression of CXCR4 receptor whiles no expression of CCR7 
receptor on SW480 cells. CXCR4 receptor has more expression than CCR7 receptor 
on PC-3 cells. (This work was conducted by Mrs. Haneen Bashir). 
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Appendix III Evaluating the cytotoxicity of some compounds using 
MTT assay. 
Compound IC50 
3, ICT5888 680 ± 20 µM (n=3) 
75, ICT13069 190 ± 20 µM (n=3) 
52, ICT13070 > 250 µM (n=3) 
78, ICT13072 > 250 µM (n=3) 
70, ICT13122 45 ± 5 µM (n=3) 
76, ICT13113 80 ± 5 µM (n=3) 
22, ICT13029 140  ± 20 µM (n=3) 
Table 16 cytotoxicity results obtained from MTT assay. (This work was conducted by 
Mrs. Haneen Bashir) 
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Appendix IV Evaluating efficacy of compound 75 using scratch assay.  
1. Assessment of PC-3 cells aptitude toward different chemoattractant 
  
PC-3 cells, control (no ligand), 
0 time 
PC-3 cells, control (no ligand), 
14 hr 
  
PC-3 cells, CCL19 (100 nM), 0 
time 
PC-3 cells, CCL19 (100 nM), 14 
hr 
  
PC-3 cells, CCL21 (100 nM), 0 
time 
PC-3 cells, CCL21 (100 nM), 14 
hr 
  
PC-3 cells, CXCL12 (100 nM), 
0 time 
PC-3 cells, CXCL12 (100 nM), 
14 hr  
Figure 51 Scratch were made on confluent monolayers of PC-3 cells. Cells were 
treated with CCL21 at 100 nM, CCL19 at 100 nM and CXCL12 100 nM or no ligand 
added (control). Wound healing is accelerated toward CXCL12 more than CCL21 and 
the least was observed with CCL19. (This work was conducted by Mrs. Haneen Bashir) 
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2. Assessment of SW480 cells aptitude toward different 
chemoattractants 
  
SW480 cells, control (no ligand), 0 time SW480 cells, control (no ligand), 21 hr 
  
SW480 cells, CCL19 (100 nM), 0 time SW480 cells, CCL19 (100 nM), 21 hr 
  
SW480 cells, CCL21 (100 nM), 0 time SW480 cells, CCL21 (100 nM), 21 hr 
  
SW480 cells, CXCL12 (100 nM), 0 time SW480 cells, CXCL12 (100 nM), 21 hr 
Figure 52 Scratch were made on confluent monolayers of SW480 cells. Cells were 
treated with CCL21 at 100 nM, CCL19 at 100 nM and CXCL12 100 nM or no ligand 
added (control). Wound healing is accelerated toward CXCL12 but not CCL21 neither 
CCL19. (This work was conducted by Mr. Roshan Patel) 
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3. Assessment of potency of compound 75 using OSC-19 cells. 
 
  
OSC-19 cells, control (no 
ligand), 0 time 
OSC-19 cells, control (no 
ligand), 18 hr 
  
OSC-19 cells, CCL21 (10 nM), 0 
time 
OSC-19 cells, CCL21 (10 nM), 
18 hr 
  
OSC-19 cells, CCL21 (10 nM) + 
100 µM compound 75, 0 time 
OSC-19 cells, CCL21 (10 nM) + 
100 µM compound 75, 18 hr 
 
  
OSC-19 cells, CCL21 (10 nM) + 
10 µM compound 75, 0 time 
OSC-19 cells, CCL21 (10 nM) + 
10 µM compound 75, 18 hr 
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OSC-19 cells, CCL21 (10 nM) + 
1 µM compound 75, 0 time 
OSC-19 cells, CCL21 (10 nM) + 
1 µM compound 75, 18 hr time 
  
OSC-19 cells, CCL21 (10 nM) + 
100 nM compound 75, 0 time 
OSC-19 cells, CCL21 (10 nM) + 
100 nM compound 75, 18 hr 
  
OSC-19 cells, CCL21 (10 nM) + 
10 nM compound 75, 0 time 
 
OSC-19 cells, CCL21 (10 nM) + 
10 nM compound 75, 18 hr 
  
OSC-19 cells, CCL21 (10 nM) + 
1 nM compound 75, 0 time 
OSC-19 cells, CCL21 (10 nM) + 
1 nM compound 75, 18 hr 
Figure 53 ICT13069 inhibits cell migration in dose dependent manner, OSC-19 cells 
were treated with ICT13069 at different concentrations for 2 h before adding CCL21. 
(This work was conducted by Mrs. Haneen Bashir) 
